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ABSTRACT OF THE DISSERTATION 
TOPOISOMERASE AND TYROSYL-DNA PHOSPHODIESTERASE RATIO AS 
AN INDICATOR FOR THE RESPONSE OF GLIOBLASTOMA CANCER TO 
TOPOISOMERASE TARGETING ANTICANCER DRUGS 
by 
Wenjie Wang 
Florida International University, 2019 
Miami, Florida 
Professor Yuk-Ching, Tse-Dinh, Major Professor 
 
Glioblastoma (GBM) patients have an estimated survival of ~15 months, 
with the standard of care (surgery, radiation, and chemotherapy) that has only 
modestly enhanced patient survival. Identifying biomarkers representing 
vulnerabilities in GBM biology may allow for the selection of effective and safe 
chemotherapy options. Irinotecan (IRT), a genotoxic compound currently in clinical 
trials for GBM, targets topoisomerase I (TOP1) by forming an irreversible ternary 
DNA-TOP1 cleavage complex (TOP1cc) and leads to apoptosis. Tyrosyl-DNA 
phosphodiesterase 1 (TDP1) is a crucial repair enzyme that rescues TOP1cc and 
reduces the effectiveness of IRT. In the current study, we evaluate the value of the 
TDP1/TOP1 activity ratio as a prospective biomarker for the personalized use of 
IRT on GBM patients.  
After analysis of susceptibility of nine GBM cell lines to IRT treatment along 
with TDP1 and TOP1 expression and activity levels in these cell lines, we found 
 viii 
that the TDP1/TOP1 activity ratio had the strongest correlation (R=0.972, 
P=1.2×10-5) with IRT IC50 values for a decrease of cell viability following IRT 
treatment. Increasing the TDP1/TOP1 activity ratio by ectopic expression of wild-
type TDP1 increased in IRT IC50, while expression of the TDP1 catalytic-null 
mutant did not alter the susceptibility to IRT. Further, after analyzing GBM patient 
tumors, TDP/TOP1 activity ratio was found to correlate (R=-0.707, P=0.03) with 
patient survival significantly. Correlations were also observed between patient age 
and survival this set of GBM patients (R=-0.929, P=0.023) as well as GBM patients 
in the TCGA database (R=-0.353, P=7.7×10-17). 
From our results, we suggested that the TDP1/TOP1 activity ratio may be a 
new predictive indicator for GBM vulnerability to IRT, which may allow for the 
selection of individual patients for IRT treatment based on risk-benefit. As a 
predictor, the lower TDP1/TOP1 activity ratio would correspond to higher IRT 
cytotoxicity. In addition, TDP1/TOP1 activity ratio might be a potential prognostic 
indicator for GBM patient survival. The lower TDP1/TOP1 ratio would correspond 
to patients with longer survival probability. Finally, inhibitors of TDP1 may be useful 
for novel combination therapy with IRT to improve GBM patient responsiveness to 
genotoxic chemotherapies. 
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CHAPTER I: INTRODUCTION 
A. GLIOBLASTOMA 
        Glioblastoma (GBM), accounting for 50% of all malignant central nervous 
system (CNS) tumors in adults (Figure 1.1), is the most deadly primary brain 
cancer with a 14.6-month median survival and a median diagnosis age around 64 
(1-3). GBM is defined as grade IV gliomas, which has the highest malignancy 
designated by the World Health Organization (WHO). GBM, with elusively 
pathophysiologic mechanism, is histologically derived from astrocytes which are 
essential for nutrients support of nervous tissues. Even with maximal surgical 
excision followed by radiotherapy, the invasive nature of GBM is most likely leading 
to an inexorable relapse, which results in poor clinical outcomes indicated by a 
~5.5% survival after five years. Thus, there is an urgent need for effective therapy 
to treat patients (4).  
 
Figure 1.1. Distribution of different classes of CNS tumors (2) 
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        With the GBM diagnostic incidence gradually rising over the past decades, 
however, the standard-of-care treatment for newly diagnosed glioblastoma has 
remained the same since the 1990s, which is typically surgery followed by 
radiotherapy and maintenance by temozolomide chemotherapy (3,5,6). 
Temozolomide (TMZ), an alkylating agent with the ability to cross the blood-brain 
barrier (BBB), has been proven by clinical results to help prolong the survival of 
patients who have silenced methylguanine methyltransferase (MGMT) gene. The 
MGMT gene silencing via promoter methylation has been found in more than 1/3 
of newly diagnosed GBM patients (7,8). It has been reported that cancer cells 
lacking MGMT enzyme fail to remove the methyl group added by TMZ onto DNA 
which then leads to cytotoxicity. Temozolomide has been shown to be effective for 
certain cases of GBM. However, the positive clinical outcomes are selective and 
lead to a merely 2-3 months improvement on median overall survival. Also, the 
cumulative toxicity of TMZ during extensive cycles of usage illustrates the need for 
other chemotherapy treatment options.  
        There are numerous obstacles facing chemotherapy as either first-line or 
second-line treatments for GBM (9). Histologically, GBM tumors are highly 
heterogeneous, which diminish the efficacy of molecular-targeting chemotherapy 
(10,11). The blood-brain barrier (BBB), working as a highly selective barrier, 
significantly reduces the drug delivery efficiency to brain tumors and limits the 
usage of chemotherapeutic drugs (12). Cancer cells survive from the initial 
chemotherapeutic treatment may finally induced tumor recurrence (13). In addition, 
the side-effects from chemotherapeutic medications may also put patient survival 
 3 
on edge (14). Therefore, finding predictive biomarkers from studying the GBM 
tumors from individual patients may improve the molecular-targeting 
chemotherapy efficacy for patients who might benefit from the specific 
chemotherapeutic treatment and prevent unnecessary side-effects for patients 
who might not respond to the treatment.  
        Genomic and proteomic studies have been applied to identify promising 
biomarkers which could predict the response of GBM to chemotherapies. 
Thousands of new cases of CNS tumors are diagnosed each year, and the 
expanded database system has allowed scientists to access the genomic and 
proteomic analyses to attempt identifying mechanisms and potential biomarkers 
for GBM drug resistance (1,15). The Cancer Genome Atlas (TCGA) is a valuable 
cancer genomic analysis database of clinical patients’ tumors (16,17). The 
CellMiner Cross Database (CellMinerCDB) enables exploration and analysis of 
cancer cell lines pharmacogenomic data across different cancer types (18). 
Previous studies have shown that by correlating gene of interests with patient 
survival provided from databases, scientists were able to identify 20 genes which 
express proteins that might be potential targets for GBM treatment (11,19). 
Besides meta-analysis, proteomic analysis of protein expressions in GBM has 
been conducted, and inhibitors targeting the overexpressed biomarkers, which 
correlated with GBM aggressiveness have been investigated (20,21). The 
epidermal growth factor receptor (EGFR) is upregulated in more than 40% of GBM 
tumors. However, treatment targeting EGFR has not shown any survival 
improvement on the basis of randomized trials (22,23). Vascular endothelial 
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growth factor (VEGF) expression in GBM is necessary for angiogenesis and tumor 
proliferation. Bevacizumab (Avaglio) with anti-VEGF activity had been tested on 
GBM patients with promising response rate in randomized clinical trials (23,24). 
However, no overall survival benefit had been found on expanded Phase III trials 
with Avaglio treatment alone (25,26). Improved effective treatment outcome was 
observed with a combination treatment of bevacizumab and Irinotecan, a 
topoisomerase I inhibitor which is able to cross BBB, in Phase II studies, although 
the underlying mechanism is not clear (27). There is also much interest in testing 
immunotherapy in clinical trials for GBM because of the immunosuppressive 
feature of GBM tumors (28). Although immune checkpoint inhibitors have been 
successfully applied in treatment of non-small cell lung cancer (NSCLC) patients, 
the inhibitors have failed in GBM treatment trials, and the biomarkers for the 
response of GBM to checkpoint inhibitors treatment remain elusive (29). Tumor 
antigen vaccines have been a promising approach for GBM treatment by targeting 
the biomarkers, which are expressed by tumors (30). Customized vaccines have 
been studied for over a decade and some impressive reports have been published 
recently, whereas additional clinical evidence is still needed to be confirmed 
(31,32). Besides, the BBB acting as a tightly surrounding armor of the brain 
requires drugs with penetrating abilities. Promising nano-scaled drug delivery 
methods have been investigated for GBM treatment. However, the outcomes are 
still insufficient (33). Therefore, more efficient GBM treatments using promising 
new biomarkers are still urgently needed.  
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        To date, the deadliest brain cancer, GBM, remains one of the most significant 
challenges in cancer treatment (34). New strategies of chemotherapy treatment of 
GBM tumor are urgently required. Novel biomarkers, which can enhance the 
likelihood for the response to the drugs that are able to cross the BBB are much 
needed.  Research conducted in this study is focusing on these aspects of GBM 
treatment needs.  
 
B. HUMAN TOPOISOMERASE I (TOP1) 
        Topoisomerases are ubiquitous enzymes that present in all kingdoms of life. 
As a result of the intertwined nature of the DNA duplex, complex topological 
structures can be generated during gene transcription, replication, recombination, 
and chromatin compactions. Accumulation of negatively supercoiled DNA behind 
and the positively supercoiled DNA ahead of RNA polymerase or replication fork 
presents topological challenges for transcription and replication processes which 
are critical for cell proliferation. The elimination of these topological barriers from 
DNA is required for the maintenance and proper function of the genome. 
Topoisomerases are essential enzymes that can resolve DNA topological 
problems during both transcription and replication. In brief, topoisomerases relax 
the accumulated supercoiled tensions from DNA through DNA cleavage and rapid 
resealing processes (35).  
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Figure 1.2. Classes of human topoisomerase and covalent topoisomerase 
cleavage complex (TOPcc) formed 
(36). (Left) Type IA topoisomerase includes topoisomerase IIIα (TOP3α) and 
topoisomerase IIIβ (TOP3β) which cut single-strand of DNA and relax the DNA 
tension by passing the intact-strand through the nick. (Middle) Type IB 
topoisomerase includes topoisomerase I (TOP1) and mitochondria topoisomerase 
I (mtTOP1) which cut single-strand of DNA and relax the DNA tension by rotating 
the broken strand around the other strand of DNA. (Right) Type IIA topoisomerase 
includes topoisomerase IIα (TOP2α) and topoisomerase IIβ (TOP2β) which cut 
double-strand of DNA and relax the DNA tension by passing the other double-
strand through the break. 
 
        In human cells, there are three types of topoisomerases, type IA (TOP3α and 
TOP3β), type IB (TOP1 and mitochondria TOP1), and type IIA (TOP2α and 
TOP2β), involving six different functioning enzymes (Figure 1.2). Topoisomerases 
cleave and re-ligate single strand (type I) or double (type II) strands of the DNA by 
forming a transient covalent intermediate. Topoisomerases use tyrosine residue(s) 
at the active site and relax the tension of DNA by passing the intact-strand(s) 
Type IA Type IB Type IIA
ATP Divalent metals
TOP3α DNA
TOP3β DNA/RNA
TOP1 DNA
TOP1mt mtDNA
TOP2α DNA
TOP2β DNA
Cofactors requirements
YES
NO
YES
Type Name Work on
Cleave 
single/double 
strand
Cleave Complex Bond & 
Relaxation mechanism
Monomer/Cleave 
single strand
3’ phosphotyrosyl bond 
strand rotation NO
Type IIA Dimer/Cleave double strands
5’ phosphotyrosyl bond 
strand passages YES
Type IA
Type IB
5’ phosphotyrosyl bond 
strand passage NO
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through the broken strand(s) (type IA, IIA) or rotating the broken strand around the 
intact strand (type IB). Type IA and type IIA topoisomerases generate 
phosphotyrosyl-bond at the 5’ end of the cleavage site and also free 3’-OH 
group(s), while type IB topoisomerases generate a phosphotyrosyl-bond at the 3’ 
end of the cleavage site and a free 5’-OH group (37,38). Divalent ions are required 
for catalysis of type IA and type IIA topoisomerases. No cofactors are required for 
human type IA or type IB topoisomerases to be functional, while adenosine 
triphosphate (ATP) is necessary for type IIA TOP2α and TOP2β enzymes to 
perform (36). During topoisomerase relaxation processes, the transient covalent 
complexes of DNA with topoisomerase are termed as TOPcc (topoisomerase 
cleavage complexes) (Figure 1.2) (39). Under normal conditions, TOPcc remains 
at a low level and the religation process is favored over the cleavage process (40).  
        Eukaryotic topoisomerase I is essential for the survival of multicellular 
organisms and relaxes both negatively and positively supercoiled DNA without any 
energy or cofactor (Figure 1.2). Previous studies have shown that the deficiency 
of topoisomerase I in mice induced an embryonic lethality at the 8-cell stage and 
aberrant topoisomerase I function in human cells might be associated with autism 
spectrum disorder (ASD), a life-long neurodevelopmental disorder concomitant 
with behavior deficiency (41,42). However, topoisomerases can also induce 
harmful DNA lesions in association with endogenous and exogenous genomic 
threats. Studies have shown that DNA apurinic/apyrimidinic (AP) sites, single base 
mismatches, reactive oxygen species (ROS), UV lesions, alkylating agents, as well 
as topoisomerase poisons, can trigger the generation and stabilization of TOP1cc 
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(43-47). Failure to release topoisomerase I from DNA in TOP1cc will result in 
protein-linked DNA breaks (PDBs). Protein-linked DNA breaks can be rescued by 
activating cell cycle checkpoint and cellular repair pathways, while the 
accumulation of PDBs may finally result in DNA damage-induced apoptosis (DDIA). 
Insufficient DNA repair of TOP1cc or defective cell apoptosis might eventually 
induce the loss of genomic stability and tumorigenesis (48).  
 
 
Figure 1.3. Human topoisomerase I inhibitors and TOP1cc ternary complex  
(49) (Above) Human topoisomerase I inhibitor structures: Camptothecin (CPT), 
Irinotecan (IRT), active metabolite of IRT (SN-38), Topotecan (TPT), and 
Belotecan. (Bottom) Human topoisomerase I inhibitors insert at the interface of 
DNA and TOP1 by forming the irreversible cleavage complexes.  
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        With the lethal feature of TOP1cc described above, human topoisomerase I 
has been shown as a promising chemotherapy target for decades, and 
topoisomerase poisons which lead to accumulation of its cleavage complexes are 
widely used for cancer therapies (Figure 1.3) (50-52). Irinotecan (IRT), its active 
metabolite SN-38, and topotecan (TPT) are chemotherapeutic camptothecin 
derivatives (CPTs) which are widely applied in cancer therapy as TOP1 poisons 
and have been approved by Food and Drug Administration (FDA) since the mid-
1990s (53-55). Topotecan is now routinely utilized to treat ovarian cancer (56,57) 
and small cell lung cancer (SCLC) (58,59). Irinotecan is routinely used for the 
treatment of colorectal cancer (60,61). It has been demonstrated that these 
topoisomerase poisons target the interface of TOP1/DNA complex and stabilize 
TOP1cc with hydrogen bonds as well as hydrophobic interactions resulting in a 
stable ternary complex which prevents the religation of DNA and the release of 
TOP1, thus inducing cell apoptosis (44,49).  
        However, resistance to TOP1 poisons has become one of the toughest tasks 
for cancer therapy. Studies have suggested that the endogenous repair systems, 
such as DNA damage response (DDR), existing in cells may result in the drug 
resistance and rescue cells from apoptosis (62,63). It has been reported that 
poly(ADP-ribose) polymerase (PARP) inhibitor, veliparib, targeting PARP, the 
critical enzyme for adenosyl ribosylation of TOP1 in the DDR pathway, in 
combination with topoisomerase I inhibitor topotecan was able to modulate 
TOP1cc mediated DNA damages in lymphomas (64). Ataxia telangiectasia and 
Rad3-related protein (ATR) inhibitor, M6620, targeting ATR, the main transducer 
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of replication stress, in combination with TPT was found to produce response from 
platinum-refractory SCLC which usually would not respond to topotecan alone (65). 
On the other hand, studies have shown the cell resistance to drug treatment could 
also be modulated by post-translational modifications (PTMs) and epigenetic 
modifications. It has been reported that the ubiquitin-proteasome pathway results 
in an elevated CPT resistance in cancer cells (62,63). Besides, histone 
deacetylase (HDAC) inhibitors could overcome colorectal cancer (CRC) cells 
resistance to IRT treatment by inhibiting H4K16 deacetylation (66). Therefore, to 
attain a better cancer cell response from chemotherapeutic treatment with 
topoisomerase poisons, combination treatment with inhibitors of enzymes in the 
DDR, PTM, or epigenetic pathways has become a promising approach (67). 
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C. HUMAN TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) 
        Tyrosyl-DNA phosphodiesterase1 (TDP1) and tyrosyl-DNA 
phosphodiesterase 2 (TDP2) are unique repair enzymes found in eukaryotes and 
are able to rescue covalent complexes, which are stabilized by either endogenous 
DNA lesions or exogenous inhibitors, formed by topoisomerases on DNA termini 
(Figure 1.4) (51,53). Human TDP1 is a member of the phospholipase D (PLD) 
superfamily (68). Following proteasome-dependent degradation of TOP1cc, TDP1 
rescues cells from the lethal DNA damage by hydrolyzing the phosphotyrosyl-bond 
of TOP1 peptide from the 3’ end of DNA single-strand breaks (SSBs) and 
covalently form a TDP1-DNA intermediate through H263 at its active site (36,69). 
Tyrosyl-DNA phosphodiesterase1 covalent complex (TDP1cc) is further rescued 
by hydrolysis of the phosphotyrosyl-bond of TDP1 by H493 in its active pocket 
followed by 3’-OH generation through the polynucleotide kinase phosphatase 
(PNKP) activity (Figure 1.5A). On the other hand, human TDP2, a member of 
Mg2+/Mn2+-dependent phosphodiesterases superfamily, releases TOP2 peptides 
from the 5’ terminus of DNA without the formation of the TDP2cc (Figure 1.5B). 
Minor overlap in repairing TOP1cc and TOP2cc have been observed between 
TDP1 and TDP2 based on published studies (68,70). 
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Figure 1.4. Human tyrosyl-DNA phosphodiesterase 1 and 2 functions for 
rescuing topoisomerase cleavage complexes  
(67) (Left) TDP1 hydrolyzes phosphotyrosyl-bond of TOP1 peptide from 3’ end of 
DNA. (Right) TDP2 hydrolyzes phosphotyrosyl-bond of TOP2 peptides from 5’-end 
of DNA. 
 
        Tyrosyl-DNA phosphodiesterase1, a ubiquitous and highly conserved repair 
enzyme, is also able to resolve various 3’ blocked termini of DNA, such as 3’-
phosphotyrosyl, 3’-abasic site, 3’-non-phosphorylated nucleotide, and 3’-
phosphoglycolate with no cofactor requirement (71). Post-translational 
ATP Divalent metals
TDP1 3’ phosphodiesterase 3’ phosphate
3’ blocking DNA (RNA) lesions      
(3’ phosphotyrosyl bond, 3’ abasic site, 3’ 
phosphoglycolate, 3’ BHQ, 3’ 6-FAM)
NO NO
TDP2 5’ phosphodiesterase 5’ phosphate 5’-phosphotyrosyl DNA (RNA) lesions NO YES
Cofactor requirementName Function Product Removal of DNA adducts
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modifications regulate TDP1 acting as a crucial enzyme in SSB and double-strand 
break (DSB) repairs. Studies have shown that TDP1 PTMs are substantially 
associated with its N-terminal domain (NTD, residues 1-148), a dispensable 
domain for TDP1 catalytic activity. Phosphorylation, SUMOylation, and PARylation 
at NTD stabilize TDP1 and promote the recruitment of TDP1 and other repair 
enzymes on DNA damage site without interfering with TDP1 activity (72-75). It has 
been reported that DSBs or CPT-induced TDP1 phosphorylation at serine 81 by 
ataxia-telangiectasia mutated (ATM) kinase increases the recruitment of TDP1 on 
DNA damage sites and also enhanced the protein-protein interaction with XRCC1 
and ligase IIIα which are crucial for PNKP recruitment (73,74). In addition, 
SUMOylation of TDP1 at lysine 111, which is independent from DNA damage, is 
able to accumulate TDP1 at TOP1cc site for further repair (75). Moreover, 
PARylations of the TDP1 on its N-terminus could stabilize TDP1 recruitment on 
TOP1cc damage sites without interfering its activities and also helped to recruit 
XRCC1 for further PNKP participation in the DNA repair pathways (72). On the 
other hand, PTM associated with TDP1 C-terminal domain was also reported. A 
recent study highlighted that the methylation of R261 and R586 of TDP1 on its 
catalytic domain (149-608), enhancing TDP1 activity as well as XRCC1 
association with TDP1, promotes cancer cell survival in response to CPT treatment 
(76). As TDP1 is involved in multiple DNA-damage-induced repair pathways, the 
deficiency of TDP1 function may induce chaos in the cells. Studies have shown 
that homozygous H493R mutation on TDP1 is associated with familial 
spinocerebellar ataxia with axonal neuropathy (SCAN1) disease, which results in 
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mental retardation and immunodeficiencies (77,78). The lymphoblastoid cells 
derived from SCAN1 patients are hypersensitive to CPTs owing to the 25-fold 
reduction in TDP1 activity (79).  
 
 
Figure 1.5. TDP1 and TDP2 catalytic mechanisms  
(36). (A) TDP1 cleaves TOP1 peptide from DNA by nucleophilic attack of 
phosphodiester backbone by H263 residue and subsequently releases from DNA 
by a second nucleophilic attack by H493 residue. (B) TDP2 cleaves TOP2 peptide 
from DNA by nucleophilic attack of its catalytic residues which are coordinated with 
two magnesium ions.  
 
        As described above, TDP1 is performing as an essential enzyme on TOP1cc 
repair pathways, thus targeting TDP1 in cells has become one of the promising 
approaches for cancer treatment. Although no FDA-approved TDP1 inhibitor has 
been published, inhibitors targeting TDP1-associated repair enzymes PARP in 
combination with TOP1 inhibitor IRT have yielded responses from lymphomas (64). 
Moreover, TDP1 protein deficiency in TDP1 knockdown cells confers a higher 
cytotoxic response to CPT treatment, whereas further depletion of TOP1 rescues 
cells from CPT-induced apoptosis (80). Additionally, TDP1 phosphorylation at 
serine 81 (pS81) could protect cells from CPT induced accumulated DNA damages 
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and deficiency of XRCC1, which closely interacts with TDP1, could cause 
hypersensitivity of cells to CPT treatment (74). With TDP1 acting as a broad-
spectrum 3’-end DNA lesion repair enzyme that crucially associates with cell 
functions, combination treatments of TDP1 inhibitors with reagents contributing to 
harmful DNA lesions, such as TOP1 inhibitors, alkylating agents, and other repair 
enzyme inhibitors are promising for anti-cancer therapies in the future treatment. 
Therefore, research focusing on finding effective TDP1 inhibitors has become a 
compelling task.  
D. OVERVIEW 
        Currently, new biomarkers for the treatment of the most aggressive brain 
tumor, GBM, are urgently needed to enhance the likelihood of patient response. 
Topoisomerases I inhibitors have been proven as a powerful chemotherapeutic 
tool in multiple anti-cancer regimens. Irinotecan possessing the ability to cross the 
BBB has been used for the treatment of GBM in clinical trials. Monotherapy of 
Irinotecan and the combination treatment with TMZ on GBM have yielded 
encouraging results and comparable with TMZ treatment alone (81,82). However, 
inconsistent responses from GBM to Irinotecan treatment has remained elusive in 
previous clinical trials, and the overall survival rate is still not showing significant 
increase over the past two decades (83,84).  Tyrosyl DNA phosphodiesterase 1 
(TDP1) is a ubiquitous and highly conserved repair enzyme in eukaryotes which 
can resolve various 3’ blocking termini of DNA lesions including 3’-phosphotyrosyl-
bond from TOP1cc induced by TOP1 inhibitors (71). The lack of TDP1 in cells may 
finally induce cancer cell apoptosis (Figure 1.6). Therefore, in this dissertation 
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project, we tested the hypothesis that TDP1/TOP1 ratio might be a new predictive 
biomarker for GBM response to Irinotecan treatment. Both cell lines and patient 
tumors were analyzed in our research. 
 
Figure 1.6 Diagram of TOP1 and TDP1 functions in GBM with IRT treatment 
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CHAPTER II: TDP1/TOP1 ACTIVITY RATIO AS AN INDICATOR FOR GBM 
CELL LINE RESPONSE TO IRT TREATMENT 
 
ABSTRACT 
        To select cancer chemotherapy for individual patients, the essentiality to 
identify predictive biomarkers, which would predict the response of the patient’s 
cancer cells to chemotherapeutic drug treatment, is significant. Topoisomerase I 
(TOP1) is an essential enzyme that modulates the topological structure of 
chromosome DNA during replication and transcription by concerted DNA cleavage 
and rejoining steps. Irinotecan (IRT), working as a TOP1 poison inhibitor, targets 
the interface of TOP1 and DNA and stabilizes an irreversible TOP1 cleavage 
complex (TOP1cc) which induces cancer cell death by apoptosis. Tyrosyl-DNA 
phosphodiesterase 1 (TDP1) is a crucial repair enzyme that efficiently removes the 
TOP1 peptide from the lethal TOP1cc. Irinotecan has been demonstrated to have 
anti-cancer activity against glioblastoma (GBM), the most aggressive primary brain 
tumor according to world health organization (WHO). The present study shows that 
TOP1 or TDP1 expression level alone does not correlate with IRT efficacy. We 
demonstrate that the TDP1/TOP1 activity ratio has the strongest correlation with 
the TOP1cc level as well as IRT sensitivities in comparison with the TDP1 or TOP1 
activity level alone, suggesting that both TDP1 and TOP1 activities in GBM cells 
play critical roles in the outcome of IRT treatment.  
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INTRODUCTION 
        Glioblastoma (GBM) is a devastating disease with poor prognosis and lack of 
predictive biomarkers (20). Irinotecan (IRT), a topoisomerase I (TOP1) poison 
specifically stabilizing and accumulating the lethal TOP1cc in cells, has been found 
in GBM clinical trials to have inconsistent efficacy. However, the explanation of the 
poor prognosis is remaining elusive (82). Therefore, our study evaluated the roles 
of TOP1 and tyrosyl-DNA phosphodiesterase 1 (TDP1), in the response of GBM 
to IRT treatment, in order to identify rational predictive biomarkers that may 
improve the chemotherapeutic outcomes. Furthermore, cytotoxicity induced by 
IRT had been evaluated by cell viability assay on nine GBM cell lines. Cytotoxicity 
data had also been gathered from Cancer Drug Resistance (CancerDR) database 
and CellMiner databases which are widely used to compare the effectiveness of 
anti-cancer drugs against well-established cancer cell lines (85-87). Also, TOP1cc 
level was measured to confirm further the DNA damage induced by IRT treatment.  
        Previous studies have shown that protein expression levels of TOP1 or TDP1 
are factors that can alter cell cytotoxicity induced by TOP1 poisons. Meisenberg et 
al. proposed the TDP1/TOP1 protein expression ratio as a promising indicator for 
the cytotoxicity of small cell lung cancer to treatment with the TOP1 poison 
topotecan (TPT) (88). Other studies have shown that camptothecin (CPT) and 
related drugs induced degradation of TOP1 protein, via SUMOylation and 
Ubiquitin-proteasome pathway (UPP), results in elevated drug resistance in cells 
(62,63). The overexpression of TDP1 in human embryonic kidney cells 
counteracted with CPT-induced DNA lesions (89). Thus, we assayed protein 
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expression level of both TDP1 and TOP1 with Western blot to determine if there is 
any correlation with cell response to IRT treatment in GBM cell lines. 
        In addition to the variation of TOP1 and TDP1 protein expression level, the 
modulation of TOP1 and TDP1 enzyme activities could also affect cell responses 
to drug treatment. It has been reported that the increased TOP1 activity level could 
sensitize the human glioma cells to IRT treatment following Delta-24 infections (90). 
Additionally, activity increase of TOP1 from phosphorylation at Thr268 and Ser506 
sites sensitized cancer cells to cytotoxicity from CPT treatment (91,92). A previous 
study has also suggested that the increased expression and activity of TDP1 along 
with DNA repair endonucleases XPF might contribute to CPT resistance in small 
cell lung cancer (NSCLC) cells (93). Therefore, in the present study, TOP1 activity 
and TDP1 activity were measured and analyzed for correlation with the responses 
to IRT treatment. In our study, we overexpressed recombinant wild-type WT-TDP1 
and mutant H263A-TDP1 in GBM cells and the resulting TDP1 activity variations 
were correlated with cell cytotoxicity from IRT treatment.  
        Human carboxylesterase 2 (CES2), belonging to serine hydrolase 
superfamily, has been reported as a critical enzyme that efficiently converts 
prodrug IRT to its active metabolite SN-38 in cancer cells as a result of its 
preference for esters with a relatively large alcohol group and a small acyl group 
as hydrolysis substrates (94). It has been reported that two GBM cell lines, U87 
and U251, can effectively convert IRT into SN-38 in vitro (95). In addition, a small 
scale clinical research study showed that patients with overexpression of CES-2 
and TOP1 were positively correlated with both progression-free survival (PFS) and 
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overall survival (OS) in metastatic colorectal cancer (mCRC) suggesting that 
patients with high CES-2 levels might benefit from IRT-based therapy (96). 
Therefore, CES2 levels were also measured for the GBM cell lines included in our 
study to determine if there is significant variation in the CES2 levels that might 
affect the cytotoxicity resulting from IRT treatment (97). 
 
MATERIAL AND METHODS 
All buffer compositions and preparation protocols are listed in Appendix I.  
 
Glioblastoma cell culture 
Table 2.1. Glioblastoma cell line information 
 
 
        Three out of nine GBM cell lines (U87, A172, and H4) were received from the 
American Type Culture Collection (ATCC). The other six cell lines (SF295, SF268, 
SF539, SNB75, SNB19, and U251) were received from the National Cancer 
Institute, Division of Cancer Treatment and Diagnosis (NCI, DCTD). All nine GBM 
cell lines used in the current study are listed in Table 2.1. Cell lines were cultured 
Cell lines Source Age Gender Disease Morphology
SF539 NCI 34 female glioblastoma
SF295 NCI 67 female glioblastoma
H4 ATCC 37 male neuroglioma epithelial
SF268 NCI 24 female ana plastic astrocytoma
SNB19 NCI 47 male glioblastoma
U251 NCI 75 male glioblastoma
A172 ATCC 53 male glioblastoma
SNB75 NCI female astrocytoma
U87 ATCC 44 male glioblastoma epithelial
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and maintained in Dulbecco’s Modified Eagle’s medium (DMEM, Corning) 
supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS, Hyclone), 1% 
Penicillin/Streptomycin (PenStrep, Gibco), and 0.1% prophylactic (InvivoGen). 
Cells were grown at 37°C in a humidified incubator with 5% CO2. 
 
Glioblastoma cell extract preparation 
        Cells were seeded in a density of 4 × 105 cells/well in 60-mm dishes and 
cultured until reaching 80% confluency. Next, cells were washed twice in 
phosphate-buffered saline (PBS, Gibco) and lysed in radioimmunoprecipitation 
assay buffer (RIPA, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM 
EGTA. 1% NP-40, 0.1% SDS and 0.5% sodium deoxycholate) supplemented with 
1 mM phenylmethanesulfonyl fluoride (PMSF), 1% (v/v) of Halt Protease inhibitor 
cocktails (Thermo Fisher), and 1% (v/v) Halt Phosphatase inhibitor cocktails 
(Thermo Fisher). Cells were incubated with lysis buffer on ice for 5 min and then 
transferred to a sterile microcentrifuge tube followed by sonication at 30% 
amplitude for 30 seconds (120 W, FB120, Fisher Scientific). The cell debris was 
removed by centrifugation at 15000 ×g at 4°C for 15 min. The protein concentration 
of the supernatant was measured using the Pierce BCA Assay Kit (Thermo Fisher) 
according to the manufacturer’s protocol. Bovine serum albumin (BSA) in 
concentrations from 31.25 ng/µL to 2 µg/µL was used to generate a standard curve 
(Figure 2.1) for determination of the GBM cell extract protein concentration. The 
isolated proteins from the whole cell extracts were aliquoted and stored at -80°C 
for further analysis. 
 22 
 
Figure 2.1. Typical color response curves for BSA using the BCA assay 
 
Western blot analysis 
        The protein expression level was measured using Western blot analysis. 
Briefly, protein from whole cell extract (WCE) was first separated by 7.5% SDS-
PAGE and then transferred onto a nitrocellulose membrane with transfer buffer (48 
mM Tris, 39 mM glycine, 0.4% SDS, 20% v/v methanol) for 1 h at 100 V, 4°C by 
the Mini-PROTEAN Tetra vertical electrophoresis system (Bio-Rad). The 
membrane was blocked with 5% BSA diluted in Tris-buffered saline (TBS) at room 
temperature (RT) for one hour followed by incubation of 1:1000 (v/v) primary 
antibody diluted in 1% Tween 20 of TBS (TBST) at 4°C for 18 h. The membrane 
was then washed three times for 5 min (3 × 5 min) with TBST buffer before 
incubation with the horse-radish peroxidase (HRP) conjugated secondary antibody 
diluted 1:5000 (v/v) in TBST at RT for additional one hour. The membrane was 
washed 3 × 5 min before the expression level of the protein of interest was 
developed with the SuperSignal West Pico Plus Chemiluminescent Substrate 
(Thermo Fisher) for 5 min in the dark. The images were obtained with the C-DiGit 
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Blot scanner (LI-COR) and the band density corresponding to the protein 
expression level was analyzed using the ImageStudio software (LI-COR). The 
standard deviation was calculated using at least three individual experiments. All 
the primary and secondary antibodies used in the study are listed in Table 2.2. 
Table 2.2. Information of primary and secondary antibody 
 
 
DNA-protein covalent complexes isolation 
        Cells were first plated at a density of 2 × 105 cells/well in 35-mm dishes and 
cultured until 70-80% confluence. A stock solution of Irinotecan (148 mM) in 
dimethyl sulfoxide (DMSO) was first diluted to 15 µM with freshly prepared culture 
media. Following the addition of IRT diluted in culture media, cells were incubated 
further for 15 min, 30 min, and 60 min. The DPCCs were then harvested (98). 
Briefly, cells were collected and lysed with 1 mL of lysis buffer (6 M guanidinium 
isothiocyanate, 10 mM Tris-HCl, pH 6.5, 20 mM EDTA, 4% TritonX-100, 1% 
Sarkosyl, and 1% dithiothreitol) at RT for 5 min without any wash step, followed by 
addition of 0.5 mL of 100% ice-cold ethanol. DNA-protein covalent complexes were 
precipitated at -20°C for 30 min and collected by centrifugation at 20000 ×g at 4°C 
Cell lines Antibody Size PI Dilutions Method Source Incubation
1:500 Slot blot
1:1000
Anti-TDP1 68 kD 7.3 1:1000 Bethyl, A301-618A-M Overnight/4°C
Anti-actin 42 kD 5.2 1:5000 Abcam, ab3280 Overnight/4°C
Anti-mouse 1:5000 Santa Cruz, sc-516102 1h/RT
Anti-rabbit 1:5000 Santa Cruz, sc-2054 1h/RT
9.3 DSHB-CPTC-Top1-2-s Overnight/4°C
Western 
blot
Secondary 
antibody
Primary 
antibody
Anti-TOP1 91 kD
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for 15 min. The precipitate was then washed twice with 75% ice-cold ethanol and 
dissolved in freshly prepared 8 mM NaOH. The DNA concentration was measured 
using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen) according to the 
manufacturer’s instruction (Figure 2.2). The isolated DNA-protein covalent 
complexes (DPCCs) from GBM cell lines were aliquoted and stored at -80°C for 
further analysis. 
 
Figure 2.2. Dynamic range and sensitivity of the Quant-iT PicoGreen dsDNA 
assay.  
 
Slot blot analysis of TOP1cc in DPCC 
        The topoisomerase I cleavage complex (TOP1cc) in DPCC was detected 
using slot blot analysis (98). Briefly, 80 ng of DPCC was diluted in 200 µL of TBS 
and loaded onto a TBS pre-soaked nitrocellulose membrane in the 48-well Bio-Dot 
SF microfiltration unit (Bio-Rad) with vacuum applied. The membrane was then 
blocked with 0.5% alkali-soluble casein (Novagen) in TBS at RT for one hour 
followed by incubation with 1:500 (v/v) diluted human TOP1 antibody purchased 
from Developmental Studies Hybridoma Bank (DSHB, CPTC-TOP1-2) at 4°C for 
18 h. The membrane was then washed 3 × 5 min and incubated at RT with 1:5000 
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(v/v) diluted goat anti-mouse secondary antibody (Santa Cruz, sc-516102) for an 
additional one hour. The membrane was washed 3 × 5 min before the TOP1cc 
signal was developed with the SuperSignal West Pico Plus Chemiluminescent 
Substrate (Thermo Fisher) for 5 min in the dark. The images were obtained with 
the C-DiGit Blot scanner (LI-COR) and the TOP1 density from the TOP1cc was 
analyzed using the ImageStudio software (LI-COR). 
 
IC50 measurement for Irinotecan treatment of GBM cell lines  
        Cells were first plated at a density range of 5 - 8.5 × 103 cells/well in a 96-well 
plate and cultured until 70-80% confluence. Serial dilutions (0.05 to 15 µM) from a 
stock solution of Irinotecan dissolved in DMSO were made in freshly prepared 
culture media and used for 72 h incubation treatment of the cells. The cell viabilities 
were then assayed with TO-PRO3 reagent (Thermo Fisher) according to the 
manufacturer’s protocol (Figure 2.3). Briefly, cells were fixed using 100 µL/well of 
4% paraformaldehyde in PBS (PFA) for 20 min at RT before permeated with 0.2% 
TritonX-100/PBS for 30 min with rocking. Cells were then treated with blocking 
buffer (LI-COR) for 30 min and stained by adding 1:1000 (v/v) diluted TO-PRO3 
reagent in blocking buffer for an additional one hour with rocking. Cells were rinsed 
four times with 0.1% Tween/PBS before reading of the fluorescence signal. The 
far-red fluorescence signal from TO-PRO3 reagent bound to double-stranded DNA 
was detected using the Odyssey CLx Imaging System (LI-COR) and analyzed 
using the ImageStudio system (LI-COR). IC50 is determined as the concentration 
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of Irinotecan which results in 50% reduction of cell viability compared to the DMSO 
control.  
 
  
Figure 2.3. Diagram of GBM cell viabilities with serial dilutions of Irinotecan 
by TO-PRO3 assay 
 
Site-Directed Mutagenesis 
        Human TDP1 cDNA clone with expression under the control of the CMV 
promoter in pCMV6-XL4 vector was obtained from OriGene. Site-directed 
mutagenesis for H263A (histidine to alanine) substitution was performed by 
polymerase chain reaction (PCR) using the Q5 Site-Directed Mutagenesis Kit from 
New England Biolabs. Forward (5’-TGG AAC ACA CGC CAC GAA AAT GAT G-
3’) and reverse (5’-AAC GCA ATA TCC AAC TTT G-3’) primers were used to 
generate a mutant TDP1 clone with null catalytic activity (99). The complete TDP1 
coding sequences in wild-type (WT) and H263A mutant clones were verified by 
DNA sequencing. Primers used for sequencing are listed in Table 2.3. The DNA 
concentration was measured using PicoGreen dsDNA Assay Kit (Invitrogen) and 
DNA was stored at -20°C for further usage.  
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Table 2.3. DNA oligo and primers used in this study 
 
 
Cell transfection with TDP1 cDNA clones 
        The transient transfection of GBM cell line H4, with WT-TDP1 and H263A-
TDP1 clones, were performed by using Lipofectamine 3000 (Invitrogen) according 
to its manufacturer’s protocol. Briefly, cells were first seeded at a density of 
1.8 × 105 cells/well in 35-mm dishes and cultured for 24 h until 60% confluence. 
The DNA in the amount of 500 ng was mixed with Lipofectamine 3000 at a ratio of 
1:2 (w/v) in 250 µL of Opti-MEM Medium (Gibco) for 20 min at RT and added to 
cells for 24h further incubation. The WCEs were then prepared with RIPA buffer 
and analyzed as described above.  
        For the measurement of Irinotecan IC50 following transfection, H4 cells were 
plated at a density of 6.5 × 103 cells/well in a 96-well plate and cultured 24 h until 
60% confluence. The DNA (18 ng) was mixed with Lipofectamine 3000 at a ratio 
of 1:2 (w/v) in 10 µL of Opti-MEM Medium for 20 min at RT and incubated with 
Assay Name Sequence Source
TDP1_SDM_FP 5'-TGG AAC ACA CGC CAC GAA AAT GAT G-3' Sigma
TDP1_SDM_RP 5'-AAC GCA ATA TCC AAC TTT G-3' Sigma
VP1.5 5'-GGA CTT TCC AAA ATG TCG-3' OriGene
TDP1_401 5'-ATG ACG GCA CTG CCC AAA G-3' Sigma
TDP1_1401 5'-ATA TCC TGC TGG GGG CTC T-3' Sigma
Gel-based TDP1 
activity assay P12Y 5'-
32PO4-GAA AAA AGA GTT-PO4-Tyr-3' TopoGEN
Fluorescence-based 
TDP1 activity assay
5'-6FAM-DNA-
BHQ1-3'
5'-6FAM-AAA GCA GGC TTC AAC GCA ACT GTG AAG 
ATC GCT TGG GTG CGT TGA AGC CTG CTT T-BHQ1-3' LGC Biosearch
Site-directed 
Mutagenesis
Sequencing
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cells for additional 24 h.  Cells were then incubated with serial dilutions of IRT for 
72 h and cell viabilities were measured with the TO-PRO3 assay as described 
above. 
Human TOP1 activity measurement by gel relaxation assay 
        Human topoisomerase I activity measurement by relaxation assay was 
carried out in a final reaction volume of 20 µL. Negatively supercoiled pBAD/Thio 
DNA (240 ng) was relaxed with serial diluted recombinant human topoisomerase 
(hTOP1) enzyme (TopoGEN) at 37°C for 30 min in relaxation buffer (10 mM Tris-
HCl, pH 7.9, 1 mM EDTA, 150 mM NaCl, 0.1% BSA, 0.1 mM spermidine, 5% 
glycerol). The reaction was stopped by adding 6 µL of 4 × SDS stop solution (6% 
SDS, 0.3% bromophenol blue, 30% glycerol) and the supercoiled DNA and relaxed 
DNA were then separated by electrophoresis in 1% agarose gel based on the 
mobility differences (Figure 2.4). The DNA molecules in the gel were stained with 
1 µg/mL of ethidium bromide (EtBr) solution and photographed over UV light. 
AlphaView SA (ProteinSimple) was used to analyze the fraction of supercoiled 
DNA substrate converted into relaxed DNA at the end of each reaction. Serial 
dilutions of the recombinant hTOP1 enzyme were used to generate a reference 
standard curve for the fraction of supercoiled DNA converted to relaxed DNA by 
units (U) of hTOP1 as defined by the supplier. The TOP1 activity in whole cell 
extracts (WCEs) was assayed under the same conditions. Serial dilutions of WCEs 
were assayed to identify amount needed to relax 50% of the supercoiled DNA 
substrate and calculate the TOP1 activity present in each WCE using the standard 
curve as U/µg of total WCE protein. The relative TOP1 activity levels present in 
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the cell lines were normalized to the TOP1 activity level in fetal normal human 
astrocyte (NHA). 
 
Figure 2.4. Diagram of TOP1 relaxation assay 
 
5’-end labeling of oligonucleotide P12Y 
        The 12-base long oligonucleotide substrate OH12Y linked to tyrosine at the 
3’-end (OH12Y, 5’-OH-GAA AAA AGA GTT-PO4-Tyr-3’) was obtained from 
TopoGEN. Radionucleotides [γ-32P] ATP (10 µCi/µL) was purchased from Perkin 
Elmer Inc. The 5’-end labeling reaction was carried out in a final reaction volume 
of 20 µL. The OH12Y oligonucleotide (800 ng) was incubated with 25 µCi of [γ-32P] 
ATP in the presence of 10 U of T4 DNA ligase (NEB) at 37°C for 30 min in reaction 
buffer (70 mM Tris-HCl, pH 7.6, 10 mM MgCl2, 5 mM DTT). The reaction was 
terminated by heating at 75°C for 15 min. The 5’-labeled oligonucleotide (P12Y, 
5’-32PO4-GAA AAA AGA GTT-PO4-Tyr-3’) was then purified by centrifugation 
through a 1.5 mL Sephadex G15 column and stored in 10 mM Tris-HCl (pH 7.5) at 
-20°C until further use. 
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Human TDP1 activity measurement by Gel-based assay 
        Human tyrosyl-DNA phosphodiesterase 1 activity measurement by gel-based 
assay was carried out in a final reaction volume of 5 µL. The recombinant human 
TDP1 (hTDP1) was received as a gift from Dr. Yves Pommier at the National 
Institute of Health (NIH) (100). The P12Y oligo (4 ng) was cleaved with serial 
dilutions of recombinant hTDP1 at 37°C for 30 min in gel-based assay reaction 
buffer (20 mM Tris-HCl, pH 7.5, 100 mM KCl, 10 mM EDTA, 1 mM DTT). The 
reaction was stopped by adding 5 µL of 2 × stop solution (96% formamide, 20 mM 
EDTA, 0.03% xylene cyanol and 0.03% bromophenol blue) followed by heating at 
95°C for 5 min. The oligonucleotide substrate and product were separated by 
electrophoresis in 20% urea-denaturing sequencing gel (SequaGel, National 
Diagnostics) using the mobility differences between P12Y substrate and P12 
product (5’-32PO4-GAA AAA AGA GTT-PO4-3’) with 3’-tyrosine removed (Figure 
2.5). The intensity of the labeled oligonucleotides was analyzed with the BiorRad 
PharoFX Plus Phosphorimager. The correlation between hTDP1 activity 
represented as fmol, and the fraction of P12 formed from P12Y is plotted as a 
standard linear curve. The TDP1 activity assay from WCE was carried out under 
the same condition with 2 µg of WCE added to each reaction. The TDP1 activity 
present in each microgram of WCE was calculated using the standard curve as 
fmol/µg. The TDP1 activities in the GBM cell lines were then normalized by TDP1 
activity in WCE of NHA.  
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Figure 2.5.  Diagram of gel-based TDP1 activity assay 
 
Human TDP1 activity measurement by fluorescence-based assay 
        The TDP1 activity was also carried out using a fluorescence-based assay 
(101). The 55 nucleotide (nt) long 5’FAM-DNA-BHQ1-3’ oligonucleotide substrate 
(5’-6-FAM-AAA GCA GGC TTC AAC GCA ACT GTG AAG ATC GCT TGG GTG 
CGT TGA AGC CTG CTT T-BHQ1-3’, purchased from LGC BioSearch) has 5’ 
phosphorothioate bond linked 6-FAM fluorophore and 3’ phosphodiester bond 
linked black hole quencher 1 (BHQ1) modifications. It forms a blunt-ended hair-pin 
DNA structure with 6-FAM fluorescence quenched by BHQ1 (Figure 2.6). Briefly, 
25 pmol of 5’FAM-DNA-BHQ1-3’ was incubated with serial dilutions of hTDP1 at 
37°C in reaction buffer of 20 mM Tris-HCl, pH 8.0, 100 mM KCl, 10 mM EDTA, 10 
mM DTT, 0.05% TritonX-100 in a final volume of 25 µL. Fluorescence signal from 
each reaction was measured every 30 s for 500 min using the CFX96 Touch Real-
Time PCR Detection System (Bio-Rad, excitation 490 nm, emission 520 nm). The 
correlation between the amount of hTDP1 utilized, represent as fmol, and the initial 
linear slope (0-125 min) of fluorescence signal increase from each reaction is 
plotted as a standard curve. The TDP1 activity present in 2 µg of WCE was 
assayed under the same experimental conditions and calculated using the 
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standard curve as fmol/µg. The relative TDP1 activity level in each cell line was 
normalized by the TDP1 activity level in NHA.  
  
Figure 2.6. Diagram of fluorescence-based TDP1 activity assay 
 
Carboxylesterase 2 activity measurement 
        The assay of carboxylesterase 2 (CES2) activity in GBM WCE was carried 
out as described (97). Briefly, 6.7 µg of WCE from each cell line were preincubated 
in 96-well plates at 37°C for 10 min in a total volume of 20 µL of reaction buffer 
(100 mM Tris-HCl, pH 7.4) in presence or absence of 300 µM of CES2 inhibitor 
loperamide (LOP, Sigma). The reaction was initiated by adding 200 µL of 1.5 mM 
4-nitrophenyl acetate (p-NPA, Sigma) in reaction buffer and incubated at 37°C. 
Absorbance at 405 nm was recorded at 0, 5, 10, 20, 30, 40, 50, and 60 min. The 
amount of the reaction product para-nitrophenol (p-NP) formed was calculated 
using the standard curve generated with serial dilutions of p-NP (Sigma). The 
carboxylesterase activity from each microgram of WCE was represented as 
pmol/min/µg. The difference in activity obtained in the presence and absence of 
LOP was considered as CES2 activity (Figure 2.7). 
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Figure 2.7. Diagram of CES2 catalytic activity measurement 
 
Statistical analysis 
        Degree of correlations between two parameters tested in this study is 
determined by using the Pearson correlation coefficient value (R) and considered 
as significant for P < 0.05. GraphPad Prism version 8.0 was used to carry out the 
data analysis. 
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RESULTS AND DISCUSSION 
Variation of Irinotecan sensitivity among GBM cell lines 
        Nine different commercially available glioblastoma (GBM) cell lines (Table 2.1) 
were treated with serial diluted Irinotecan (IRT) and the cell viabilities were 
measured with the TO-PRO3 assay (Figure 2.8A). The IC50 values, defined as the 
concentration that induces 50% loss of viability, are listed in Table 2.4, column 1. 
Cells with the higher IC50s, such as SNB75 (IRT IC50 = 10.02 µM), are more 
resistant to drug treatment, whereas the cells with lower IC50s, such as SF539 (IRT 
IC50 = 1.91 µM), are more likely to respond to IRT treatment. Drug sensitivities data 
(Z-score) from the NCI-60 panel provided on CellMiner database 
(https://discover.nci.nih.gov/cellminer/) and the IC50s from Cancer Cell Line 
Encyclopedia (CCLE) panel provided on the CancerDR database 
(http://crdd.osdd.net/raghava/cancerdr/) are also listed in Table 2.4, column 3 and 
column 2, respectively. A higher Z-score indicates the cells are more sensitive to 
the drug treatment, such as SF539 (IRT, Z-score = 0.9367), while the lower Z-
score indicates that the cell lines are more resistant, such as SNB75 (IRT, Z-score 
= 0.1333). The significant correlation between experimental IRT IC50 and 
database-gathered IRT sensitivities demonstrates that the viability assay we used 
based on TO-PRO3 reagent is reliable (Figure 2.8, panels B, C). 
        The TOP1 expression level was first analyzed in the following section to 
identify biomarkers correlated with the variation of IRT sensitivities among GBM 
cell lines, 
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Table 2.4. Topoisomerase I/II inhibitors sensitivity data for GBM cell lines 
 
*1 Drug IC50 based on experimental results 
*2 Drug IC50 based on CancerDR Database  
*3Drug activity Z-score based on CellMiner Database 
N/A: not available 
 
  
Figure 2.8. Comparison of experimental IRT IC50s against GBM cell lines to 
IRT sensitivities from databases  
(A) The cell viabilities of GBM cell lines were measured by TO-PRO3 assay after 
72 h treatment with serial dilutions of IRT (0.05 µM to 15 µM). DMSO treatment 
was used as control. The IC50 values used for the correlation analysis are the 
average values of data collected from three individual experiments. (B) 
Experimental IC50 is significantly correlated with IC50 for CCLE panel provided on 
Irinotecan 
IC50(µM)
Irinotecan  
IC50(µM)
Irinotecan 
activity Z-score
Camptothecin 
activity Z-score
Topotecan 
activity Z-score
Etoposide 
activity Z-score
Doxorubicin 
activity Z-score
SF539 1.91 N/A 0.91 0.76 0.88 0.55 0.41
SF295 2.83 0.197 0.74 0.96 0.88 0.46 0.46
H4 2.98 N/A N/A*2 N/A N/A N/A N/A
SF268 3.66 N/A 0.81 0.97 0.88 0.05 0.02
SNB19 3.68 N/A 0.64 0.77 0.71 0.35 0.79
U251 5.15 N/A 0.78 0.98 0.88 0.51 0.8
A172 8.42 0.509 N/A N/A N/A N/A N/A
SNB75 10.02 N/A 0.24 0.12 0.5 0.08 0.53
U87 10.5 0.792 N/A N/A N/A N/A N/A
CellMiner databased *3
Topoisomerase I inhibitors Topoisomerase II inhibitorsCell lines
Experimental 
results*1
CancerDR 
database *2
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CancerDR database. (C) Experimental IC50 is significantly correlated with IRT 
sensitivity Z-score for NCI-60 panel from CellMiner database. 
 
TOP1 expression level is not correlated with GBM cell line sensitivities to 
Irinotecan 
        On the basis of the Coomassie blue staining following SDS-PAGE, total 
proteins found in 10 µg of whole cell extracts (WCEs) prepared from the GBM cell 
lines are comparable (Figure 2.9), which indicates that the expression level of 
individual proteins of interests among GBM cell lines can be compared by Western 
blot analysis of the WCEs. Cells were collected from three independent sets of 
cultures (set #1, set #2, set #3) along with fetal NHA (Normal Human Astrocyte). 
The TOP1 protein level in 10 µg of WCEs was measured by Western blotting 
(Figure 2.10, panels A1, B1, C1). The signal intensity was first normalized to actin 
signal to correct for loading, then divided by the NHA signal intensity for 
comparison. The data from each set were collected from at least three individual 
experiments. The TOP1 expression variations observed among the GBM cell lines 
are shown in Table 2.5. Results from GBM set #1 (Fig 2.10, panel A2) revealed 
that the GBM cell lines tested mostly had higher level of TOP1 protein expression 
than NHA (relative ratios ≥1). The TOP1 protein expression showed up to 2-fold 
variation (relative ratio from 0.98 to 1.96). Similar results were also observed in set 
#2 (Figure 2.10, panel B2) and set #3 GBM cell cultures (Figure 2.10, panel C2). 
The TOP1 relative expression levels measured ranged from 1.34 to 2.46 in the set 
#2 experiments, and from 1.16 to 2.20 in the set #3 experiments. The expression 
of TOP1 calculated from averaging the results of set #1, #2, and #3 (Figure 2.10, 
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panel D1), ranged from 1.14 to 1.97. According to our data, TOP1 expression level 
is comparable throughout experiments set #1, #2, and #3 which indicates the 
stability of cells cultured from three individual aliquots of cryopreserved GBM cells. 
In addition, elevated expression of TOP1 in GBM cell lines in comparison to NHA 
suggests that TOP1 is required for GBM proliferation and increased TOP1 target 
level might enhance the cytotoxicity from IRT treatment.  However, no significant 
correlation (R = -0.254, Figure 2.10, panel A3) was observed between the TOP1 
protein level in GBM set #1 with experimental IC50s. The lack of correlation 
between TOP1 protein level and IRT IC50s was also observed for data set #2 (R = 
0.189, Figure 2.10, panel B3), set #3 (R = -0.291, Figure 2.10, panel C3), as well 
as the average of TOP1 protein levels (R = -0.139, Figure 2.10, panel D2). 
Furthermore, the TOP1 protein levels measured here also showed no significant 
correlation with IRT sensitivities reported in databases (Figure 2.10, panel A4, B4, 
C4, D3). 
        An extensive analysis of TOP1 mRNA expression levels in GBM cell lines 
available from various cancer cell databases was conducted next to determine if 
there is any correlation with IRT IC50s. The CellMiner Cross Database 
(CellMinerCDB) (https://discover.nci.nih.gov/cellminercdb/) is a robust platform 
which provides pharmacogenomic data of cancer cell lines across different 
sources (18). We analyzed the TOP1 mRNA expression of GBM cell lines included 
in three separate panels (CCLE, NCI-60, and Genomics of Drug Sensitivity in 
Cancer (GDSC)) of CellMinerCDB. The mRNA expression level of TOP1 is 
available for 45 GBM cell lines included in the CCLE panel, 41 GBM cell lines 
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included in the GDSC panel, and 5 GBM cell lines included in the NCI-60 panel 
(Table 2.6). The TOP1 mRNA expression data from both CCLE and GDSC were 
analyzed against the IC50s provided in the CCLE database since no IRT drug 
sensitivity data is available in GDSC. Additionally, the mRNA expression from cell 
lines in the NCI-60 panel was compared with its Z-score provided by CellMiner 
database. Analysis of the TOP1 mRNA expression level and IRT drug sensitivities 
revealed that there is no significant correlation (Figure 2.11) as expected from our 
previous results which no correlation was obtained between TOP1 protein level 
and IRT IC50s. In addition, TOP1 protein level is not comparable with TOP1 mRNA 
expression level (Figure 2.12). 
        It can be concluded that TOP1 expression levels in GBM cell lines, measured 
for both protein and mRNA, do not correlate with IRT sensitivities. The TOP1 
protein needs to bind and cleave the DNA substrate before the TOP1cc can be 
trapped by inhibition of DNA rejoining by IRT. Therefore, GBM sensitivity to IRT 
may not only depend on the amount of TOP1 existing in cells but is more 
dependent on TOP1 activities. To further support our hypotheses about TOP1 
activity playing a more significant role in IRT drug sensitivity, TOP1 relaxation 
assay was conducted and the results will be discussed in the following section 
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Figure 2.9. Coomassie blue staining of GBM cell lines 
(A) For set #1 collection, the total proteins in 10 µg of WCEs of nine glioblastoma 
cell lines (SF295, SF269, SF539, SNB75, SNB19, U251, U87, A172, H4) as well 
as normal human astrocyte (NHA) were visualized by Coomassie blue staining 
following SDS PAGE. For (B) set #2 and (C) set #3 collections, the WCE proteins 
were also visualized by Coomassie blue staining. 
 
 
Table 2.5. Relative TOP1 protein expression level of GBM cell lines 
 
 
 
Cell lines Set #1, GBM Set #2, GBM Set #3, GBM Average of Set #1, 2, 3, GBM
SF539 1.259 ± 0.227 1.698 ± 0.548 1.886 ± 0.199 1.501 ± 0.415
SF295 1.387 ± 0.346 1.838 ± 0.226 1.501 ± 0.376 1.448 ± 0.360
H4 1.956 ± 0.277 2.125 ± 0.446 1.860 ± 0.186 1.974 ± 0.299
SF268 1.095 ± 0.248 1.489 ± 0.399 2.056 ± 0.435 1.374 ± 0.483
SNB19 1.652 ± 0.333 1.394 ± 0.441 2.198 ± 0.960 1.681 ± 0.500
U251 1.610 ± 0.362 1.738 ± 0.213 1.545 ± 0.366 1.623 ± 0.332
A172 0.977 ± 0.281 1.742 ± 0.144 1.563 ± 0.278 1.321 ± 0.430
SNB75 1.037 ± 0.253 1.340 ± 0.494 1.162 ± 0.344 1.136 ± 0.340
U87 1.686 ± 0.301 2.450 ± 0.681 2.134 ± 0.557 1.961 ± 0.546
Experimental TOP1 protein levels 
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Figure 2.10. Comparison of topoisomerase I protein level in GBM cell lines to assess potential correlation with 
Irinotecan sensitivities from experiments and databases 
(A1) The relative levels of TOP1 protein expression from set #1 GBM cell lines were measured by western blotting and 
normalized against NHA. The signal from actin was used to control the loading of 10 µg of WCE. For (B1) set #2 (C1) 
set #3, TOP1 protein expression levels were also detected by western blotting. (A2) TOP1 protein levels from set #1 
collection were higher than NHA (gray bar) (relative ratios >1). For (B2) set #2, (C2) set #3, and (D1) the average of 
TOP1 protein expression level, TOP1 protein expression in GBM cell lines was also observed to be higher than NHA. 
(A3) The relative TOP1 protein level from set #1 does not correlate with Irinotecan IC50. For (B3) set #2, (C3) set #3, 
(D2) and the average of TOP1 protein expression level from the 3 sets of experiments, the same insignificant correlations 
were observed. The (A4) set #1, (B4) set #2, (C4) set #3, and (D3) the average of TOP1 protein expression levels do 
not correlate with IRT Z-score from NCI-60 panel on the CellMiner database. 
SF295  SF268  SF539  SNB75 SNB19  NHA         SF295  U251  U87    A172    H4
TOP1
Actin
Set #2
SF295  SF268  SF539  SNB75 SNB19  NHA      SF295   U251    U87    A172     H4
TOP1
Actin
Set #3
C1
SF295  SF268  SF539  SNB75 SNB19  NHA        SF295   U251   U87    A172    H4
TOP1
Actin
Set #1
A1
C3
B1
A3 B3
C2A2 B2
D2
D1
C4A4 B4 D3
0 3 6 9 12
0
1
2
3
IC50 (µM)
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(S
et
 #
1)
A172 SNB75SF268
SF539
SF295
U251
SNB19
U87
H4
R=-0.254 (not significant)
0 3 6 9 12
0
1
2
3
4
IC50 (µM)
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(S
et
 #
2)
A172
SNB75
SF268
SF539
SF295
U251
SNB19
U87H4
R=0.189 (not significant)
0 3 6 9 12
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
IC50 (µM)
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(S
et
 #
3)
A172
SNB75
SF268
SF539
SF295
U251
SNB19
U87H4
R=-0.294 (not significant)
0 3 6 9 12
0.0
0.5
1.0
1.5
2.0
2.5
3.0
IC50 (µM)
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(A
ve
ra
ge
 o
f S
et
 #
1,
 2
, 3
)
A172
SNB75
SF268
SF539
SF295
U251
SNB19
U87
H4
R=-0.139 (not significant)
0.0 0.3 0.6 0.9 1.2
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Irinotecan senstivity Z-score
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(S
et
 #
1)
U251
SNB75 SF295
SNB19
SF268
R=0.330 (not significant)
SF539
0.0 0.3 0.6 0.9 1.2
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Irinotecan senstivity Z-score
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(S
et
 #
2)
U251
SNB75
SF295
SNB19
SF268
R=0.667 (not significant)
SF539
0.0 0.3 0.6 0.9 1.2
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Irinotecan senstivity Z-score
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(S
et
 #
3)
U251
SNB75
SF295
SNB19
SF268
R=0.604 (not significant)
SF539
H4 U8
7
SN
B1
9
U2
51
SF
29
5
SF
53
9
SF
26
8
SN
B7
5
NH
A
A1
72
0.0
0.5
1.0
1.5
2.0
2.5
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(S
et
 #
1)
1.96
1.09
1.69 1.65 1.61
1.39
1.26
0.981.04 1.0
U8
7 H4
SF
29
5
A1
72
U2
51
SF
53
9
SF
26
8
SN
B1
9
SN
B7
5
NH
A
0
1
2
3
4
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(S
et
 #
2)
2.46
1.49
2.12
1.84 1.74 1.73 1.70
1.0
1.39 1.34
SN
B1
9
U8
7
SF
26
8
SF
53
9 H4
A1
72
U2
51
SF
29
5
SN
B7
5
NH
A
0
1
2
3
4
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(S
et
 #
3)
2.20
1.55
2.13 2.06
1.89 1.86 1.56
1.0
1.50
1.16
0.0 0.3 0.6 0.9 1.2
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Irinotecan senstivity Z-score
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(A
ve
ra
ge
 o
f S
et
 #
1,
 2
, 3
)
U251
SNB75
SF295
SNB19
SF268
R=0.642 (not significant)
SF539
H4 U8
7
SN
B1
9
U2
51
SF
53
9
SF
29
5
SF
26
8
A1
72
SN
B7
5
0
1
2
3
R
el
at
iv
e 
TO
P1
 p
ro
te
in
 le
ve
l
(A
ve
ra
ge
 o
f S
et
 #
1,
 2
, 3
)
 41 
Table 2.6. The mRNA expression of TOP1 and TDP1 in GBM cell lines and 
their IRT IC50s available in the CellMinerCDB database  
 
 
 
Cell Line mRNA TOP1 mRNA TDP1 log(IC50) of 
Irinotecan
Cell Line mRNA TOP1 mRNA TDP1 Cell Line mRNA TOP1 mRNA TDP1 Z-score
SF539 9.347 7.136
SF-295 10.256 5.600 6.706 SF295 9.410 5.574 CNS:SF-295 8.460 6.992 0.740
H4 9.362 5.681 H4 9.298 6.920
SF268 9.681 8.242 CNS:SF-268 8.708 8.238 0.810
SNB-19 9.937 5.676 CNS:SNB-19 8.269 7.501 0.64
U-251 MG 9.027 5.660 U251 9.361 7.700 CNS:U251 7.877 7.649 0.780
A172 9.716 6.127 6.294 A172 9.361 7.392
SNB75 8.785 7.406 CNS:SNB-75 8.079 7.897 0.240
U-87 MG 10.004 6.073 6.101 U-87-MG 8.823 7.620
42-MG-BA 10.238 6.218 42-MG-BA 9.221 7.633
8-MG-BA 10.347 5.211 8-MG-BA 9.774 6.758
AM-38 10.224 6.451 AM-38 9.805 8.615
Becker 9.694 6.053 Becker 9.359 6.126
CAS-1 10.798 5.747 6.109 CAS-1 9.839 7.755
CCF-STTG1 9.279 5.961 CCF-STTG1 10.516 7.212
DBTRG-05MG 11.059 5.701 7.070 DBTRG-05MG 10.879 6.703
DK-MG 9.793 5.117 6.233 DK-MG 9.202 6.627
GB-1 9.906 6.126 7.104 GB-1 9.556 7.539
GI-1 10.360 6.021 GI-1 10.026 7.200
GMS-10 10.675 6.063 5.553 GMS-10 9.990 7.889
KNS-81 9.595 5.358 6.660 KNS-81-FD 9.465 6.324
KS-1 9.716 6.087 KS-1 8.679 7.038
LN-18 10.481 5.877 6.125 LN-18 9.738 8.313
LN-229 10.124 5.895 LN-229 9.990 7.839
SF126 9.742 6.132 6.902 SF126 9.851 7.980
SW 1088 10.108 5.817 SW1088 10.297 7.507
T98G 10.456 5.509 6.023 T98G 9.274 7.013
U-118 MG 9.849 5.516 6.719 U-118-MG 8.582 7.038
YH-13 9.435 5.650 YH-13 8.709 7.158
YKG1 10.640 5.557 5.766 YKG-1 9.261 5.912
D-247MG 9.783 7.912
D-263MG 9.608 8.006
D-392MG 9.465 7.087
D-423MG 9.849 7.842
D-542MG 8.618 7.263
D-566MG 9.968 8.242
LN-405 10.338 7.883
LNZTA3WT4 9.125 7.786
M059J 10.105 7.403
MOG-G-CCM 9.821 7.677
MOG-G-UVW 9.231 6.447
SK-MG-1 9.130 7.949
KG-1-C 10.719 5.253
KNS-60 9.502 6.078 6.360
LN-235 10.158 5.894
LN-319 9.932 6.317
LN-340 10.475 5.741
LN-443 10.638 6.597
LN382 10.487 5.587
LNZ308 9.648 5.919
M059K 10.289 6.203
SF-172 10.905 6.276
SNU-1105 9.359 6.191
SNU-201 9.286 5.464
SNU-466 9.192 5.783
SNU-489 9.417 5.664
SNU-626 9.742 5.160
U-138 MG 9.629 5.447
U-178 9.304 6.100
U343 10.283 5.641
Data from CellMinerCDB database
CCLE panel GDSC panel NCI-60 panel
Cellminer 
database 
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Figure 2.11. Lack of correlation between TOP1 mRNA expression data and 
Irinotecan IC50s against GBM cell lines from CellMinerCDB database.  
(A) The TOP1 mRNA expression in GBM cell lines (n = 15) does not correlate with 
IRT IC50s from the CCLE panel. (B) The TOP1 mRNA expression of GBM cell lines 
(n = 14) does not correlate with IRT IC50s from the GDSC panel. (C) The TOP1 
mRNA expression of GBM cell lines (n = 5) does not correspond with IRT IC50s 
from the NCI-60 panel.  
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Figure 2.12. Comparison of TOP1 protein level with TOP1 mRNA level.  
The average of TOP1 protein levels are not correlated with mRNA levels on (A) 
CCLE panel, (B) GDSC panel, and (C) NCI-60 panel.  
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TOP1 activity level in GBM cell lines does not correlate with Irinotecan 
sensitivities  
 
        The TOP1 catalytic activity present in WCE of GBM cell lines was assayed 
using negatively (-) supercoiled plasmid DNA as substrate. Human TOP1 belongs 
to the type IB topoisomerase family that does not require ATP or divalent metal 
ions for its catalytic activity (35). Therefore, cells were collected and lysed in RIPA 
buffer containing EDTA and EGTA to chelate the metal ions required for 
endogenous nuclease activities. In addition, EDTA was also included in the TOP1 
reaction buffer to suppress the activities from the metal ion-dependent type IA and 
type IIA topoisomerase activities present in WCE. The TOP1 relaxation activity 
from each GBM cell line was assayed with serial dilutions of WCE (from 5 ng to 
750 ng, Figure 2.14, panels A1, B1, C1). Recombinant human TOP1 (hTOP1) was 
used to generate a standard linear curve of the increase in the fraction of relaxed 
DNA with increasing level of TOP1 activity (Figure 2.13). The TOP1 activities were 
calculated using the standard curve. The relative activity levels were normalized 
to the TOP1 activity present in NHA. Both activity and relative activity levels of 
TOP1 are listed in Table 2.7.  
        The TOP1 activity measured in set #1 experiments (Fig 2.14, panel A2) 
showed that the majority of GBM cell lines tested had a higher level of TOP1 
activity than NHA (ranging from 0.79 to 1.57). Similar trends were observed in set 
#2 and #3, but the TOP1 activity measured in set #2 experiments (Figure 2.14, 
panel B2) has a broader range (relative activity levels from 0.21 to 2.83) than the 
TOP1 relative activity levels measured in set #3 experiments (Figure 2.14, panel 
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C2, from 1.06 to 3.09). The average of TOP1 activity level was calculated using 
the three sets of data (Figure 2.14, panel D2, ranging from 0.74 to 2.43). On the 
basis of these results, there is a more significant variation of TOP1 activity level 
among the three sets of data, despite the observed similarity in TOP1 protein 
expression levels. The TOP1 activity levels from set #1, #2, #3, and the average 
of TOP1 activity level (Figure 2.15) do not correlate with TOP1 protein levels, 
suggesting TOP1 activity in GBM is most likely to be modulated by post-
translational modifications as previously reported (92,102,103). There is also a 
lack of significant correlation between the TOP1 activity level and IRT IC50s (Figure 
2.14, panels A3, B3, C3, D3). Besides, the examination of TOP1 activity level 
against IRT sensitivities available from databases also showed that there was no 
significant correlation (Figure 2.14, panels A4, B4, C4, D4).  
        To sum up, the TOP1 activity level is not significantly correlated with 
Irinotecan sensitivities of GBM cell lines. However, it might be a better predictor of 
Irinotecan response than TOP1 protein level, due to TOP1 activity level is 
negatively correlated with IC50s throughout all sets of data. 
 
Figure 2.13. Topoisomerase I activity from recombinant human TOP1  
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(A) Negatively supercoiled plasmid DNA was relaxed with serial dilutions of 
recombinant hTOP1 (TopoGEN) and separated by electrophoresis in 1% agarose 
gel. SC: supercoiled DNA; R: relaxed DNA; PR: partially relaxed DNA. (B) The 
standard linear curve generated by quantitation of fraction of DNA relaxed by 
hTOP1 activity (U). 
 
Table 2.7. TOP1 activity and the relative TOP1 activity level of GBM cell lines 
 
 
TOP1 activity 
(U/µg)
Relative TOP1 
activity
TOP1 activity 
(U/µg)
Relative TOP1 
activity
TOP1 activity 
(U/µg)
Relative TOP1 
activity
TOP1 activity 
(U/µg)
Relative TOP1 
activity
SF539 0.661 ± 0.021 0.787 ± 0.026 1.739 ± 0.118 2.071 ± 0.141 1.941 ± 0.052 2.313 ± 0.063 1.402 ± 0.618 1.670 ± 0.736
SF295 1.021 ± 0.100 1.217 ± 0.119 2.380 ± 0.254 2.835 ± 0.303 2.590 ± 0.151 3.086 ± 0.180 2.037 ± 0.698 2.427 ± 0.831
H4 1.320 ± 0.104 1.572 ± 0.125 2.172 ± 0.131 2.587 ± 0.157 2.154 ± 0.202 2.566 ± 0.241 1.837 ± 0.449 2.189 ± 0.534
SF268 1.070 ± 0.106 1.275 ± 0.127 0.189 ± 0.015 0.226 ± 0.017 1.124 ± 0.110 1.340 ± 0.130 0.888 ± 0.409 1.058 ± 0.487
SNB19 1.239 ± 0.090 1.476 ± 0.107 1.887 ± 0.200 2.249 ± 0.238 2.451 ± 0.098 2.920 ± 0.117 1.905 ± 0.536 2.269 ± 0.639
U251 1.077 ± 0.112 1.283 ± 0.134 0.963 ± 0.147 1.147 ± 0.175 1.903 ± 0.204 2.267 ± 0.243 1.359 ± 0.474 1.620 ± 0.564
A172 0.878 ± 0.081 1.046 ± 0.096 1.250 ± 0.196 1.489 ± 0.233 1.778 ± 0.158 2.118 ± 0.189 1.256 ± 0.383 1.499 ± 0.456
SNB75 0.742 ± 0.018 0.884 ± 0.022 0.179 ± 0.007 0.214 ± 0.009 0.886 ± 0.022 1.056 ± 0.026 0.624 ± 0.315 0.744 ± 0.376
U87 0.832 ± 0.076 0.991 ± 0.091 0.535 ± 0.095 0.637 ± 0.113 1.966 ± 0.196 2.342 ± 0.234 1.050 ± 0.626 1.251 ± 0.746
Experimental TOP1 activity levels 
Cell 
lines
Set #1, GBM Set #2, GBM Set #3, GBM Average of Set #1, 2, 3, GBM
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Figure 2.14. Comparison of TOP1 activity in GBM cell lines to assess potential correlation with Irinotecan 
sensitivities from experiments and databases  
(A1) Negatively supercoiled plasmid DNA was relaxed by serial dilutions of WCE from GBM cells set #1 and separated 
by electrophoresis in 1% agarose gel. SC: supercoiled DNA, R: relaxed DNA, PR: partially relaxed DNA. For (B1) set 
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#2, and (C1) set #3 experiments, TOP1 activity was also measured by relaxation assay. (D1) Diagram of DNA relaxation 
by TOP1. (A2) TOP1 activity levels in the majority of set #1 GBM cell lines are higher than TOP1 protein level in NHA 
(grey bar) (relative ratios >1). (B2) Set #2, (C2) set #3, and (D2) the average of TOP1 activity from three sets have 
similar trends as in set #1. The (A3) set #1, (B3) set #2, (C3) set #3, and (D3) the average of TOP1 activity levels do 
not correlate with IRT IC50 values. The results shown for each set of data represent the average from three replicated 
measurements. The (A4) set #1, (B4) set #2, (C4) set #3, and (D4) the average of TOP1 activity expression levels do 
not correlate IRT Z-score from NCI-60 panel on CellMiner database. 
 
 
Figure 2.15. Lack of correlation between TOP1 protein levels and TOP1 activity levels 
The relative TOP1 protein level does not correlate with TOP1 activity level in (A) set #1, (B), set #2, (C) set #3, and (D) 
the average levels. 
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TDP1 expression level is moderately correlated with Irinotecan sensitivities 
among GBM cell lines 
         
        The TDP1 expression level in 10 µg of WCE was also measured by Western 
blotting to determine the expression variations (Figure 2.16, panels A1, B1, C1). 
The TDP1 protein expression level from set #1 (Fig 2.16, panel A2) revealed that, 
in contrary to TOP1 expression level, the majority of GBM cell lines had lower 
TDP1 expression level than NHA (relative ratios <1) (ranging from 0.57 to 1.10). 
Similar results were observed from experiments set #2 (Figure 2.16, panel B2) and 
set #3 (Figure 2.16, panel C2) with relative TDP1 expression level ranging from 
0.39 to 1.07 in set #2, and from 0.48 to 1.23 in set #3. The average of relative 
TDP1 protein expression level is calculated using the three sets of data (Figure 
2.16, panel D1) and ranges from 0.53 to 1.12. According to these data, the TDP1 
protein expression levels determined in each set of experiments are quite similar, 
indicating once again that the reproducibility of results from three individual aliquot 
of cryopreserved cells as described above. The relative protein level of TDP1 from 
three sets of GBM experiments are listed in Table 2.8.  
        Interestingly, the TDP1 expression level observed in the three sets of 
experiments showed significant and mostly moderate correlation with experimental 
IC50s (Figure 2.16, panels A3, B3, C3, D2). The down-regulated TDP1 protein 
expression level in GBM cell lines in comparison with NHA suggests that the GBM 
cell lines may benefit from IRT treatment. However, there is no consistent 
correlation between the TDP1 protein level and the IRT sensitivities available in 
the databases (Figure 2.16, panel A4, B4, C4, D4). In addition, TDP1 protein level 
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is not consistently comparable with TDP1 mRNA expression level (Figure 2.19) 
and no significant correlation was observed between TDP1 mRNA expressions 
and IRT sensitivities in GBM cell lines from CCLE (Figure 2.18, panel A), GDSC 
(Figure 2.18, panel B), as well as the NCI-60 (Figure 2.18, panel C) collections. 
We also concluded that there is no inherent correlation between TOP1 expression 
and TDP1 expression in both protein and mRNA levels (Figure 2.17). 
        In summary, the TDP1 expression is moderately correlated with IC50s in GBM 
cell lines and most likely to be a better predictor of Irinotecan response than TOP1 
expression or activity, as the TDP1 protein level associated significantly with IC50s 
throughout all three sets of experiments with GBM cell lines. A lower level of the 
TDP1 repair activity is expected to result in a higher degree of TOP1cc-induced 
cytotoxicity following IRT treatment.  However, the inconsistency of the correlation 
between TDP1 expression level with IRT sensitivity results in the databases 
indicated that TDP1 expression level might not be a reliable biomarker of GBM for 
IRT treatment. To further explore other potential biomarkers, TDP1 activities were 
measured in the following section.  
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Figure 2.16. Comparison of TDP1 protein levels in GBM cell lines to assess potential correlation with Irinotecan 
sensitivities from experiments and databases  
TDP1 protein expression from (A) set #1, (B) set #2, and (C) set #3 experiments on GBM cell lines were compared 
against NHA. Signal from actin was used to control loading of 10 µg of WCE. The majority of TDP1 protein levels from 
(A2) set #1, (B2) set #2, (C2) set #3, and (D1) the average of TDP1 protein expression are lower than TDP1 protein 
level in NHA (grey bar) (relative ratios <1). TDP1 protein level from (A3) set #1, (B3) set #2, and (D3) the relative TDP1 
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protein levels have moderate correlations with Irinotecan IC50. TDP1 protein levels from (C3) set #3 has a relatively 
strong correlation with Irinotecan IC50s The TDP1 protein levels reported for each data set represent the average of at 
least triplicated measurements. TDP1 protein level from (A3) set #1, (B3) set #2, and (D3) the relative TDP1 protein 
levels do not correlate with Irinotecan z-score from CellMiner database. TDP1 protein level from (C3) set #3 is correlated 
with and z-score from CellMiner database. 
 
 
Figure 2.17. Comparison of TOP1 level with TDP1 level  
(A) The average of TOP1 protein level is not associated with the average of TDP1 protein level. (B) On CCLE panel, 
TOP1 mRNA expression level is not associated with TDP1 mRNA expression level. (EC On GDSC panel, TOP1 mRNA 
expression level is not associated with TDP1 mRNA expression level. (D) On NCI-60 panel, TOP1 mRNA expression 
level is not associated with TDP1 mRNA expression level. 
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Figure 2.18. Comparison of TOP1 mRNA expression and Irinotecan IC50s 
against GBM cell lines from CellMinerCDB database 
(A) The TOP1 mRNA expression of GBM cell lines (n = 15) is not correlated with 
IRT IC50s from CCLE panel. (B) The TOP1 mRNA expression of GBM cell lines (n 
= 14) is not correlated with IRT IC50s from GDSC panel. (C) The TOP1 mRNA 
expression of GBM cell lines (n = 5) is not correlated with IRT IC50s from NCI-60 
panel.  
  
A1 A2
B1 B2
C1 C2
5.1 5.4 5.7 6.0 6.3 6.6 6.9 7.2 7.5 7.8
4.5
5.0
5.5
6.0
6.5
7.0
-log10(IC50) of Irinotecan
lo
g 2
(m
R
N
A
 In
t.)
 o
f T
D
P
1 
(C
C
LE
)
R=0.036 (n = 15, not significant)
GB
-1
DB
TR
G-
05
MG
SF
12
6
U-
11
8-
MG
SF
29
5
KN
S-
81
-F
D
A1
72
DK
-M
G
LN
-1
8
CA
S-
1
U-
87
-M
G
T9
8G
YK
G-
1
GM
S-
10
4
5
6
7
8
lo
g 2
(m
R
N
A
 In
t.)
 o
f T
D
P
1 
(G
D
S
C
)
5.6        to      7.1
SF
12
6
A1
72
GB
-1
KN
S-
60
U-
87
 M
G
GM
S-
10
LN
-1
8
CA
S-
1
DB
TR
G-
05
MG
SF
-2
95
YK
G1
U-
11
8 M
G
T9
8G
KN
S-
81
DK
-M
G
4
5
6
7
lo
g 2
(m
R
N
A
 In
t.)
 o
f T
D
P
1 
(C
C
LE
)
5.1        to      6.1
CN
S:
SF
-2
68
CN
S:
SN
B-
75
CN
S:
U2
51
CN
S:
SN
B-
19
CN
S:
SF
-2
95
6
7
8
9
lo
g 2
(m
R
N
A
 In
t.)
 o
f T
D
P
1 
(N
C
I-6
0)
7.0        to      8.2
0.0 0.3 0.6 0.9 1.2
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
Irinotecan senstivity Z-score
lo
g 2
(m
R
N
A
 In
t.)
 o
f T
D
P
1 
(N
C
I-6
0)
R=-0.149 (n = 5, not significant)
5 6 7 8 9
5.0
5.5
6.0
6.5
7.0
7.5
8.0
-log10(IC50) of Irinotecan
lo
g 2
(m
R
N
A
 In
t.)
 o
f T
D
P
1 
(G
D
S
C
)
R= -0.140 (n = 14, not significant)
 54 
Table 2.8. Relative TDP1 protein expression level in GBM cell lines 
 
 
 
 
 
Figure 2.19. Comparison of TDP1 protein level with TDP1 mRNA level 
The average of TDP1 protein level is not associated with mRNA levels on (B) 
GDSC and (C) NCI-60 panels. The average of TDP1 protein level is significantly 
correlated with mRNA levels on (A) CCLE panel. 
 
 
 
 
Cell lines Set #1, GBM Set #2, GBM Set #3, GBM Average of Set #1, 2, 3, GBM
SF539 0.751 ± 0.119 0.560 ± 0.125 0.547 ± 0.098 0.639 ± 0.148
SF295 0.636 ± 0.194 0.443 ± 0.121 0.495 ± 0.081 0.573 ± 0.185
H4 0.766 ± 0.177 0.749 ± 0.356 0.493 ± 0.091 0.706 ± 0.251
SF268 0.671 ± 0.141 0.617 ± 0.183 0.596 ± 0.056 0.638 ± 0.140
SNB19 0.570 ± 0.059 0.538 ± 0.182 0.480 ± 0.055 0.541 ± 0.112
U251 0.595 ± 0.116 0.391 ± 0.217 0.590 ± 0.168 0.526 ± 0.182
A172 0.867 ± 0.204 0.961 ± 0.319 0.853 ± 0.370 0.885 ± 0.267
SNB75 0.913 ± 0.081 0.806 ± 0.270 1.094 ± 0.339 0.914 ± 0.226
U87 1.099 ± 0.248 1.074 ± 0.343 1.232 ± 0.319 1.124 ± 0.278
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TDP1 activity level is moderately correlated with Irinotecan sensitivities 
among GBM cell lines 
 
        Two approaches were applied to measure TDP1 catalytic activity in WCEs of 
GBM cell lines. Previous studies have demonstrated that human TDP1 is an ATP- 
and divalent ion-independent enzyme that can hydrolyze the phosphotyrosyl-
linkage at the 3’ end of DNA (69). Therefore, both RIPA lysis buffer and TDP1 
reaction buffers were supplemented with EDTA to suppress the activities from 
metal ion-dependent exonucleases present. In addition, TDP1 can act as a broad-
spectrum 3’ exonuclease which is able to hydrolyze various phosphodiester 
linkages at the 3’ ends of DNA and its activity is efficient on single-stranded or 
blunt-ended oligonucleotides without sequence specificity (36,69,104). Thus, we 
conducted a traditional gel-based assay that utilizes a 5’-32P labeled single-
stranded oligonucleotide with a 3’ tyrosine modification (P12Y) as substrate (Fig 
2.22, panel D1) and also an alternative fluorescence-based assay using a blunt-
ended oligonucleotide with a 5’ fluorophore (6FAM) and a 3’ quencher (BHQ1) 
modifications as a substrate (Fig 2.23, panel D1) (101). The fluorescence signal is 
suppressed as a result of the hairpin structure formed by this oligonucleotide 
substrate. Recombinant human TDP1 (hTDP1) was used to generate the standard 
linear curve for the increase in fraction of cleaved DNA (P12) with increasing level 
of TDP1 activity measured by the gel-based assay (Figure 2.20, panels A, B), and 
also for the increase in fluorescence signal (ΔF/min) measured by the 
fluorescence-based assay (Figure 2.20, panels C, D). The TDP1 activities in the 
GBM cell lines WCEs were calculated using standard curves and the TDP1 
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activities measured by both assays were normalized by the TDP1 activity level in 
NHA. The activity and relative activity of TDP1 from the gel-based assay and the 
fluorescence-based assay are listed in Table 2.9 and 2.10, respectively.  
        The two assays showed outstanding correlations with each other in results 
from set #1 experiments (R = 0.968, P = 4.7 × 10-6), set #2 experiments (R = 0.914, 
P = 0.0002), set #3 experiments (R = 0.897, P = 0.0004), as well as the average 
of TDP1 activities from all three set of experiments (R = 0.943, P = 4.4 × 10-5), 
demonstrating the similar capabilities of the two assays for measuring TDP1 
activities in vitro (Figure 2.24). In addition, the activities of TDP1 from gel-based 
and fluorescence-based assay have an approximate 1:1 ratio in set #1 (y = 
0.9854x), set #2 (y = 0.9059x), set #3 (y = 0.9405x), as well as average of TDP1 
activities (y = 0.9333x), further demonstrating that the two assays produce 
comparable results for TDP1 activity measurements (Figure 2.24). The 
fluorescence-based assay has the advantage of not requiring the handling of 
radioactive material and can also be easily adapted for high throughput 
measurements. 
        The results from set #1 experiments showed that the GBM cell lines had a 
lower level of TDP1 activity than NHA, with relative TDP1 activity levels from the 
fluorescence-based assay ranging from 0.23 to 0.71 (Figure 2.23, panel A2) while 
the relative TDP1 levels from the gel-based assay ranged from 0.21 to 0.80 (Figure 
2.22, panel A2). The relative TDP activity levels in set #2 experiments measured 
by the fluorescence-based assay ranged from 0.22 to 0.96 (Figure 2.23, panel B2), 
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and ranged from 0.11 to 1.26 in the gel-based assay (Figure 2.22, panel B2). The 
relative TDP1 activity levels measured in set #3 experiments by the gel-based 
assay ranged from 0.42 to 1.19 (Figure 2.22, panel C2), and ranged from 0.20 to 
1.17 in the gel-based assay (Figure 2.23, panel C2). The average TDP1 activity 
level for each cell line is calculated using the three individual sets of experiments 
and ranged from 0.36 to 0.99 and from 0.38 to 0.87(Figure 2.22, panel D2; Figure 
2.23, panel D2). On the basis of our data, TDP1 activity levels correlate moderately 
with TDP1 protein levels measured (Figure 2.25, panels A1, C2, D2). However, 
inconsistent correlations between TDP1 activities and protein expressions were 
also observed (Figure 2.18, panels A2, B1, B2, C1, D1), suggesting that TDP1 
protein level might not always represent the TDP1 activity in cells. We also 
concluded that there is no inherent correlation between TOP1 and TDP1 activities 
in GBM cell lines, suggesting TDP1 activity level, acting differently from TOP1 
activity level, is worth to compare with IRT sensitivities (Figure 2.21). We then 
assessed if there is any correlation between TDP1 activities and IRT sensitivities. 
We found that although set #1 TDP1 activity levels from gel-based assay (Figure 
2.22, panel A3) and the majority of TDP1 activity levels from fluorescence-based 
assay  (Figure 2.23, panels A3, C3, D3) could correlate significantly with 
experimental IC50s, insignificant correlations were sometimes observed (Figure 
2.22, panels B3, C3, D3, Figure 2.23, panel B3). Moreover, the significant 
correlations between TDP1 activities and IRT sensitivity values in the databases 
were not consistently observed (Figure 2.22 and 2.23, panels A4, B4, C4, D4). 
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        In summary, similar to the relative TDP1 protein levels, the relative TDP1 
activity levels in GBM cell lines also show moderate correlation with Irinotecan 
sensitivities. Still, TDP1 activity level might not be a consistent biomarker for 
prediction of IRT sensitivity. Therefore, we started to incorporate both TOP1 and 
TDP1 as contributing factor which modulates the IRT response in GBM cell lines.  
Table 2.9. TDP1 activity and relative TDP1 activity levels in GBM cell lines 
 
 
Table 2.10. TDP1 activity and relative TDP1 activity levels in GBM cell lines 
 
TDP1 activity 
(fmol/µg)
Relative TDP1 
activity
TDP1 activity 
(fmol/µg)
Relative TDP1 
activity
TDP1 activity 
(fmol/µg)
Relative TDP1 
activity
TDP1 activity 
(fmol/µg)
Relative TDP1 
activity
SF539 0.441 ± 0.144 0.215 ± 0.070 1.084 ± 0.170 0.529 ± 0.083 0.985 ± 0.112 0.481 ± 0.054 0.780 ± 0.335 0.381 ± 0.163
SF295 0.917 ± 0.067 0.447 ± 0.032 1.344 ± 0.151 0.656 ± 0.074 1.261 ± 0.133 0.615 ± 0.065 1.137 ± 0.227 0.555 ± 0.111
H4 1.426 ± 0.655 0.696 ± 0.320 1.409 ± 0.235 0.688 ± 0.115 1.401 ± 0.115 0.684 ± 0.056 1.413 ± 0.400 0.690 ± 0.195
SF268 0.970 ± 0.303 0.473 ± 0.148 0.235 ± 0.044 0.114 ± 0.022 0.858 ± 0.130 0.419 ± 0.063 0.728 ± 0.383 0.355 ± 0.187
SNB19 0.908 ± 0.116 0.443 ± 0.056 1.010 ± 0.172 0.493 ± 0.084 1.017 ± 0.134 0.496 ± 0.066 0.985 ± 0.139 0.481 ± 0.068
U251 0.794 ± 0.125 0.388 ± 0.061 1.363 ± 0.216 0.666 ± 0.106 1.310 ± 0.184 0.637 ± 0.090 1.187 ± 0.302 0.579 ± 0.148
A172 1.273 ± 0.397 0.621 ± 0.194 2.589 ± 0.251 1.264 ± 0.123 2.431 ± 0.272 1.187 ± 0.133 2.034 ± 0.695 0.993 ± 0.339
SNB75 1.248 ± 0.133 0.609 ± 0.065 0.785 ± 0.146 0.383 ± 0.071 0.877 ± 0.141 0.428 ± 0.069 0.945 ± 0.236 0.461 ± 0.115
U87 1.638 ± 0.359 0.800 ± 0.175 1.792 ± 0.256 0.875 ± 0.125 2.331 ± 0.310 1.138 ± 0.151 1.899 ± 0.422 0.927 ± 0.206
Experimental TDP1 activity level by gel-based assay
Cell 
lines
Set #1, GBM Set #2, GBM Set #3, GBM Average of Set #1, 2, 3, GBM
TDP1 activity 
(fmol/µg)
Relative TDP1 
activity
TDP1 activity 
(fmol/µg)
Relative TDP1 
activity
TDP1 activity 
(fmol/µg)
Relative TDP1 
activity
TDP1 activity 
(fmol/µg)
Relative TDP1 
activity
SF539 0.564 ± 0.130 0.234 ± 0.054 1.501 ± 0.111 0.622 ± 0.046 0.907 ± 0.018 0.376 ± 0.007 0.948 ± 0.420 0.393 ± 0.174
SF295 1.067 ± 0.053 0.442 ± 0.022 1.315 ± 0.090 0.545 ± 0.037 1.010 ± 0.011 0.419 ± 0.005 1.114 ± 0.134 0.462 ± 0.056
H4 1.452 ± 0.135 0.602 ± 0.056 1.091 ± 0.067 0.453 ± 0.028 1.025 ± 0.082 0.425 ± 0.034 1.255 ± 0.231 0.520 ± 0.096
SF268 1.340 ± 0.052 0.556 ± 0.022 0.530 ± 0.054 0.220 ± 0.022 0.491 ± 0.017 0.204 ± 0.007 0.925 ± 0.435 0.384 ± 0.180
SNB19 1.092 ± 0.113 0.453 ± 0.047 1.236 ± 0.047 0.512 ± 0.020 0.990 ± 0.049 0.411 ± 0.020 1.102 ± 0.122 0.457 ± 0.051
U251 0.904 ± 0.059 0.375 ± 0.025 1.745 ± 0.141 0.724 ± 0.059 1.676 ± 0.059 0.695 ± 0.025 1.308 ± 0.429 0.542 ± 0.178
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Figure 2.20. Tyrosyl-DNA phosphodiesterase 1 activity from recombinant 
human TDP1 
(A) Gel-based assay for the conversion of radiolabeled P12Y DNA substrate into 
P12 product under serial dilutions of recombinant hTDP1 (B) The standard curve 
for fraction of DNA substrate cleaved by increasing amounts of TDP1. (C) 
Fluorescence-based assay for the increase in FL-signal under serial dilutions of 
recombinant hTDP1. (D) The standard curve generated using the initial velocity of 
fluorescence increase. 
 
 
Figure 2.21. Comparison of TOP1 activity level with TDP1 activity level  
The average of relative TOP1 activity level is not associated with TDP1 activity by 
both (A) gel-based and (B) fluorescence-based assays. 
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Figure 2.22. Comparison of TDP1 activity by gel-based assay in GBM cell lines to assess potential correlation 
with Irinotecan sensitivities from experiments and databases 
TDP1 activity levels from 2 µg of GBM WCE from (A1) set #1, (B1) set #2, and (C1) set #3 experiments were conducted 
by gel-based assay. P12Y: radiolabeled DNA substrate (5'-32P-GAA AAA AGA GTT-PO4-Tyr-3'); P12: product by TDP1 
(5'-32P -GAA AAA AGA GTT-OH-3'). (D1) Diagram of TDP1 activity measurement by gel-based assay. (A2) TDP1 activity 
levels in set #1 GBM cell lines are all lower than TDP1 activity level in NHA (grey bar) (relative ratios <1). The (B2) set 
#2, (C2) set #3, and (D2) the average of TDP1 activity from three sets have similar trends as in set #1. TDP1 activity 
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level from (B3) set #2, (C3) set #3, and (D3) the relative TDP1 activity levels do not correlate with Irinotecan IC50. TDP1 
protein levels from (A3) set #1 has a moderate correlation with Irinotecan IC50s. TDP1 protein level from (B3) set #2, 
(C3) set #3, and (D3) the average of relative TDP1 activity levels do not correlate with Z-score from CellMiner 
database.TDP1 protein levels from (A3) set #1 has a moderate correlation with Z-score from CellMiner database. 
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Figure 2.23. Comparison of TDP1 activity by fluorescence-based assay in GBM cell lines to assess potential 
correlation with Irinotecan sensitivities from experiments and databases 
TDP1 activity levels from 2 µg of GBM WCE from (A1) set #1, (B1) set #2, and (C1) set #3 experiments were conducted 
by fluorescence-based assay. (D1) Diagram of TDP1 activity measurement by fluorescence-based assay. (A2) TDP1 
activity levels in set #1 GBM cell lines are all lower than TDP1 activity level in NHA (grey bar) (relative ratios <1). The 
(B2) set #2, (C2) set #3, and (D2) the average of TDP1 activity from three sets have similar trends as in set #1. TDP1 
activity level from (A3) set #1, (C3) set #3, and (D3) the relative TDP1 activity levels do not correlate with Irinotecan IC50. 
TDP1 protein levels from (B3) set #2 has a moderate correlation with Irinotecan IC50s. TDP1 protein level from (A3) set 
#1, (B3) set #2, (C3) set #3, and (D3) the average of relative TDP1 activity levels do not correlate with Z-score from 
CellMiner database. 
 
 
 
Figure 2.24. Comparison of gel-based and fluorescence-based assays for TDP1 activity measurement 
Strong correlations of TDP1 activity level in GBM WCE were observed from (A) set #1, (B) set #2, (C) set #3, and (D3) 
the average of relative TDP1 activity levels measured by gel-based and fluorescence-based assay protocols. 
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Figure 2.25. Correlation between TDP1 protein levels and TOP1 activity levels  
The relative TDP1 protein level does not correlate with gel-based TDP1 activity level in (B1) set #2, (C1), set #3, and 
(D1) the average of relative TDP1 activity levels, and fluorescence-based TDP1 activity in (A2) set #1 and (B2) set #2. 
The relative TDP1 protein level is moderately correlated with gel-based TDP1 activity level in (A1) set #1, and 
fluorescence-based TDP1 activity in (C2) set #3 and (D2) the average of relative TDP1 activity levels. 
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TDP1/TOP1 activity ratio has the strongest correlation with Irinotecan 
sensitivities in GBM cell lines 
 
        Our studies above have demonstrated that protein expression level, mRNA 
level, and activity level of TOP1 and TDP1 alone does not function consistently as 
a predictor of the sensitivity of GBM cell lines to Irinotecan treatment. To further 
identify more promising predictive indicators, we calculated the TDP1/TOP1 
protein ratio and activity ratio from each set of experiments conducted with the 
GBM cell lines (Table 2.11). The TDP1/TOP1 mRNA ratio available for GBM cell 
lines was extracted from the databases (Table 2.12). 
        Variations in TDP1/TOP1 protein ratio were observed among the GBM cell 
lines (Figure 2.26). The results revealed that the GBM cell lines tested all had lower 
level of TDP1/TOP1 protein ratio than NHA (relative ratios <1). The TDP1/TOP1 
protein ratio ranged from 0.36 to 0.93 in set #1 experiments (Figure 2.26, panel 
A1), from 0.23 to 0.67 in set #2 experiments (Figure 2.26, panel B1), from 0.26 to 
1.01 in set #3 experiments (Figure 2.26, panel C1), and from 0.36 to 0.88 for the 
average from all three sets of experiments (Figure 2.26, panel D1). According to 
our results, TDP1/TOP1 protein expression ratios are comparable among the 
different sets of cultured GBM cells. The experimental IC50s for Irinotecan showed 
significant correlation with the TDP1/TOP1 protein ratios from set #1 experiments 
(R = 0.696, P = 0.037, Figure 2.26, panel A2), set #2 experiments (R = 0.698, P = 
0.037, Figure 2.26, panel B2),  set #3 experiments (R = 0.862, P = 0.003, Figure 
2.26, panel C2),  as well as the average of TDP1/TOP1 protein ratios from all three 
sets of experiments (R = 0.744, P = 0.02, Figure 2.26, panel D2). However, the 
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correlation of TDP1/TOP1 protein ratio with Irinotecan sensitivities available in the 
database is still inconsistent (Figure 2.26, panels A3, B3, C3, D3; Figure 2.32, 
panel A).  
        We continued our analysis on TDP1/TOP1 mRNA expression ratio in GBM 
cell lines to assess potential correlation with Irinotecan sensitivities against GBM 
cell lines from information available in CellMinerCDB databases which provide 
results from three different cancer cell panels (CCLE, GDSC, and NCI-60). The 
TDP1/TOP1 mRNA ratio ranged from 0.49 to 0.66 in CCLE (Figure 2.27, panel 
A1), from 0.59 to 0.88 in GDSC (Figure 2.27, panel B1), from 0.83 to 0.98 in NCI-
60 (Figure 2.27, panel C1), revealing the TDP1/TOP1 mRNA ratio has much lower 
variations among GBM cell lines in comparison to TDP1/TOP1 protein ratio. In 
addition, TDP1/TOP1 mRNA ratio is not comparable with TDP1/TOP1 protein ratio 
(Figure 2.28) and no significant correlation was observed between TDP1/TOP1 
mRNA ratio and IRT sensitivities in GBM cell lines from CCLE (Figure 2.27, panel 
A2), GDSC (Figure 2.27, panel B2), and the NCI-60 (Figure 2.27, panel C2) 
collections. 
        Next, we focused on gel-based TDP1/TOP1 activity ratio. Variations in the 
activity ratio were observed among the GBM cell lines (Figure 2.29). Similar to 
TDP1/TOP1 protein ratio, the majority of GBM cell lines tested had a lower relative 
activity ratio than NHA (relative ratios <1). The gel-based TDP1/TOP1 activity ratio 
ranged from 0.30 to 0.72 in set #1 experiments (Figure 2.29, panel A1), from 0.18 
to 1.98 in set #2 experiments (Figure 2.29, panel B1), from 0.14 to 0.65 in set #3 
 66 
experiments (Figure 2.29, panel C1), from 0.22 to 0.94 for the average from all 
three set of experiments (Figure 2.29, panel D1). Although the gel-based 
TDP1/TOP1 activity ratio had relatively large variations among different sets of 
GBM cell experiments in comparison to TDP1/TOP1 protein ratio, the majority of 
TDP1/TOP1 activity ratios are moderately correlated with TDP1/TOP1 protein 
ratios (Figure 2.31, panels A1, D1). In addition, TDP1/TOP1 activity ratios in each 
set of experiment maintain significant correlations with the measured Irinotecan 
IC50s. Very strong correlations were observed in set #1 (R = 0.917, P = 0.0005, 
Figure 2.29, panel A2), set #2 (R = 0.940, P = 0.0002, Figure 2.29, panel B2),  set 
#3 (R = 0.860, P = 0.003, Figure 2.29, panel C2),  and the average of activity ratio 
from all three sets of experiments (R = 0.972, P =1.2 × 10-5, Figure 2.29, panel D2). 
Strikingly, the majority of gel-based TDP1/TOP1 activity ratio also correlates 
consistently with Irinotecan sensitivities found in the databases (Figure 2.29, 
panels A3, B3, D3; Figure 2.32, panel B).  
        The fluorescence-based TDP1/TOP1 activity ratio showed similar variations 
among the GBM cell lines as the gel-based assay described above. The activity 
ratio ranged from 0.30 to 0.72 in set #1 experiments (Figure 2.30, panel A1), from 
0.18 to 1.98 in set #2 experiments (Figure 2.30, panel B1), from 0.14 to 0.65 in set 
#3 experiments (Figure 2.30, panel C1), and from 0.24 to 0.99 for the average 
activity ratio of TDP1/TOP1 based on all three sets of experiments (Figure 2.30, 
panel D1). Although the fluorescence-based TDP1/TOP1 activity ratio had 
relatively large variations between different sets of GBM cell experiments in 
comparison to TDP1/TOP1 protein ratio, all of the TDP1/TOP1 activity ratios are 
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significantly correlated with TDP1/TOP1 protein ratios (Figure 2.31, panels A2, B2, 
C2, D2). Besides, the fluorescence-based activity ratios measured in all three sets 
could correlate significantly with experimental IC50s as gel-based activity ratios. 
Strong correlations were observed in set #1 (R = 0.922, P = 0.0004, Figure 2.30, 
panel A2), set #2 (R = 0.827, P = 0.006, Figure 2.30, panel B2),  set #3 (R = 0.953, 
P = 6.8 × 10-5, Figure 2.30, panel C2),  and the average of activity ratio (R = 0.952, 
P =7.7 × 10-5, Figure 2.30. panel D2). In addition, both the fluorescence-based 
TDP1/TOP1 activity ratios also correlate with Irinotecan sensitivities from 
databases (Figure 2.30, panels A3, C3, D3; Figure 2.32, panel C). 
         In summary, the TDP1/TOP1 mRNA ratio is not a useful biomarker for 
predicting GBM cell lines sensitivity to Irinotecan treatment. Both the TDP1/TOP1 
protein ratio and TDP1/TOP1 activity ratio correlate significantly and consistently 
with Irinotecan sensitivities, whereas TDP1/TOP1 activity ratio has a stronger 
correlation compared to the TDP1/TOP1 protein ratio.  
        The relatively lower TDP1/TOP1 activity ratio in GBM cell lines in comparison 
with TDP1/TOP1 activity ratio in NHA demonstrated that GBM has a lower capacity 
to counter the toxicity induced by TOP1 poison inhibitors. Consequently, TOP1 
inhibitor treatment is more likely to result in a stronger cytotoxic effect on GBM 
cancer cells compared to normal astrocyte cells. To further explore this, we 
assessed the correlation between TDP1/TOP1 activity ratio with the Z-scores of 
GBM treatment with two other TOP1 poisons, camptothecin (CPT) and topotecan 
(TPT) (Table 4, column 4 and 5). Topoisomerase II inhibitors, etoposide (ETP) and 
doxorubicin (DOX) (Table 4, column 6 and 7), were used as negative controls. 
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Interestingly, significant correlations between TDP1/TOP1 activity ratio and Z-
scores for GBM cancers were observed for both CPT and TPT (Figure 2.33A and 
B), whereas no such correlation was observed for topoisomerase II inhibitors 
(Figure 2.33C and D). These observations furthered supported our finding that the 
outcome of GBM cell lines treatment by topoisomerase I poison is influenced 
significantly by the TDP1/TOP1 activity ratio. The results suggested that TOP1 
poisons may be promising for the treatment of certain GBM cancers, and the 
development of TDP1 inhibitors might help improve the efficacy of GBM treatment. 
        In conclusion, TDP1/TOP1 activity ratio might be a useful predictive 
biomarker for GBM treatment with Irinotecan. To further support our finding, 
increase in TOP1cc level following IRT treatment were measured and correlated 
with TDP1/TOP1 ratios in the following section. 
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Table 2.11. TDP1/TOP1 protein ratio and TDP1/TOP1 activity ratio of GBM cell 
lines 
 
  
TDP1/TOP1 
protein ratio
TDP1/TOP1 
protein ratio
Western blotting Gel-based assay FL-based assay Western blotting Gel-based assay FL-based assay
SF539 0.614 ± 0.138 0.273 ± 0.084 0.297 ± 0.062 0.367 ± 0.161 0.256 ± 0.039 0.301 ± 0.026
SF295 0.493 ± 0.209 0.370 ± 0.040 0.366 ± 0.035 0.244 ± 0.068 0.234 ± 0.034 0.194 ± 0.024
H4 0.399 ± 0.101 0.445 ± 0.189 0.385 ± 0.042 0.364 ± 0.174 0.267 ± 0.042 0.174 ± 0.013
SF268 0.641 ± 0.178 0.374 ± 0.115 0.439 ± 0.045 0.433 ± 0.148 0.510 ± 0.093 0.978 ± 0.107
SNB19 0.360 ± 0.087 0.302 ± 0.038 0.308 ± 0.036 0.415 ± 0.175 0.221 ± 0.041 0.230 ± 0.025
U251 0.388 ± 0.113 0.305 ± 0.050 0.295 ± 0.033 0.228 ± 0.120 0.590 ± 0.113 0.641 ± 0.094
A172 0.954 ± 0.343 0.597 ± 0.178 0.662 ± 0.093 0.555 ± 0.197 0.867 ± 0.155 0.658 ± 0.105
SNB75 0.929 ± 0.234 0.690 ± 0.065 0.700 ± 0.040 0.673 ± 0.317 1.797 ± 0.307 1.975 ± 0.252
U87 0.677 ± 0.205 0.812 ± 0.176 0.716 ± 0.070 0.459 ± 0.162 1.413 ± 0.319 1.390 ± 0.273
TDP1/TOP1 
protein ratio
TDP1/TOP1 
protein ratio
Western blotting Gel-based assay FL-based assay Western blotting Gel-based assay FL-based assay
SF539 0.292 ± 0.053 0.208 ± 0.0215 0.163 ± 0.005 0.512 ± 0.191 0.249 ± 0.068 0.253 ± 0.078
SF295 0.343 ± 0.084 0.200 ± 0.022 0.136 ± 0.007 0.478 ± 0.210 0.279 ± 0.080 0.261 ± 0.101
H4 0.267 ± 0.049 0.268 ± 0.030 0.167 ± 0.018 0.385 ± 0.117 0.345 ± 0.154 0.289 ± 0.113
SF268 0.300 ± 0.065 0.315 ± 0.051 0.153 ± 0.014 0.563 ± 0.210 0.381 ± 0.116 0.450 ± 0.274
SNB19 0.259 ± 0.127 0.170 ± 0.021 0.141 ± 0.008 0.361 ± 0.113 0.220 ± 0.062 0.240 ± 0.077
U251 0.397 ± 0.133 0.284 ± 0.045 0.309 ± 0.032 0.365 ± 0.128 0.391 ± 0.160 0.380 ± 0.155
A172 0.558 ± 0.230 0.563 ± 0.071 0.542 ± 0.044 0.835 ± 0.360 0.693 ± 0.203 0.638 ± 0.100
SNB75 1.013 ± 0.422 0.406 ± 0.059 0.653 ± 0.039 0.881 ± 0.295 0.940 ± 0.648 0.986 ± 0.568
U87 0.607 ± 0.206 0.490 ± 0.075 0.505 ± 0.050 0.618 ± 0.215 0.926 ± 0.426 0.849 ± 0.367
Set #3, GBM Average of Set #1, 2, 3, GBM
TDP1/TOP1 activity ratio TDP1/TOP1 activity ratio
Experimental TDP1/TOP1 ratio
Cell lines
Cell lines
TDP1/TOP1 activity ratio TDP1/TOP1 activity ratio
Set #2, GBMSet #1, GBM
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Table 2.12. TDP1/TOP1 protein ratio and TDP1/TOP1 activity ratio of GBM cell 
lines 
 
Cell Line TDP1/TOP1 Cell Line TDP1/TOP1 Cell Line TDP1/TOP1
SF539 0.763
SF-295 0.546 SF295 0.592 CNS:SF-295 0.826
H4 0.607 H4 0.744
SF268 0.851 CNS:SF-268 0.946
SNB-19 0.571 CNS:SNB-19 0.907
U-251 MG 0.627 U251 0.823 CNS:U251 0.971
A172 0.631 A172 0.790
SNB75 0.843 CNS:SNB-75 0.977
U-87 MG 0.607 U-87-MG 0.864
42-MG-BA 0.607 42-MG-BA 0.828
8-MG-BA 0.504 8-MG-BA 0.691
AM-38 0.631 AM-38 0.879
Becker 0.624 Becker 0.655
CAS-1 0.532 CAS-1 0.788
CCF-STTG1 0.642 CCF-STTG1 0.686
DBTRG-05MG 0.515 DBTRG-05MG 0.616
DK-MG 0.523 DK-MG 0.720
GB-1 0.618 GB-1 0.789
GI-1 0.581 GI-1 0.718
GMS-10 0.568 GMS-10 0.790
KNS-81 0.558 KNS-81-FD 0.668
KS-1 0.626 KS-1 0.811
LN-18 0.561 LN-18 0.854
LN-229 0.582 LN-229 0.785
SF126 0.629 SF126 0.810
SW 1088 0.575 SW1088 0.729
T98G 0.527 T98G 0.756
U-118 MG 0.560 U-118-MG 0.820
YH-13 0.599 YH-13 0.822
YKG1 0.522 YKG-1 0.638
D-247MG 0.809
D-263MG 0.833
D-392MG 0.749
D-423MG 0.796
D-542MG 0.843
D-566MG 0.827
LN-405 0.763
LNZTA3WT4 0.853
M059J 0.733
MOG-G-CCM 0.782
MOG-G-UVW 0.698
SK-MG-1 0.871
KG-1-C 0.490
KNS-60 0.640
LN-235 0.580
LN-319 0.636
LN-340 0.548
LN-443 0.620
LN382 0.533
LNZ308 0.613
M059K 0.603
SF-172 0.576
SNU-1105 0.661
SNU-201 0.588
SNU-466 0.629
SNU-489 0.601
SNU-626 0.530
U-138 MG 0.566
U-178 0.656
U343 0.549
CCLE panel GDSC panel
Data from CellMinerCDB database
NCI-60 panel
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Figure 2.26. Comparison of TDP1/TOP1 protein ratio in GBM cell lines to assess potential correlation with 
Irinotecan sensitivities 
The TDP1/TOP1 protein ratio from (A1) set #1, (B1) set #2, (C1) set #3, and the (D1) average of TDP1/TOP1 protein 
ratio are all lower than the ratio in NHA (grey bar) (relative ratios <1). The TDP1/TOP1 protein ratio from (A2) set #1, 
(B2) set #2, (C2) set #3, and (D2) the average of TDP1/TOP1 protein ratio significantly correlate with Irinotecan IC50s. 
The TDP1/TOP1 protein ratio from (C3) set #3 and (D3) the average of TDP1/OPT1 protein ratio are significantly 
correlated with Z-scores from CellMiner database, whereas (A3) set #1 and (B3) set #2 do not.  
A1 B1 C1 D1
A2 B2 C2 D2
A3 B3 C3 D3
A1
72
SN
B7
5
U8
7
SF
26
8
SF
53
9
SF
29
5 H4
U2
51
SN
B1
9
0.0
0.5
1.0
1.5
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(S
et
 #
1)
0.95
0.40
0.93
0.68 0.64
0.61 0.49
0.39 0.36
SN
B7
5
A1
72 U8
7
SF
26
8
SN
B1
9
SF
53
9 H4
SF
29
5
U2
51
0.0
0.3
0.6
0.9
1.2
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(S
et
 #
2)
0.67
0.37
0.55
0.46 0.43 0.41
0.23
0.36
0.24
SN
B7
5
U8
7
A1
72
U2
51
SF
29
5
SF
26
8
SF
53
9 H4
SN
B1
9
0.0
0.3
0.6
0.9
1.2
1.5
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(S
et
 #
3)
1.01
0.29
0.61 0.56
0.40
0.34 0.30 0.27 0.26
0 3 6 9 12
0.0
0.3
0.6
0.9
1.2
1.5
IC50 (µM)
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(S
et
 #
1) A172 SNB75
SF268SF539
SF295
U251
SNB19
U87
H4
R=0.696 (*, P = 0.037)
0 3 6 9 12
0.0
0.3
0.6
0.9
1.2
IC50 (µM)
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(S
et
 #
2)
A172
SNB75
SF268
SF539
SF295
U251
SNB19
U87
H4
R=0.698 (*, P = 0.037)
0 3 6 9 12
0.0
0.3
0.6
0.9
1.2
1.5
IC50 (µM)
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(S
et
 #
3)
A172
SNB75
SF268
SF539
SF295
U251
SNB19
U87
H4
R=0.862 (**, P = 0.003)
0 3 6 9 12
0.0
0.3
0.6
0.9
1.2
1.5
IC50 (µM)
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(A
ve
ra
ge
 o
f S
et
 #
1,
 2
, 3
)
A172
SNB75
SF268
SF539
SF295
U251
SNB19
U87
H4
R=0.744 (*, P = 0.02)
0.0 0.3 0.6 0.9 1.2
0.0
0.3
0.6
0.9
1.2
1.5
Irinotecan senstivity Z-score
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(S
et
 #
1) SNB75 SF268
SF539
SF295
U251SNB19
R=-0.622 (not significant)
0.0 0.3 0.6 0.9 1.2
0.0
0.3
0.6
0.9
1.2
Irinotecan senstivity Z-score
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(S
et
 #
2)
SNB75
SF268
SF539
SF295 U251
SNB19
R=-0.786 (not significant)
0.0 0.3 0.6 0.9 1.2
0.0
0.4
0.8
1.2
1.6
Irinotecan senstivity Z-score
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(S
et
 #
3) SNB75
SF268
SF539
SF295
U251
SNB19
R=-0.905 (*, P =0.013)
0.0 0.3 0.6 0.9 1.2
0.0
0.4
0.8
1.2
1.6
Irinotecan senstivity Z-score
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(A
ve
ra
ge
 o
f S
et
 #
1,
 2
, 3
)
SNB75 SF268
SF539
SF295
U251
SNB19
R=-0.744 (not significant)
SN
B7
5
A1
72 U8
7
SF
26
8
SF
53
9
SF
29
5 H4
U2
51
SN
B1
9
0.0
0.5
1.0
1.5
TD
P1
/T
O
P1
 p
ro
te
in
 ra
tio
(A
ve
ra
ge
 o
f S
et
 #
1,
 2
, 3
)
 72 
 
Figure 2.27. Comparison of TDP1/TOP1 mRNA ratio in GBM cell lines from 
CellMinerCDB database to assess potential correlation with Irinotecan 
sensitivities 
The TDP1/TOP1 mRNA ratio from (A) CCLE, (B) GDSC, and (C) NCI-60 panels 
do not correlate with Irinotecan sensitivities. 
 
 
Figure 2.28. Comparison of TDP1/TOP1 protein ratio with TDP1/TOP1 mRNA 
ratio 
The average of TDP1/TOP1 protein ratio is not correlated with mRNA ratio on (A) 
CCLE, (B) GDSC, and (C) NCI-60 panels.  
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Figure 2.29. Comparison of gel-based TDP1/TOP1 activity ratio in GBM cell lines to assess potential correlation 
with Irinotecan sensitivities 
 The majority of TDP1/TOP1 activity ratios from GBM cells measured in (A1) set #1, (B1) set #2, (C1) set #3, and (D1) 
the average of all three sets of experiments, are lower than the TDP1/TOP1 ratio in NHA (grey bar) (relative ratios <1). 
The TDP1/TOP1 activity ratio from (A2) set #1, (B2) set #2, (C2) set #3, and (D2) the average of TDP1/TOP1 protein 
ratio correlate significantly with Irinotecan IC50s. The TDP1/TOP1 activity ratio from (A3) set #1, (B3) set #2, and (D3) 
the average of TDP1/TOP1 activity ratios correlate significantly with Irinotecan sensitivities from the CellMiner database, 
except set #3 (C3).  
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Figure 2.30. Comparison of fluorescence-based TDP1/TOP1 activity ratio in GBM cell lines to assess potential 
correlation with Irinotecan sensitivities  
The majority of TDP1/TOP1 activity ratios from (A1) set #1, (B1) set #2, (C1) set #3, and (D1) the average of TDP1/TOP1 
activity ratio are lower than the ratio in NHA (grey bar) (relative ratios <1). The TDP1/TOP1 activity ratio from (A2) set 
#1, (B2) set #2, (C2) set #3, and (D2) the average of TDP1/TOP1 activity ratio correlate significantly with Irinotecan 
IC50s. The TDP1/TOP1 activity ratio from (A3) set #1, (C3) set #3, and (D3) the average of TDP1/TOP1 activity ratios 
correlate significantly with Irinotecan sensitivities from the CellMiner database, except for #2 (B3).   
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Figure 2.31. Correlation between TDP1/TOP1 protein ratios and TDP1/TOP1 activity ratios  
The relative TDP1/TOP1 protein ratios significantly correlate with gel-based TDP1/TOP1 activity ratios in (A1) set #1, 
(B1) set #2, and (D1) the average of the relative TDP1/TOP1 activity ratios, with the exception of set #3 (B1). The relative 
TDP1/TOP1 protein ratios significantly correlate with fluorescence-based TDP1/TOP1 activity ratios in (A2) set #1, (B2) 
set #2, (C2) set #3, and (D2) the average of the relative TDP1/TOP1 activity ratios. 
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Figure 2.32. Comparison of TDP1/TOP1 ratio in GBM cell lines with Irinotecan 
sensitivities from CancerDR database  
The average of TDP1/TOP1 protein ratio is weakly correlated with IC50s from 
CancerDR database. The average of the gel-based and fluorescence-based 
TDP1/TOP1 activity ratios are highly correlated with IC50s from CancerDR 
database.  
 
 
Figure 2.33. Assessment of potential correlation between sensitivities of 
GBM cell lines to human topoisomerase I/II poisons and TDP1/TOP1 ratios 
in GBM cell lines 
Structure of human topoisomerase I poisons (A1) Camptothecin, (B1) Topotecan, 
(C1) Etoposide, and (D1) Doxorubicin. The average of TDP1/TOP1 protein ratio 
from three sets of experiments on GBM cell lines is significantly correlated with 
both Z-scores of (A2) Camptothecin, while not correlated with (B2) Topotecan, (C2) 
Etoposide, and (D2) Doxorubicin from CellMiner database. The average of 
TDP1/TOP1 activity ratio from three sets of experiments on GBM cell lines is 
significantly correlated with both Z-scores of (A3, A4) Camptothecin, while not 
correlated with (B3, B4) Topotecan, (C3, C4) Etoposide, and (D3, D4) Doxorubicin 
from CellMiner database.   
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Irinotecan resistance for GBM cells with higher TDP1/TOP1 activity ratio is 
linked to lower level of IRT-induced TOP1cc 
 
        Three relatively sensitive GBM cell lines (SNB19, H4, and SF295), and two 
relatively resistant cell lines (A172 and SNB75) were chosen for analysis of 
TOP1cc level following IRT treatment. The level of topoisomerase I cleavage 
complexes (TOP1cc) was measured using the RADAR assay (98). Cells were 
treated with 15 µM of IRT and the accumulated TOP1cc levels were compared 
among these different cell lines (Figure 2.34, panel A). The decrease of 
accumulated TOP1cc level at 15 min after addition of IRT is most likely because 
of the proteolysis of the DNA bound TOP1 polypeptide from cellular response 
instead of IRT-induced cytotoxicity, because there were no significant changes in 
the overall TOP1 and TDP1 protein levels as well as their activity levels after up to 
22 h of IRT treatment (Figure 2.35). The fold-increase in TOP1cc level (relative to 
no drug treatment) at 15 min after treatment with 15 µM of IRT showed a significant 
correlation (R= -0.892, P = 0.042, Figure 2.34, panel B) with IRT IC50s, as well as 
with the potential predictor, TDP1/TOP1 activity ratio from both gel-based assay 
(R= -0.932, P = 0.02, Figure 2.34, panel D1) and fluorescence-based assay (R= -
0.885, P = 0.046, Figure 2.34, panel E1). We demonstrated that a lower 
TDP1/TOP1 activity ratio leads to increased TOP1cc accumulations as well as a 
higher degree of IRT sensitivity (i.e., lower IC50). However, there is no significant 
correlation between the fold-increase in TOP1cc level and TDP1/TOP1 protein 
ratio (Figure 2.34, panel B) which is in agreement with the earlier results that the 
TDP1/TOP1 activity ratio is a better predictor of IRT sensitivity than the 
 78 
TDP1/TOP1 protein ratio. The correlation between TOP1cc and TDP1/TOP1 
activity ratio became less significant at 60 min (Figure 2.34, panels D3, E3) 
following IRT treatment, when TOP1cc might already be proteolyzed and the TOP1 
antibody signal is no longer an indicator of the cytotoxic effect from IRT-induced 
TOP1cc accumulation.   
 
Figure 2.34. TOP1cc level in GBM cell lines following IRT treatment 
(A1) Immunoblotting of TOP1cc isolated on chromosomal DNA using the RADAR 
protocol following treatment with 15 µM IRT for 15 min, 30 min, and 60 min in three 
relatively sensitivity cell lines (SF295, H4, SNB19) and two relatively resistant cell 
lines (A172, SNB75). (B) The fold-increase in TOP1cc level from 15 min, 15 µM 
IRT treatment is significantly correlated with Irinotecan IC50s. The average of 
TDP1/TOP1 protein ratio does not correlate with the fold-increase in TOP1cc level 
at (C1) 15 min, (C2) 30 min, and (C3) 60 min. The average of TDP1/TOP1 activity 
ratio is significantly correlated with the fold-increase in TOP1cc level at (D1, E1) 
15 min, (D2, E2) 30 min, while not significantly correlated with TOP1cc level at (D3, 
E3) 60 min.  
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Figure 2.35. No significant changes of TOP1 and TDP1 protein and activity 
levels from treatment with 15 µM IRT for up to 22 h 
(A) Total proteins present in 10 µg of WCEs of GBM cell lines (SF295, SNB75, 
SNB19, A172, H4) following treatment with 15 µM IRT for 0, 1, 4 and 22 h were 
visualized by Coomassie blue staining after SDS PAGE. (B) TOP1 and (D) TDP1 
expressed in 10 µg of WCEs of GBM cell lines treated with 15 µM IRT for 0, 1, 4, 
and 22 h were measured by western blots. (C) TOP1 activity level in 75 ng of 
WCEs of GBM cell lines treated with 15 µM IRT for 0, 1, and 22 h were measured 
by agarose gel relaxation assay. (E) TDP1 activity level in 2 µg of WCEs of GBM 
cell lines treated with 15 µM IRT for 0, 1, and 22 h were measured by fluorescence-
based assay. The data shown here is the average of results from two individual 
experiments. 
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IRT resistance for GBM is not due to lack of carboxylesterase CES2 activity 
 
        The human carboxylesterase 2 (CES2) activity converts IRT into a more 
active metabolite SN-38 (Figure 2.36, panel A). To demonstrate that IRT 
resistance observed in GBM cell lines was not the result of a lack of CES2 activity, 
we conducted the CES2 activity assay by using p-NPA as a substrate which will 
produces a yellow colored p-NP product following esterase catalysis in the 
presence and absence of 300 µM Loperamide (LOP) (Figure 2.36, panel B). The 
LOP is an anti-diarrhea drug which strongly inhibits CES2 and has been widely 
used in obtaining the ability of cells on converting IRT into SN-38 (105,106). The 
activity of CES2 was calculated using the picomolar of product produced in 1 min 
with 1 µg of WCE (∆pmol/min/µg). The reaction curves are shown in Figure 2.36, 
panel C and CES2 activity was calculated (Figure 2.36, panel D). There is only 
1.3-fold variation of CES2 activity (from 3.58 to 4.64(∆pmol/min/µg) among all the 
GBM cell lines studied here, and only 1.06-fold CES2 protein expression level 
(from 4.26 to 4.51) for the NCI-60 GBM cells in the CellMinerCDB database (Figure 
2.36, panel E). Therefore, variation in expression and activity level of CES2 among 
the GBM cell lines is unlikely to play a role in IRT sensitivities and no significant 
correlations were observed (Figure 2.38, panel F). Furthermore, there is no 
significant correlation between CES2 activity level and the fold-increase in TOP1cc 
level at 15 min. 
        In summary, the metabolic conversion of IRT to SN-38 would be a significant 
factor for IRT treatment efficacy in vivo. Nevertheless, there is little variation of 
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CES2 activity among the GBM cell lines studied here. The observation made from 
our experiments that GBM cell lines with lower TDP1/TOP1 activity ratio are more 
sensitive to TOP1 poisons and induces more TOP1cc, remains valid after the GBM 
CES activity data is taken into consideration.  
 
Figure 2.36. Carboxylesterase 2 (CES2) activity in GBM cell lines 
(A) CES2 converts IRT to its active form SN-38. (B) p-NPA is used as the esterase 
substrate to produce p-NP. CES2 activity from other esterases found in the WCE 
is subtracted based on p-NP produced in the presence of LOP, a specific inhibitor 
for CES2.  (C) The time course of p-NP production corrected with results obtained 
in the presence of 300 µM LOP. (D) The variation of CES2 activity among the nine 
different GBM cell lines measured in the initial 20 min reaction. (E) The variation 
of CES2 expression in NCI-60 GBM cells from the CellMinerCDB database. (F) 
CES2 activity does not correlate with experimental IRT IC50s. 
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Transfection of recombinant TDP1 led to increased resistance of GBM to 
Irinotecan treatment 
 
        We conclude that the TDP1/TOP1 activity ratio in GBM correlates strongly 
with IRT sensitivities. In order to find further evidence that IRT sensitivity is 
dependent on TDP1/TOP1 activity ratio, we transfected H4 GBM cell line with wild-
type TDP1 (WT-TDP1) clone and null activity mutant H263-TDP1 clone. The 
overexpression of TDP1 protein following transfections with both clones was 
detected, and similar expression levels were observed (Figure 2.37, panel C). The 
TDP1 catalytic activity increased 4-fold following transfection with WT-TDP1, 
whereas H4 cells transfection with mutant H263-TDP1 exhibited TDP1 activity 
similar to control (Figure 2.37, panel D). The TOP1 protein expression (Figure 2.37, 
panel A) and activity (Figure 2.37, panel B) remained unchanged following 
transfections. The resulting increase in TDP1/TOP1 activity ratio for H4 cells 
transfected with WT-TDP1 led to a significantly higher IRT IC50 than H4 cells 
transfected with H236A-TDP1 clone (P = 0.0096, Fig 2.37, panel E). The H4 cells 
transfected with null-activity mutant TDP1 protein exhibited a similar IC50 (3.2 µM) 
as non-transfected cells (2.98 µM, Table 2.4). Therefore, the IC50 increase was a 
result of elevated TDP1/TOP1 activity ratio and not caused by the increase in 
TDP1/TOP1 protein ratio or TDP1 protein expression alone. Our result further 
demonstrated that TDP1 activity plays a vital role in GBM cell lines for IRT 
treatment outcome. 
        However, the fold-increase in TDP1/TOP1 activity level (4.45-fold) does not 
correspond to fold-increase in IC50 (1.56-fold) at 1:1 ratio. Expression level of TDP1 
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changes over time following transfection. We observed the highest TDP1 
expression level at 24 h (Figure 2.38) and a decreased TDP1 expression at 48 h 
post-transfection. Therefore, the small magnitude of IC50 increase following 
transfection of WT-TDP1 clone might because of the decrease of TDP1 activity 
over time following transfection. It is also possible that other cellular determinants 
limit the magnitude of increase in drug sensitivity from increase in TDP1/TOP1 
activity ratio. 
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Figure 2.37. Transfection induced increase of TDP1/TOP1 activity ratio in 
H4 GBM cell line results in a higher Irinotecan IC50.  
(A) TOP1 protein level based on western-blot and (B) activity level based on 
relaxation assay were not affected after transfection with wild-type (WT-TDP1) or 
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mutant (H263-TDP1) clones. (C) TDP1 protein level and (D) activity level 
measured by gel-based assay after transfection with WT-TDP1 or H263-TDP1 
clones showed that both clones increased theTDP1 protein level, but only the WT 
clone resulted in elevated TDP1 activity. (E) A significantly higher IRT IC50 for H4 
cells transfected with WT-TDP1 clone versus H263 mutant TDP1 clone (n=7, 
P=0.0096). 
 
 
Figure 2.38. Time effects on post-transfection of TDP1 in H4 cell line 
(A) Total protein expression level from 10 µg of H4 cell line at 0, 24, and 48 h post-
transfection with WT-TDP1 or mutant H263-TDP1 clones. (B) Microscopy images 
of H4 cells under 40 x magnification at 0, 24, and 48 h post-transfection with lipid 
vehicle only, WT-TDP1 or mutant H263-TDP1 clones. The TDP1 protein 
expression from 10 µg of H4 cell line at 0, 24, and 48 h post-transfection with (C) 
WT-TDP1 or (D) mutant H263-TDP1 clones. The TDP1 activity level from 1 µg of 
H4 cell line at 0, 24, and 48 h post-transfection with (E) WT-TDP1 or (F) mutant 
H263-TDP1 clones.  
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CONCLUSION 
        Glioblastoma is the most aggressive primary brain cancer with a poor 
prognosis and lack of predictive biomarkers for chemotherapeutic treatments (20). 
Investigations focusing on the improvement of GBM treatment outcomes by 
chemotherapy that employs topoisomerase I inhibitors, as well as other anticancer 
drugs, have been attempted in preclinical and clinical studies for decades. 
However, the basis of inconsistency in the observation of modest efficacy remains 
unclear. Irinotecan (IRT) acts as a prodrug of the active metabolite SN-38, which 
functions as a topoisomerase I poison stabilizing TOP1cc on chromosomal DNA 
to induce cell toxicity. With its ability to cross the blood-brain barrier (BBB), IRT is 
the focus of our study to find potential predictive biomarkers for GBM. Biomarkers 
in cancer cells have been sought for improving the diagnosis, prognosis, as well 
as predicting chemotherapeutic efficacy of cancer treatment. Genomics and 
proteomics are two main approaches for discovering promising biomarker and the 
overexpression of epidermal growth factor receptor (EGFR), promoter methylation 
on MGMT gene, and isocitrate dehydrogenase (IDH) gene mutations, have been 
routinely tested as predictive biomarkers for clinical treatment of GBM (107,108) 
with limitations. Different targets based on genetics, epigenetics, protein 
overexpression, and cellular subpopulations have been broadly explored to 
identify predictive biomarkers in GBM cancer treatment research (109).  
        Carboxylesterase 2 (CES2) is the primary enzyme responsible for converting 
IRT to its active form SN-38 and might also contribute to the efficacy in cancer 
treatment by IRT. From our study, we found that activity variation of CES2 in the 
 87 
GBM cell lines studied is relatively small and does not correlate with IRT 
sensitivities. The lack of CES2 expression variation in GBM cell lines was also 
further confirmed by the constant CES2 expression level in results available in the 
database for NCI-60 GBM cancer cells. It has been reported that CPTs-induced 
degradation of TOP1, via SUMOylation and the ubiquitin-proteasome pathway 
(UPP), results in elevated drug resistance in cancer cells (62,63). Although the 
degradation of TOP1cc is necessary for exposure of the phosphodiester linkage 
to TDP1 hydrolysis, the overall TOP1 proteolysis may reduce the TOP1 poison 
efficacy in cancer treatment (110). The mechanism of proteolytic processing of 
DNA-protein crosslinks (DPCs) in human cells is still not fully elucidated (111). We 
conducted experiments to measure the TOP1 protein expression and activity 
levels after IRT treatment. We observed no significant decrease of overall TOP1 
levels and a consistent TOP1 activity level in GBM with 15 µM IRT treatment for 
up to 22 hours (Figure 2.35), whereas the signal from TOP1cc trapped on the 
chromosome started to decrease within 30 minutes (Figure 2.34). The invariant 
CES2 activity level and lack of significant IRT-induced degradation of TOP1 protein 
pool, suggest that the TOP1cc repair activities need to be further investigated as 
determinants of IRT sensitivity in GBM.  
        Studies have reported the apoptotic TOP1cc can be stimulated by a wide 
range of exogenous factors, such as physiological ligands tumor necrosis factor 
related apoptosis-inducing ligand (TRAIL), reactive oxygen species (ROS), and 
TOP1 poisons (43,112-114). The cytotoxicity from apoptotic TOP1cc induced by 
TOP1 poison IRT is closely associated with TOP1 and TDP1 levels. A study has 
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proven that the overexpression of TDP1 or the depletion of TOP1 in colorectal 
cancer cell lines increased resistance to IRT treatment (115). Three out of nine 
clinical colorectal patients tumors with the highest TOP1 expression levels 
responded to IRT treatment in a preliminary study (116). Additionally, TOP1 activity 
increment by adenovirus Delta-24 infection of GBM cell lines enhanced the anti-
glioma effect of IRT treatment (90). As described above, TDP1 and TOP1 are 
expected to have opposite effects on IRT treatment outcome and numerous efforts 
have been devoted to demonstrating TDP1 or TOP1 level alone as potential 
biomarkers for cancer treatment. However, little effort has been spent on enzyme 
ratio or activity analysis for predictive biomarker discovery (88,117). Meisenberg 
et al. reported that TDP1/TOP1 protein expression ratio correlated with IRT 
sensitivities in 8 out of 10 small cell lung cancer (SCLC) cell lines (88). Proszek et 
al. suggested that the combined measurement of TDP1 and TOP1 activity might 
be able to predict the CPT response on colorectal cancer cells (117). According to 
our data, the higher expression and activity level of TOP1 in comparison with NHA 
may indicate the significant role of TOP1 in GBM cell proliferation, the lower 
expression and activity level of TDP1 may reflect repair pathway deficiencies in 
cancer development which make GBM cancer cells more sensitive to IRT than 
NHA (Figure 2.39). Therefore, we evaluated the correlation of TOP1, TDP1, as 
well as TDP1/TOP1 ratio in protein, mRNA, and activity levels, with the variation 
of IRT cytotoxicity for GBM. The potential role of TDP1/TOP1 activity ratio has 
been highlighted for the first time in our study to find promising predictors of GBM 
response to IRT treatment. 
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        Remarkably, we found that both TDP1/TOP1 protein ratio and TDP1/TOP1 
activity ratio correlate significantly with experimental IC50s, IRT sensitivities in 
databases, as well as fold-increase in TOP1cc levels with 15 min, 15 µM IRT 
treatment in GBM cell lines (Table 2.13, 2.14, 2.19). In addition, by correlating 
TOP1/TOP1 protein ratios and activity ratios with GBM sensitivities to FDA-
approved TOP1 poisons (CPT and TPT) (Table 2.15, 2.16) and TOP2 poisons 
(ETP and DOX) (Table 2.17, 2.18), the ratios are strongly correlated with TOP1 
poisons whereas not with TOP2 poisons, suggesting TDP1/TOP1 ratios could 
specifically predict TOP1 poison induced cytotoxicity in GBM cell lines. The 
TDP1/TOP1 activity ratio has the strongest correlation in comparison to 
TDP1/TOP1 protein ratio, indicating TDP1/TOP1 activity ratio might be a promising 
predictive biomarker of GBM response to IRT treatment.  
        CellMinerCDB is a pharmacological and genomic analysis website which 
provides a wide range of information on cancer cell lines and has been used to 
identify genomic signatures for topoisomerase poisons (18). TDP1/TOP1 mRNA 
ratios, TDP1/TOP1 protein ratio and TDP1/TOP1 activity ratio are all comparable 
among different experimental sets (Table 2.20). However, neither TOP1, TDP1 
mRNA alone, nor TDP1/TOP1 mRNA ratio, could correlate with Irinotecan 
sensitivities in GBM cell lines according to our analysis of the database information. 
The result might be explained by the lack of correlation between mRNA level and 
protein expression level of TOP1, TDP1, and TDP/TOP1 ratio in GBM cell lines 
studied here (Table 2.23). Besides, the limitation of sequencing analysis has been 
addressed and the inability to predict protein levels from mRNA levels has been 
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widely observed (118). Our results suggest that the TOP1, TDP1 protein and 
activity levels in GBM cell lines might be more relevant than mRNA level for finding 
GBM biomarkers to predict the outcome of IRT treatment. Our analysis indicated 
that TDP1/TOP1 protein ratio and to a higher degree activity ratio, rather than 
mRNA ratio, could be promising biomarkers for IRT treatment.   
        In addition, according to the results from the WT-TDP1 transfection 
experiment, TOP1 expression and activity levels were not affected by the 5-fold 
elevation of TDP1 expressions in transfected GBM cells which are resistant to IRT 
treatment (Figure 2.37). We also found no inherent relationship between TOP1 
and TDP1, at either the protein level or activity level, can be observed for GBM cell 
lines (Table 2.21). Consistent with our experimental analysis, mRNA level of TOP1 
and TDP1 also does not correlate with each other for three different sets of cancer 
cells with data available in CellMinerCDB database (Table 2.21). Furthermore, 
inhibition of TOP1 with 15 µM IRT did not result in any significant changes in TDP1 
expression and activity in measurements at up to 22 h of treatment (Figure 2.35). 
Thus, we can conclude that the protein level as well as the activity level of TOP1 
and TDP1 are independent of each other. In addition, there is no evidence 
supporting the existence of overlapping signaling pathways of regulation of TDP 
and TOP1 in GBM cells. Therefore, TOP1 and TDP1 are two independent 
parameters that would determine the TDP1/TOP1 ratio as a biomarker. 
        Furthermore, we found that the TDP1/TOP1 activity ratio is superior to 
TDP1/TOP1 protein ratio as a predictor for the response of GBM cell lines to IRT 
treatment. We also observed that TOP1 protein level does not correlate with TOP1 
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activity level. Although TDP1 protein and activity have a stronger correlation than 
TOP1, TDP1 protein levels are still not able to represent the activity levels in GBM 
cell lines (Table 2.22). The result might be explained by post-translational 
modifications (PTMs) that modulate the activity level of proteins by phosphorylation, 
acetylation, ubiquitylation, PARylation, SUMOylation, or glycosylation. Numerous 
investigations of PTMs that may regulate TOP1 activity have been conducted. It 
has been demonstrated that O-GlcNAcylation on TOP1 contributed to the elevation 
of TOP1 activity in porcine proximal tubular epithelial cells (LLC-PK1) (119). 
Bromodomain-containing protein 4 (BRD4)-dependent phosphorylation of RNA 
polymerase II (RNAPII) stimulates TOP1 activity according to enzyme assay 
results, and the combination treatment of BRD4 and TOP1 inhibitors could induce 
more cytotoxicity in colon colorectal cell line (120). It has also been reported that 
the increased activity of TOP1 by hyperphosphorylation at T268 or S506 sensitized 
cancer cells to CPT-induced cytotoxicity (91,92). We propose that the wear 
correlation between TOP1 protein and activity levels in GBM cell lines might due 
to the PTMs in GBM cell lines. In contrast, the lesser influence of PTMs on TDP1 
activity might account for the stronger correlations between TDP1 protein and its 
activity level. According to the previous studies, majority of the PTMs of TDP1 is 
associated with the TDP1 catalytic activity dispensable N-terminal domain (1-148 
residue), which promote TDP1 binding at DNA lesion sites and also enhance TDP1 
association with other essential repair factors such as XRCC1, without affecting its 
catalytic activity (72-75). Only one recently published study reported that the 
methylation of R261 and R586 of TDP1 at its catalytic domain (149-608) enhances 
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TDP1 activity and facilitates the association of XRCC1 with TDP1 to promote 
cancer cell survival in response to CPT treatment in colon carcinoma cell line 
(HCT116), human kidney origin (HEK293), and human breast cancer cell line 
(MCF7) models (76). Although, our experimental results showed a relatively strong 
correlation between TDP1/TOP1 protein ratio with its activity ratio in GBM cell lines 
(Table 2.22), assay of both protein and activity levels of TOP1 and TDP1 might still 
be necessary in order to optimize the cancer treatment. Additionally, TDP1 
possesses the versatility of precisely hydrolyzing a variety of 3’ adducts from DNA. 
Therefore, screening of TDP1 inhibitors and combination therapy with TOP1 
poisons may produce promising treatment regimens for GBM. Advances in finding 
predictive biomarkers for cancer cells is a paradigm shift towards personalized 
cancer medicine (121). Thus, research based on clinical samples will be described 
in the following chapter.  
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Figure 2.39. Protein expression level and activity level of TOP1 and TDP1 from all three sets of GBM cell line 
experiments 
The box plots of (A1) TOP1 and (B1) TDP1 protein expression level from set #1, #2, #3 GBM cell line experiments. The 
bar graphs of (A2) TOP1, (B2) gel-based TDP1, and (B3) fluorescence-based TDP1 activity level from set #1, #2, #3 
GBM cell line experiments. The box plots show the median of data from all three sets of experiments with minimum and 
maximum values at the bottom and top tail-ends. The relative levels were normalized to the levels present in NHA (red 
dotted line, relative ratio = 1)   
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Table 2.13. Correlation of experimental TOP1, TDP1, and TDP1/TOP1 ratio with experimental IC50 of IRT in 
GBM cell lines 
 
 
Table 2.14. Correlation of experimental TOP1, TDP1, and TDP1/TOP1 ratio with Z-score of IRT in GBM cell lines 
from CellMiner database 
 
 
 
 
 
 
Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9) R=-0.254; P=0.510     (ns)
R=0.797; P=0.010     
(*)
R=0.696; P=0.037    
(*)
R=-0.445; P=0.230     
(ns)
R=0.687; P=0.041     
(*)
R=0.729; P=0.026    
(*)
R=0.917; P=0.0005 
(***)
R=0.922; P=0.0004 
(***)
Set #2, GBM (n = 9) R=0.139; P=0.722     (ns)
R=0.770; P=0.015     
(*)
R=0.698; P=0.04      
(*)
R=-0.660; P=0.053     
(ns)
R=0.389; P=0.301     
(ns)
R=0.461; P=0.211     
(ns)
R=0.940; P=0.0001 
(***)
R=0.827; P=0.006     
(**)
Set #3, GBM (n = 9) R=-0.294; P=0.442     (ns)
R=0.955; P=5.8 × 10-5 
(****)
R=0.862; P=0.003    
(**)
R=0.464; P=0.208     
(ns)
R=0.565; P=0.113     
(ns)
R=0.841; P=0.004   
(**)
R=0.860; P=0.003   
(**)
R=0.953; P=6.8 × 10-5 
(****)
Average of Set #1, 
2, 3 (n = 9)
R=-0.139; P=0.720     
(ns)
R=0.863; P=0.003   
(**)
R=0.744; P=0.02       
(*)
R=-0.665; P=0.051     
(ns)
R=0.585; P=0.100     
(ns)
R=0.829; P=0.006    
(**)
R=0.972; P=1.2 × 10-5 
(****)
R=0.952; P=7.7 × 10-5 
(****)
GBM cell 
lines
 Experimental IRT IC50 
Cell type
vs Protein levels vs Activity levels
TOP1 protein TDP1 protein TDP1/TOP1 protein ratio TOP1 activity 
TDP1 activity TDP1/TOP1 activity ratio
Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9)
R=0.330; P=0.523     
(ns)
R=-0.633; P=0.177     
(ns)
R=-0.620; P=0.190    
(ns)
R=0.174; P=0.741     
(ns)
R=-0.834; P=0.039     
(*)
R=-0.738; P=0.094    
(ns)
R=-0.916; P=0.010    
(*)
R=-0.862; P=0.027    
(*)
Set #2, GBM (n = 9)
R=0.854; P=0.030     
(*)
R=-0.720; P=0.107     
(ns)
R=-0.788; P=0.063      
(ns)
R=0.422; P=0.404     
(ns)
R=-0.145; P=0.783     
(ns)
R=-0.247; P=0.638     
(ns)
R=-0.875; P=0.022     
(*)
R=-0.787; P=0.063     
(ns)
Set #3, GBM (n = 9)
R=0.604; P=0.204     
(ns)
R=-0.861; P=0.028     
(*)
R=-0.905; P=0.013    
(*)
R=0.464; P=0.352     
(ns)
R=-0.335; P=0.516     
(ns)
R=-0.577; P=0.231   
(ns)
R=-0.640; P=0.171   
(ns)
R=-0.861; P=0.028    
(*)
Average of Set #1, 
2, 3 (n = 9)
R=0.642; P=0.169     
(ns)
R=-0.785; P=0.065   
(ns)
R=-0.740; P=0.092     
(ns)
R=0.447; P=0.375      
(ns)
R=-0.150; P=0.777     
(ns)
R=-0.769; P=0.074    
(ns)
R=-0.871; P=0.024    
(*)
R=-0.862; P=0.027    
(*)
Iriontecan Z-score of CellMiner
Cell type
vs Protein levels vs Activity levels
TOP1 protein TDP1 protein TDP1/TOP1 protein ratio TOP1 activity 
TDP1 activity TDP1/TOP1 activity ratio
GBM cell 
lines
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Table 2.15. Correlation of experimental TOP1, TDP1, and TDP1/TOP1 ratio with Z-score of Camptothecin in 
GBM cell lines from CellMiner database 
 
 
 
Table 2.16. Correlation of experimental TOP1, TDP1, and TDP1/TOP1 ratio with Z-score of Topotecan in GBM 
cell lines from CellMiner database 
 
 
 
 
 
Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9)
R=0.506; P=0.306     
(ns)
R=-0.862; P=0.027     
(*)
R=-0.790; P=0.061    
(ns)
R=0.560; P=0.248     
(ns)
R=-0.526; P=0.284     
(ns)
R=-0.465; P=0.353    
(ns)
R=-0.861; P=0.028    
(*)
R=-0.832; P=0.040    
(*)
Set #2, GBM (n = 9)
R=0.950; P=0.004     
(**)
R=-0.859; P=0.028     
(*)
R=-0.889; P=0.018      
(*)
R=0.415; P=0.413     
(ns)
R=-0.182; P=0.731     
(ns)
R=-0.174; P=0.741     
(ns)
R=-0.866; P=0.026     
(*)
R=-0.778; P=0.068     
(ns)
Set #3, GBM (n = 9)
R=0.546; P=0.263     
(ns)
R=-0.900; P=0.014     
(*)
R=-0.901; P=0.014    
(*)
R=0.556; P=0.252     
(ns)
R=-0.535; P=0.274     
(ns)
R=-0.498; P=0.315   
(ns)
R=-0.615; P=0.194   
(ns)
R=-0.862; P=0.027    
(*)
Average of Set #1, 
2, 3 (n = 9)
R=0.701; P=0.120     
(ns)
R=-0.914; P=0.011   
(ns)
R=-0.845; P=0.034     
(*)
R=0.564; P=0.243      
(ns)
R=-0.153; P=0.772     
(ns)
R=-0.594; P=0.214    
(ns)
R=-0.853; P=0.031    
(*)
R=-0.847; P=0.033    
(*)
Camptothecin Z-score of CellMiner
Cell type
vs Protein levels vs Activity levels
TOP1 protein TDP1 protein TDP1/TOP1 protein ratio TOP1 activity 
TDP1 activity TDP1/TOP1 activity ratio
GBM cell 
lines
Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9)
R=0.308; P=0.553     
(ns)
R=-0.652; P=0.160     
(ns)
R=-0.611; P=0.178    
(ns)
R=0.232; P=0.659     
(ns)
R=-0.702; P=0.120     
(ns)
R=-0.626; P=0.183    
(ns)
R=-0.837; P=0.038    
(*)
R=-0.797; P=0.058    
(ns)
Set #2, GBM (n = 9)
R=0.898; P=0.015     
(*)
R=-0.789; P=0.062     
(ns)
R=-0.867; P=0.025      
(*)
R=0.392; P=0.433     
(ns)
R=-0.193; P=0.714     
(ns)
R=-0.234; P=0.656     
(ns)
R=-0.820; P=0.045     
(*)
R=-0.734; P=0.096     
(ns)
Set #3, GBM (n = 9)
R=0.437; P=0.387     
(ns)
R=-0.824; P=0.044     
(*)
R=-0.844; P=0.034    
(*)
R=0.455; P=0.365     
(ns)
R=-0.478; P=0.337     
(ns)
R=-0.502; P=0.310   
(ns)
R=-0.550; P=0.259   
(ns) R=-0.881; P=0.05    (*)
Average of Set #1, 
2, 3 (n = 9)
R=0.562; P=0.245     
(ns)
R=-0.786; P=0.064   
(ns)
R=-0.711; P=0.113     
(*)
R=0.444; P=0.377      
(ns)
R=-0.011; P=0.983     
(ns)
R=-0.661; P=0.153    
(ns)
R=-0.803; P=0.068    
(ns)
R=-0.804; P=0.054    
(ns)
GBM cell 
lines
Topotecan Z-score of CellMiner
Cell type
vs Protein levels vs Activity levels
TOP1 protein TDP1 protein TDP1/TOP1 protein ratio TOP1 activity 
TDP1 activity TDP1/TOP1 activity ratio
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Table 2.17. Correlation of experimental TOP1, TDP1, and TDP1/TOP1 ratio with Z-score of Etoposide in GBM 
cell lines from CellMiner database 
 
 
Table 2.18. Correlation of experimental TOP1, TDP1, and TDP1/TOP1 ratio with Z-score of Doxorubicin in GBM 
cell lines from CellMiner database 
 
 
Table 2.19. Correlation of experimental TOP1, TDP1, and TDP1/TOP1 ratio with fold-increase in TOP1cc level 
at 15 min, 30 min, and 60 min following 15 µM IRT treatment of GBM cell lines 
 
 
Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9)
R=0.667; P=0.148     
(ns)
R=-0.459; P=0.360     
(ns)
R=-0.643; P=0.169    
(ns)
R=0.032; P=0.952     
(ns)
R=-0.779; P=0.068     
(ns)
R=-0.902; P=0.014   
(*)
R=-0.687; P=0.132    
(ns)
R=-0.781; P=0.067    
(ns)
Set #2, GBM (n = 9)
R=0.619; P=0.190     
(*)
R=-0.773; P=0.071     
(ns)
R=-0.768; P=0.075      
(ns)
R=0.773; P=0.072     
(ns)
R=-0.865; P=0.026     
(*)
R=-0.900; P=0.014     
(*)
R=-0.614; P=0.195     
(ns)
R=-0.763; P=0.078     
(ns)
Set #3, GBM (n = 9)
R=0.074; P=0.890     
(ns)
R=-0.606; P=0.202     
(ns)
R=-0.510; P=0.302    
(ns)
R=0.774; P=0.070     
(ns)
R=-0.745; P=0.089     
(ns)
R=-0.152; P=0.774   
(ns)
R=-0.710; P=0.114   
(ns)
R=-0.446; P=0.375    
(*)
Average of Set #1, 
2, 3 (n = 9)
R=0.688; P=0.130     
(ns)
R=-0.635; P=0.176     
(ns)
R=-0.672; P=0.143    
(ns)
R=0.703; P=0.119     
(ns)
R=-0.464; P=0.354     
(ns)
R=-0.116; P=0.826    
(ns)
R=-0.627; P=0.183    
(ns)
R=-0.699; P=0.122    
(ns)
Etoposide Z-score of CellMiner
Cell type
vs Protein levels vs Activity levels
TOP1 protein TDP1 protein TDP1/TOP1 protein ratio TOP1 activity 
TDP1 activity TDP1/TOP1 activity ratio
GBM cell 
lines
Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9)
R=0.770; P=0.073     
(ns)
R=-0.278; P=0.593     
(ns)
R=-0.464; P=0.354    
(ns)
R=0.254; P=0.628     
(ns)
R=-0.030; P=0.954     
(ns)
R=-0.244; P=0.641     
(ns)
R=-0.105; P=0.842    
(ns)
R=-0.255; P=0.625    
(ns)
Set #2, GBM (n = 9)
R=0.023; P=0.966     
(*)
R=-0.344; P=0.505     
(ns)
R=-0.197; P=0.708      
(ns)
R=0.366; P=0.476     
(ns)
R=-0.746; P=0.089     
(ns)
R=-0.787; P=0.081     
(ns)
R=-0.014; P=0.980     
(ns)
R=-0.196; P=0.710     
(ns)
Set #3, GBM (n = 9)
R=0.175; P=0.740     
(ns)
R=-0.038; P=0.944     
(ns)
R=-0.089; P=0.867    
(ns)
R=0.478; P=0.340     
(ns)
R=-0.552; P=0.256     
(ns)
R=-0.706; P=0.117   
(ns)
R=-0.265; P=0.611   
(ns)
R=-0.194; P=0.712    
(ns)
Average of Set #1, 
2, 3 (n = 9)
R=0.505; P=0.307     
(ns)
R=-0.247; P=0.637     
(ns)
R=-0.362; P=0.480    
(ns)
R=0.417; P=0.411     
(ns)
R=-0.736; P=0.096     
(ns)
R=-0.604; P=0.204    
(ns)
R=-0.029; P=0.956    
(ns)
R=-0.097; P=0.856    
(ns)
GBM cell 
lines
Doxorubicin Z-score of CellMiner
Cell type
vs Protein levels vs Activity levels
TOP1 protein TDP1 protein 
TDP1/TOP1 
protein ratio 
TOP1 activity 
TDP1 activity TDP1/TOP1 activity ratio
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Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9)
R=0.606; P=0.278     
(ns)
R=-0.980; P=0.0033     
(**)
R=-0.873; P=0.053     
(ns)
R=0.664; P=0.222     
(ns)
R=-0.750; P=0.144     
(ns)
R=-0.934; P=0.020     
(*)
R=-0.966; P=0.0074     
(**)
R=-0.942; P=0.017     
(*)
Set #2, GBM (n = 9)
R=0.336; P=0.557     
(ns)
R=-0.926; P=0.024     
(*)
R=-0.873; P=0.053    
(ns)
R=0.829; P=0.083     
(ns)
R=-0.299; P=0.625     
(ns)
R=-0.307; P=0.615     
(ns)
R=-0.838; P=0.076     
(ns)
R=-0.756; P=0.139     
(ns)
Set #3, GBM (n = 9)
R=0.629; P=0.256     
(ns)
R=-0.889; P=0.044     
(*)
R=-0.792; P=0.110     
(ns)
R=0.901; P=0.037     
(*)
R=-0.356; P=0.557     
(ns)
R=-0.754; P=0.140   
(ns)
R=-0.892; P=0.047     
(*)
R=-0.926; P=0.024     
(*)
Average of Set #1, 
2, 3 (n = 9)
R=0.529; P=0.370     
(ns)
R=-0.994; P=0.0006   
(***)
R=-0.111; P=0.870     
(ns)
R=0.417; P=0.411     
(ns)
R=-0.745; P=0.149     
(ns)
R=-0.899; P=0.038    
(*)
R=-0.932; P=0.021     
(*)
R=-0.885; P=0.046     
(*)
GBM cell 
lines
R=-0.892; P=0.042     
(*)
vs IC50 
Fold-increase in TOP1cc level at 15 min
Cell type
vs Protein levels vs Activity levels
TOP1 protein TDP1 protein TDP1/TOP1 protein ratio TOP1 activity 
TDP1 activity TDP1/TOP1 activity ratio
Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9)
R=0.491; P=0.401     
(ns)
R=-0.911; P=0.031     
(*)
R=-0.769; P=0.129     
(ns)
R=0.580; P=0.306     
(ns)
R=-0.713; P=0.177     
(ns)
R=-0.844; P=0.072     
(ns)
R=-0.913; P=0.030     
(*)
R=-0.867; P=0.057     
(ns)
Set #2, GBM (n = 9)
R=0.474; P=0.420     
(ns)
R=-0.854; P=0.065     
(ns)
R=-0.936; P=0.02      
(*) R=0.893; P=0.04     (*)
R=-0.062; P=0.921     
(ns)
R=-0.095; P=0.879     
(ns)
R=-0.872; P=0.054     
(ns)
R=-0.825; P=0.086     
(ns)
Set #3, GBM (n = 9)
R=0.524; P=0.364     
(ns)
R=-0.881; P=0.048     
(*)
R=-0.814; P=0.093     
(ns)
R=0.949; P=0.013     
(*)
R=-0.126; P=0.840     
(ns)
R=-0.596; P=0.054   
(ns)
R=-0.751; P=0.143     
(ns)
R=-0.893; P=0.042     
(*)
Average of Set #1, 
2, 3 (n = 9)
R=0.453; P=0.443     
(ns)
R=-0.930; P=0.022   
(*)
R=-0.784; P=0.117     
(ns)
R=0.928; P=0.023     
(*)
R=-0.198; P=0.749     
(ns)
R=-0.575; P=0.311    
(ns)
R=-0.909; P=0.032     
(*)
R=-0.892; P=0.042     
(*)
GBM cell 
lines
R=-0.877; P=0.051     
(ns)
Fold-increase in TOP1cc level at 30 min
Cell type
vs Protein levels vs Activity levels
vs IC50 
TOP1 protein TDP1 protein TDP1/TOP1 protein ratio TOP1 activity 
TDP1 activity TDP1/TOP1 activity ratio
Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9)
R=0.077; P=0.902     
(ns)
R=-0.805; P=0.10     
(ns)
R=-0.469; P=0.426     
(ns)
R=0.156; P=0.802     
(ns)
R=-0.945; P=0.015     
(*)
R=-0.886; P=0.046     
(*)
R=-0.705; P=0.184     
(ns)
R=-0.603; P=0.281     
(ns)
Set #2, GBM (n = 9)
R=0.008; P=0.990     
(ns)
R=-0.868; P=0.056     
(ns)
R=-0.666; P=0.220    
(ns)
R=0.548; P=0338     
(ns)
R=-0.194; P=0.755     
(ns)
R=-0.076; P=0.903     
(ns)
R=-0.530; P=0.0359     
(ns)
R=-0.465; P=0.430     
(ns)
Set #3, GBM (n = 9)
R=0.705; P=0.234    
(ns)
R=-0.342; P=0.545     
(ns)
R=-0.445; P=0.453     
(ns)
R=0.693; P=0.194     
(ns)
R=-0.256; P=0.677     
(ns)
R=-0.450; P=0.447   
(ns)
R=-0.631; P=0.254     
(ns)
R=-0.591; P=0.294     
(ns)
Average of Set #1, 
2, 3 (n = 9)
R=0.021; P=0.973     
(ns)
R=-0.780.; P=0.120   
(ns)
R=-0.458; P=0.438     
(ns)
R=0.622; P=0.262     
(ns)
R=-0.378; P=0.530     
(ns)
R=-0.514; P=0.375    
(ns)
R=-0.624; P=0.261     
(ns)
R=-0.566; P=0.320     
(ns)
GBM cell 
lines
R=-0.547; P=0.340     
(ns)
Fold-increase in TOP1cc level at 60 min
Cell type
vs Protein levels vs Activity levels
vs IC50 
TOP1 protein TDP1 protein 
TDP1/TOP1 
protein ratio 
TOP1 activity 
TDP1 activity TDP1/TOP1 activity ratio
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Table 2.20. Comparison of TOP1, TDP1, TDP1/TOP1 levels in three sets of 
experiments and three different database panels 
 
 
 
Table 2.21. Correlation of TOP1 level with TDP1 level in GBM cell lines 
 
 
  
Set #1, GBM (n = 9) Set #1, GBM (n = 9) vs Set #2, GBM (n = 9) CCLE CCLE GDSC
vs Set #2, GBM (n = 9) vs Set #3, GBM (n = 9) vs Set #3, GBM (n = 9) vs GDSC (n = 27) vs NCI-60 (n = 3) vs NCI-60 (n = 4)
R=0.575; P=0.106     
(ns)
R=0.450; P=0.224     
(ns)
R=0.193; P=0.444     
(ns)
N/A N/A
R=0.919; P=0.0005  
(***)
R=0.903; P=0.0009  
(***)
R=0.806; P=0.009   (**) N/A N/A
R=0.836; P=0.006   (**) R=0.758; P=0.018   (*) R=0.758; P=0.018   (*) N/A N/A
R=0.407; P=0.277     
(ns)
R=0.424; P=0.255     
(ns)
R=0.868; P=0.002   (**) N/A N/A
Gel-based 
assay
R=0.395; P=0.293     
(nt)
R=0.619; P=0.0758     
(nt)
R=0.900; P=0.0009  
(***)
N/A N/A
FL-based 
assay
R=0.179; P=0.645     
(ns)
R=0.596; P=0.090     
(ns)
R=0.855; P=0.003   (**) N/A N/A
Gel-based 
assay
R=0.873; P=0.002   (**) R=0.836; P=0.005   (**) R=0.739; P=0.023   (*) N/A N/A
FL-based 
assay
R=0.789; P=0.01   (*) R=0.807; P=0.009   (**) R=0.886; P=0.001   (**) N/A N/A
N/A N/A R=0.389; P=0.05     (*) R=0.997; P=0.05     (*) R=0.620; P=0.380     
(nt)
N/A N/A R=0.585; P=0.0017   
(**)
R=0.914; P=0.266     
(ns)
R=0.945; P=0.055     
(nt)
N/A N/A R=0.459; P=0.016     (*) R=0.961; P=0.179     
(ns)
R=0.966; P=0.034     (*)
Databases 
data
TOP1 mRNA
TDP1 mRNA
TDP1/TOP1 mRNA ratio
Results
Experimental GBM Panels
Experimental 
results
TOP1 protein
TDP1 protein
TDP1/TOP1 protein ratio
TOP1 activity
TDP1 activity
TDP1/TOP1 
activity ratio
 Database panel
TOP1 protein TOP1 mRNA
Gel-based assay FL-based assay
Set #1, GBM (n = 9)
R=-0.114; P=0.771     
(ns)
R=0.141; P=0.717      
(ns)
R=0.072; P=0.854       
(ns) N/A
Set #2, GBM (n = 9)
R=0.475; P=0.198      
(ns)
R=0.266; P=0.490      
(ns)
R=0.085; P=0.829      
(ns) N/A
Set #3, GBM (n = 9)
R=-0.201; P=0.603     
(ns)
R=0.210; P=0.588      
(ns)
R=-0.059; P=0.881     
(ns) N/A
Average of Set #1, 2, 
3 (n = 9)
R=0.091; P=0.836      
(ns)
R=0.016; P=0.967      
(ns)
R=-0.298; P=0.436     
(ns) N/A
CCLE (n = 45) N/A N/A N/A
R=0.065; P=0.673      
(ns)
GDSC (n = 41) N/A N/A N/A
R=0.234; P=0.142      
(ns)
NCI-60 (n = 5) N/A N/A N/A
R=0.142; P=0.819      
(ns)
vs TDP1 mRNA
GBM cell 
lines
GBM cell 
lines from 
database
Cell type and Databases
Experimental results 
TOP1 activity 
vs TDP1 protein 
vs TDP1 activity
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Table 2.22. Comparison of protein level with activity level of TOP1 and 
TDP1 in GBM cell  
 
 
 
Table 2.23. Correlation of protein level with mRNA level in GBM cell lines 
 
 
TOP1 protein 
vs TOP1 activity
Western blotting Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9) R=0.629; P=0.069     
(ns)
R=0.708; P=0.033     
(*)
R=0.664; P=0.051     
(ns)
R=0.669; P=0.05     
(*)
R=0.829; P=0.0006     
(**)
Set #2, GBM (n = 9) R=0.182; P=0.639      
(ns)
R=0.495; P=0.176     
(ns)
R=0.427; P=0.251     
(ns)
R=0.745; P=0.021    
(*)
R=0.720; P=0.029     
(*)
Set #3, GBM (n = 9) R=0.338; P=0.374      
(ns)
R=0.512; P=0.158     
(ns)
R=0.774; P=0.014     
(*)
R=0.643; P=0.062     
(ns)
R=0.926; P=0.0004     
(***)
Average of Set #1, 2, 
3 (n = 9)
R=0.446; P=0.229      
(ns)
R=0.644; P=0.061     
(ns)
R=0.812; P=0.008     
(**)
R=0.799; P=0.01      
(*)
R=0.827; P=0.006     
(**)
TDP/TOP1 protein ratio 
vs TDP1/TOP1 activity ratio
Experimental results
GBM cell 
lines
Cell type
TDP1 protein
vs TDP1 activity
mRNA level of 
TOP1
mRNA level of 
TDP1
mRNA level of 
TDP1/TOP1
mRNA level of 
TOP1
Gel-based 
assay
Fluorescence-
based assay
Gel-based 
assay
Fluorescence-
based assay
Set #1, GBM R=-0.281; P=0.761     (ns)
R=0.842; P=0.036     
(*)
R=0.427; P=0.398     
(ns)
R=-0.344; P=0.503     
(ns)
R=0.680; P=0.137     
(ns)
R=0.859; P=0.029     
(*)
R=0.361; P=0.482     
(ns)
R=0.405; P=0.426     
(ns)
Set #2, GBM R=-0.177.; P=0.738     (ns)
R=0.904; P=0.013     
(*)
R=0.383; P=0.453     
(ns)
R=-0.252; P=0.630     
(ns)
R=0.867; P=0.035     
(*)
R=0.878; P=0.031     
(*)
R=0.547; P=0.272     
(ns)
R=0.485; P=0.329     
(ns)
Set #3, GBM R=-0.252; P=0.631     (ns)
R=0.869; P=0.034     
(*)
R=0.513; P=0.298     
(ns)
R=-0.578; P=0.229     
(ns)
R=0.968; P=0.002     
(**)
R=0.947; P=0.004     
(**)
R=0.687; P=0.132     
(ns)
R=0.708; P=0.116     
(ns)
Average of 
Set #1, 2, 3 
R=-0.182; P=0.730     
(ns)
R=0.886; P=0.02     
(*)
R=0.382; P=0.455     
(ns)
R=-0.249; P=0.634     
(ns)
R=0.948; P=0.004     
(**)
R=0.985; P=0.0004     
(***)
R=0.542; P=0.266     
(ns)
R=0.533; P=0.276     
(ns)
Set #1, GBM R=-0.129; P=0.761     (ns)
R=0.228; P=0.587     
(ns)
R=0.377; P=0.358     
(ns)
R=-0.455; P=0.258     
(ns)
R=0.121; P=0.775     
(ns)
R=0.237; P=0.572     
(ns)
R=0.434; P=0.282     
(ns)
R=0.468; P=0.242     
(ns)
Set #2, GBM R=-0.147; P=0.729     (ns)
R=0.302; P=0.467     
(ns)
R=0.533; P=0.174     
(ns)
R=-0.324; P=0.434     
(ns)
R=0.218; P=0.604     
(ns)
R=0.048; P=0.911     
(ns)
R=0.614; P=0.106     
(ns)
R=0.696; P=0.055     
(ns)
Set #3, GBM R=-0.257; P=0.540     (ns)
R=0.352; P=0.393     
(ns)
R=0.419; P=0.302     
(ns)
R=-0.197; P=0.639     
(ns)
R=0.032; P=0.939     
(ns)
R=0.173; P=0.681     
(ns)
R=0.558; P=0.151     
(ns)
R=0.532; P=0.174     
(ns)
Average of 
Set #1, 2, 3 
R=-0.121; P=0.775     
(ns)
R=0.262; P=0.530     
(ns)
R=0.350; P=0.395     
(ns)
R=-0.400; P=0.325     
(ns)
R=0.020; P=0.993     
(ns)
R=0.165; P=0.696     
(ns)
R=0.592; P=0.130     
(ns)
R=0.623; P=0.099     
(ns)
Set #1, GBM R=-0.402; P=0.503     (ns)
R=0.382; P=0.526     
(ns)
R=0.404; P=0.500     
(ns)
R=-0.225; P=0.716     
(ns)
R=0.360; P=0.552     
(ns)
R=0.596; P=0.289     
(ns)
R=0.374; P=0.535     
(ns)
R=0.405; P=0.498     
(ns)
Set #2, GBM R=-0.339; P=0.576     (ns)
R=0.576; P=0.310     
(ns)
R=0.498; P=0.393     
(ns)
R=-0.056; P=0.928     
(ns)
R=0.844; P=0.072     
(ns)
R=0.630; P=0.254     
(ns)
R=0.639; P=0.254     
(ns)
R=0.708; P=0.181     
(ns)
Set #3, GBM R=-0.511; P=0.379     (ns)
R=0.436; P=0.463     
(ns)
R=0.490; P=0.402     
(ns)
R=-0.012; P=0.985     
(ns)
R=0.744; P=0.150     
(ns)
R=0.116; P=0.802     
(ns)
R=0.746; P=0.148     
(ns)
R=0.637; P=0.248     
(ns)
Average of 
Set #1, 2, 3 
R=-0.151; P=0.808     
(ns)
R=0.422; P=0.479     
(ns)
R=0.371; P=0.539     
(ns)
R=-0.078; P=0.901     
(ns)
R=0.779; P=0.121     
(ns)
R=0.104; P=0.868     
(ns)
R=0.598; P=0.287     
(ns)
R=0.626; P=0.258     
(ns)
mRNA level of TDP1/TOP1
vs relative TDP1 activity vs relative TDP1/TOP1 protein
mRNA level from CellMinerCDB database
vs relative TOP1 
protein
vs relative TDP1 
protein
vs relative 
TDP1/TOP1 
protein
vs relative TOP1 
activity
Databases
mRNA level of TDP1
CCLE (n =5)
GDSC (n =9)
NCI-60 (n 
=5)
Panels
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CHAPTER III: STUDY OF TOP1 AND TDP1 IN GBM STEM CELLS AND GBM 
PATIENT TUMORS 
 
ABSTRACT 
        The TDP1/TOP1 activity ratio, shown in our previous chapter to be a 
predictive indicator for GBM cell lines response to IRT treatment, was further 
analyzed with the IRT cytotoxicity against GBM stem cell lines (GSC). We 
observed that IRT IC50s are not correlated with TOP1, TDP1, nor with TDP1/TOP1 
ratios in four GSC cell lines, suggesting TDP1/TOP1 activity ratio might not be a 
predictive indicator for stem cells treatment. 
        No correlations of TOP1 or TDP1 with GBM patient age has ever been 
reported. The potential prognostic role of TOP1 and TDP1 in GBM patients who 
underwent chemotherapy remains to be explored. In our study, a total of ten patient 
GBM tumors were analyzed. We observed a positive correlation of TOP1 activity 
with patients age (R = 0.717, P = 0.02) and also a negative correlation of 
TDP1/TOP1 activity with patients age at diagnosis (R = -0.707, P = 0.03). Because 
of the significant correlation between patient age and survival from both our set of 
GBM patients data (n = 10, R = -0.929, P = 0.023) and TCGA database (n = 451, 
R = -0.353, P = 7.7 × 10-17), TDP1/TOP1 activity ratio might be a potential 
prognosis biomarker for GBM patients.  
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INTRODUCTION 
        The heterogeneity of GBM is one of the factors that limit the efficacy of 
chemotherapeutic treatment. It has been proposed that cancer stem cells (CSC) 
have the ability to drive tumor growth and are significantly associated with 
heterogeneity in GBM (122). Glioblastoma stem cells (GSC) are a subpopulation 
of cancer cells displaying tumorigenic and recurrent potentials and are highly 
resistant to chemotherapies (123). Therefore, targeting GSC has become a 
promising chemotherapeutic approach that has been investigated extensively 
(124). Studies have shown that inhibition of signaling check-point kinases might 
sensitize the GSC cancer cells to radiotherapy (125). A recent study has also 
demonstrated that inhibiting the autophagic process could make GSC more 
sensitive to Temozolomide (TMZ) treatment in vitro (126). Whereas lack of bone 
morphogenetic protein (BMP)-induced GSC differentiation suggested that BMP-
based therapies may not be an effective treatment for GSC (127). Even though 
much efforts have been devoted to GSC studies, the drug resistance and lack of 
treatment efficacy remain as the main obstacles. Therefore, we analyzed the IRT 
sensitivity of four GSC cell lines and their levels of TOP1, TDP1 and TDP/TOP1 
ratio in order to determine if promising indicators can be identified for IRT treatment 
of GSC. 
        The Cancer Genome Atlas (TCGA), also known as Genomic Data Commons 
(GDC) (https://portal.gdc.cancer.gov), is a valuable source of a variety of cancer 
genomic data platforms, including RNA sequencing, DNA sequencing, microRNA 
sequencing, single nucleotide polymorphism (SNP)-based platforms, array-based 
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DNA methylation sequencing, and reverse-phase protein array (RPPA), which 
provides as a powerful tool that supports scientific investigations towards precision 
medicine (128). Glioblastoma was the very first cancer subject for TCGA, with data 
on specific characteristics that include survival analysis, promoter DNA 
methylation, and nucleotide aberrations (129-131). Analyses using the TCGA 
database have led to hypotheses which are then further investigated by scientists 
for increasing the likelihood of positive drug responses (132,133). Here, we 
analyzed RNA sequencing results provided by the TCGA database to study TOP1 
and TDP1 expressions and their potential correlations in cancer therapy. A small 
set of GBM patient tumors (n = 10) were also analyzed in our study to compare 
with the database contents.   
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MATERIAL AND METHODS 
All buffer compositions are listed in Appendix I.  
Western blot analysis 
        Protein expression levels were detected with western blots. Briefly, proteins 
in WCE were first separated by 7.5% SDS-PAGE and then transferred to 
nitrocellulose membrane with transfer buffer (48 mM Tris, 39 mM glycine, 0.4% 
SDS, 20% v/v methanol) at 100 V for 1 h. The membrane was blocked with 5% 
BSA in 1 × TBS at RT for 1 h followed by incubation with 1:1000 (v/v) primary 
antibody diluted in 1 × TBST at 4°C overnight. The membrane was washed 3 × 5 
min by TBST and the HRP-conjugated secondary antibody 1:5000 (v/v) diluted in 
TBST was incubated with the membrane at RT for additional 1 h. The membrane 
was then washed 3 × 5 min before the signal for the target protein was developed 
with the SuperSignal West Pico Plus Chemiluminescent Substrate (Thermo Fisher) 
for 5 min in the dark. The images were obtained by C-DiGit Blot scanner (LI-COR) 
and the expression density for the target protein was analyzed by ImageStudio (LI-
CORE).  
 
Glioblastoma neurosphere cell lines culture  
        The adult neurosphere cell lines, GSC-11 and GSC-23, a kind gift from 
Frederick Lang at UT MD Anderson Cancer Center, were established from acute 
cell dissociation of human GBM surgical specimens. The neurosphere cell lines 
GBM1A and GBM1B were originally derived and characterized by Vescovi and his 
coworkers (134). All GSC cell lines were cultured and maintained in serum-free 
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medium containing DMEM/nutrient mixture F12 (1:1, v/v) (Thermo Fisher) 
supplemented with 1% of Penicillin/Streptomycin (Lonza), 10 × of B27 supplement 
(Thermo Fisher), and 20 ng/mL of both EGF and FGF (Sigma-Aldrich) according 
to the procedures described by Galli (134). All cell lines were grown at 37°C in a 
humidified incubator with 5% CO2. 
 
Glioblastoma neurosphere cell collection  
        To isolate proteins for analysis, cells were plated at a density of 2.5 × 105 
cells/well in 60-mm dishes. Cells were then collected as described as following. 
Cells were washed twice in PBS and lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 5 mM EDTA, 1 mM EGTA. 1% NP-40, 0.1% SDS and 0.5% sodium 
deoxycholate) supplemented with 1 mM PMSF, Halt Protease and Phosphatase 
inhibitor cocktails. Cells were incubated with gentle rocking at 4°C for 5 min and 
then transferred to a sterile microcentrifuge tube. After 2 min on ice, cell disruption 
was completed using sonication. The lysate was cleared by centrifuging at 15000 
× g for 15 min at 4°C. Supernatant protein concentrations were measured using 
the Pierce BCA Assay kit.  
 
IC50 measurement for treatment of GSC cell lines with Irinotecan 
        To determine the sensitivity of the GSCs lines, cells were treated with 
increasing concentrations (0–10 µM) of IRT. GSCs were plated at 6.5 × 103 cells 
per well in black-walled, clear bottom plates (PerkinElmer), which were previously 
coated with 10 µg/mL laminin (Corning) and grown overnight. The cells were then 
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treated with IRT for 72h h. The cells were washed three times with PBS, fixed in 
4% paraformaldehyde/PBS and permeabilized with 0.2% TritonX-100/PBS. The 
cells were then blocked using the Licor Blocking Buffer and stained with 
CellTag700 stain (1:1000 dilution) for 60min at RT. The cells were then washed 
three times in Hank's Buffered Saline Solution (HBSS). The plate was imaged 
using the Odyssey CLx scanner (LI-COR) and analyzed using the Image Studio 
2.0 software (LI-COR). The IC50s were collected by Dr. Dr. Arlet Maria Acanda De 
La Rocha from Dr. Chambers’s lab and  calculated using the GraphPad Prism7© 
software. 
 
Collection and storage of brain tumor samples from patients 
Table 3.1 GBM Patient information 
 
 
        Glioblastoma brain tumors were collected from patients undergoing 
operations at Miami Neuroscience Center of Larkin Hospital according to the 
protocol approved by Florida International University Institutional Review Board 
Patient 
Code
Tumor 
ID Age Sex Dignosed Surgery
Collected 
date Radiosurgery CHEMO Reccurrence Deceased
Status 
unknown 
after
Stable 
after
Survival
/month
331475 #17 78 F 05/09/16 ×1 05/12/2016 Gammma knife x 1 08/2016 3
516-46837B #22 92 F × 1 11/09/2016 Temodar 12/2016 1
758058 #29 80 F 12/2016 × 1 12/19/2016 Gammma knife x 3 Avastin 08/2017 01/2018 12
780540 #42 71 M 03/2017 × 1 08/30/2017 Gammma knife x 3 Temodar 
& Avastin
08/2017 09/2017
782691 #44 30 F 04/2015 × 2 09/27/2017 Gammma knife x 2 09/2017 05/30/2018 36
791171 #47 60 M 12/2017 × 2 12/22/2017 Gammma knife x 2 Temodar 
& Avastin
07/2018 12/2018
792371 #49 67 M 09/2017 × 1 01/19/2018 Gammma knife x 2 2018
795033 #50 51 F 09/2015 × 3 02/09/2018 Gammma knife x 3 Avastin 01/16 
06/1601/18
10/2018 36
763107 #62 44 M 02/2017 × 1 02/21/2017 Gammma knife x 1 Temodar 
& Avastin
05/2017
772697 #66 71 F 06/2017 × 1 06/09/2017 Gammma knife x 1 06/2017
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(FIU IRB, No. IRB-16-0355-CR02), and snap-frozen in cryotubes which were pre-
cooled on dry ice.  Samples were then sent by courier to FIU and cryopreserved 
in liquid nitrogen for further analysis.  Information on the glioblastoma patient 
tumors is listed in Table 3.1. 
 
Protein extraction from GBM patient samples 
        To extract proteins for analysis, Tumor tissues were carefully transferred on 
an ice-cooled 100 mm cell culture dish and sliced into small pieces. The tumor 
segments were then weighed, and RIPA/inhibitors lysis buffer was added at a ratio 
of 1:10 (v/w). Samples were then homogenized with the Dounce Homogenizer and 
rotated with a rotator at 4°C for additional 2 h, followed by centrifugation at 15000 
×g for 15 min.  Protein concentration was then determined with the BioPhotometer 
(Eppendorf). 
 
Human TOP1 activity measurement by gel relaxation assay 
        Human topoisomerase I activity measurement was carried out in a final 
reaction volume of 20 µL. Negatively supercoiled pBAD/Thio DNA (240 ng) was 
relaxed by a serial diluted WCE at 37°C for 30 min in 1 × relaxation buffer (10 mM 
Tris-HCl, pH 7.9, 1 mM EDTA, 150 mM NaCl, 0.1% BSA, 0.1 mM spermidine, 5% 
glycerol). Reactions were stopped by adding 4 µL of 6 × SDS stop buffer and DNAs 
were then separated on 1% agarose gel electrophoresis on the basis of the 
topological differences. The DNA lanes were stained by 1 µg/mL of EtBr solution 
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and analyzed by AlphaView SA (ProteinSimple) using the intensity of the 
supercoiled DNA fractions.  
Human TDP1 activity measurement by Gel-based assay 
        Human tyrosyl-DNA phosphodiesterase 1 (TDP1) activity measurement by 
gel-based assay was carried out in a final reaction volume of 5 µL.  The P32-labeled 
P12Y oligo (4 ng) was cleaved by 2 µg WCE, at 37°C for 30 min in gel-based assay 
reaction buffer (20 mM Tris-HCl, pH 7.5, 100 mM KCl, 10 mM EDTA, 1 mM DTT). 
The reaction was stopped by adding 5 µL of 2 × stop buffer (96% formamide, 20 
mM EDTA, 0.03% xylene cyanol and 0.03% bromophenol blue) followed by heat-
inactivation at 95°C for 5 min. The  oligonucleotides were separated by 20% urea-
denaturing sequencing gel based on the mobility difference between the P12Y 
substrate and P12.oligonucleotide product with the 3’-tyrosyl removed from the 
substrate. 
 
Human TDP1 activity measurement by fluorescence-based assay 
        The TDP1 activity was also measured with the fluorescence-based assay as 
described (101). Briefly, 25 pmol of 5’FAM-DNA-BHQ1-3’ was incubated with 2 µg 
WCE at 37°C in TDP1 reaction buffer (20 mM Tris-HCl, pH 8.0, 100 mM KCl, 10 
mM EDTA, 10 mM DTT, 0.05% TritonX-100) with a final volume of 25 µL. 
Fluorescence signal from each reaction was recorded every 30 s for 500 min by 
CFX96 Touch Real-Time PCR Detection System (Bio-Rad).  
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RESULTS AND DISCUSSION 
TDP1/TOP1 activity ratio and IRT sensitivity measured for GSC cell lines 
        It has been reported that the malignant progression of GBM is primarily 
contributed by the GBM stem cells (GSCs) which play a significant role in the 
recurrence of the tumors and resistance of drug treatment (123). In our study, four 
different GSC cell lines (GSC-11, GSC-23, GBM1A, and GBM1B) derived from two 
individual labs were used for analysis. GSC cell lines were treated with serial 
dilutions of IRT and the cell viabilities were measured with the TO-PRO3 assay 
(Figure 3.1, panel B). TOP1, TDP1, and TDP1/TOP1 ratio levels were analyzed 
for potential correlation with GSC sensitivity to IRT treatment,  
        From Coomassie blue staining, the proteins present in 10 µg of the GSC 
WCEs were comparable to NHA (Figure 3.1, panel A). Results from western blot 
showed that relative TOP1 expression level was higher in the GSC WCEs, ranging 
from 2.96 to 3.78, whereas relative TDP1 protein levels in GSC were lower in 
comparison to NHA, ranging from 0.71 to 1.02 (Figure 3.1, panels C1, D1). 
Meanwhile, TOP1 activity was measured by the relaxation assay and TDP1 activity 
was measured by the fluorescence-based assay. Activities were calculated based 
on their standard curves as described in the previous chapter. The results showed 
that all of the GSC cell lines tested had a higher level of relative TOP1 activity 
ranging from 1.57 to 2.41, and a lower level relative TDP1 activity ranging from 
0.167 to 0.575 (Figure 3.2, panels A1, B1). Subsequently, TDP1/TOP1 protein 
ratio and activity level were calculated. There is a greater variety of TDP1/TOP1 
activity ratio (ranging from 0.081 to 0.333) compared to the variation of 
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TDP1/TOP1 protein ratio (ranging from 0.24 to 0.314) (Figure 3.3, panels A1, B1). 
The protein and activity levels are listed in Table 3.2. 
        According to our analysis above, GSC cell lines have the same trend as GBM 
cell lines, with relatively higher TOP1 and relatively lower TDP1 levels in 
comparison with NHA for both protein expression and activity levels. However, 
neither TOP1, TDP1 alone, nor TDP1/TOP1 ratios are significantly correlated with 
IRT IC50s (Figure 3.1, panels C2, D2; Figure 3.2, panels A2, B2; Figure 3.3, panels 
A2, B2).  
Table 3.2 TOP1, TDP1, and TDP1/TOP1 ratio of GSC cell lines 
 
 
Relative TOP1 Relative TDP1 TDP1/TOP1 TOP1 activity (U/µg)
Relative TOP1 
activity
TDP1 activity 
(fmol/µg)
Relative TDP1 
activity
activity ratio 
(fmol/U)
relative 
activity ratio 
GBM1A 3.408 ± 0.764 1.019 ± 0.106 0.299 2.201 ± 0.130 2.414 ± 0.142 1.675 ± 0.383 0.575 ± 0.131 0.761 0.238
GBM1B 2.961 ± 0.815 0.749 ± 0.064 0.253 1.885 ± 0.0206 2.068 ± 0.142 0.486 ± 0.186 0.167 ± 0.0639 0.258 0.081
GSC11 2.994 ± 0.195 0.714 ± 0.167 0.239 1.433 ± 0.050 1.571 ± 0.0545 1.522 ± 0.104 0.522 ± 0.0356 1.062 0.332
GSC23 3.874 ± 1.052 0.869 ± 0.235 0.224 1.982 ± 0.0139 2.174 ± 0.0152 1.352 ± 0.211 0.464 ± 0.0724 0.682 0.213
GSC cell 
lines
TOP1, TDP1, TOP1/TDP1 ratios of GSC cell lines
Protein level TOP1 Activity level TDP1 Activity level TDP1/TOP1 Activity Ratio
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Figure 3.1. Analysis of WCE of glioblastoma stem cells  
(A) Coomassie blue staining of proteins in GSC WCEs (10 µg total proteins) 
following SDS PAGE. (B) The cell viabilities of GSC cell lines were measured by 
TO-PRO3 assay following treatment with serial dilutions of IRT. DMSO treatment 
was used as control. The (C1) TOP1 and (D1) TDP1 expression levels in GSC cell 
lines were measured by western blots. The signal intensity was first normalized to 
actin signal to correct for loading, then divided by the NHA signal intensity for 
comparison. The (C2) TOP1 and (D2) TDP1 expression levels in GSC cell are not 
significantly correlated with IRT IC50s. 
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Figure 3.2. Comparison of TOP1, TDP1, and TD1P/TOP1 ratio levels in GSC 
cell lines with Irinotecan sensitivities  
(A1) TOP1 activity of GSC was measured by relaxation assay. (B1) TDP1 activity 
level was measured by fluorescence-based assay. The (A2) TOP1 and (B2) TDP1 
activity levels in GSC cell are not significantly correlated with IRT IC50s. 
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Figure 3.3.TOP1 and TDP1 levels in GBM and GSC cell lines 
Bar-graph of (A1) TDP1/TOP1 protein ratio and (B1) TDP1/TOP1 activity ratio. 
The (A2) TDP1/TOP1 protein ratio and (B2) TDP1/TOP1 activity ratio in GSC cell 
are not significantly correlated with IRT IC50s. 
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The variation of TDP1/TOP1 ratios observed among GBM patient tumors 
       Ten GBM tumors from patients (Table 3.1) were collected from surgery. 
Coomassie blue staining following SDS PAGE showed similar overall protein 
expression in WCEs of patient tumors (Figure 3.4, panel A). The TOP1 and TDP1 
expression level of GBM tumors were much lower than GBM cell lines. Therefore 
60 µg WCE were used for western blotting. In order to normalized protein 
expression level to NHA, patient tumor (ID: #22) with the highest expression level 
was used to compare with NHA. From our results, the expression level of TOP1 
and TDP1 can vary up to 12.5-fold (ranging from 0.011 to 0.138, Figure 3.4, panel 
C) and 3.4-fold (ranging from 0.14 to 0.47, Figure 3.5, panel B) respectively. The 
relative activity level of TOP1 and TDP1 can vary up to 6.5-fold (ranging from 0.133 
to 0.860, Figure 3.4, panel B) and 13-fold (ranging from 0.059 to 0.770, Figure 3.5, 
panel A) respectively. Additionally, TDP1/TOP1 protein and activity ratio can vary 
up to 12.7-fold (from 1.88 to 23.86, Figure 3.6, panel A) and 9.3-fold (from 0.223 
to 2.087, Figure 3.6, panel B) differences, respectively. Relative levels of TOP1, 
TDP1, as well as TDP/TOP1 ratios found in GBM patient tumors are listed in Table 
3.3.  
        On the basis of these results, there is a more considerable variation of TOP1, 
TDP1, as well as TDP1/TOP1 ratio levels among the patient tumors than GBM cell 
lines, suggesting the variation of TDP1/TOP1 activity ratios has the potential to 
represent as a predictive biomarker in clinical trials. The TOP1 activity in patient 
samples is highly correlated with TOP1 protein levels (Figure 3.4, panel D), 
suggesting TOP1 activity in patient tumors is most likely not as modulated by post-
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translational modifications as in GBM cell lines (92,102,103). Although, the TDP1 
activity in patient samples are significantly correlated with TDP1 protein levels 
(Figure 3.5, panel C), the TDP1/TOP1 activity ratios are still not significantly 
correlated with TDP1/TOP1 protein ratios (Figure 3.6, panel C), suggesting activity 
assays are necessary for finding rational predictive biomarkers for both GBM cell 
lines and patient tumors.  
        Among the tumors we tested, 5 out of 10 patients have the survival 
information (Table 3.1). Interestingly, we observed a strong correlation (R = -0.929, 
P = 0.023) between patient age at diagnosis with patient survival (Figure 3.7, panel 
A). With the increased patient age, the survival duration time was decreased. A 
significant correlation (R = -0.353, P = 7.7 × 10-17) was also observed in GBM 
patient samples provided from TCGA database (Figure 3.7, panel B). TCGA is a 
powerful database tool with abundant genomic data from patient tumors available 
for analysis. The data we used from the TCGA database including 451 GBM 
patients who had already deceased and their survival days after diagnosis were 
provided (Table 3.5). Furthermore, comparison of the correlations of patient age 
with its survival among 26 different cancers provided by TCGA database showed 
that only GBM, lower grade glioma (LGG), skin cutaneous melanoma (SKCM), and 
breast invasive carcinoma (BRCA) are significantly as well as negatively correlated 
with patient age (Table 3.4). Among those, GBM patient age has the strongest 
correlation with survival. Furthermore, we observed a significantly positive 
correlation between patient age at diagnosis and TOP1 activity levels (Figure 3.8, 
panel A2) and a significantly negative correlation between patient age and 
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TDP1/TOP1 activity ratio according to our results (Figure 3.8, panel C2), 
suggesting TDP1/TOP1 activity ratio might also be a prognostic indicator for GBM. 
Whereas, no correlation was observed between patient age and protein 
expression levels or mRNA expression levels of TDP1 and TOP1 (Figure 3.8, 
panel D). 
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Table 3.3. Relative levels of TOP1, TDP1 protein and activity plus TDP1/TOP1 protein and activity ratio in GBM 
tumors  
 
 
 
Relative TOP1 Relative TDP1 TDP1/TOP1
TOP1 activity 
(U/µg)
Relative TOP1 
activity
TDP1 activity 
(fmol/µg)
Relative TDP1 
activity
activity ratio 
(fmol/U)
relative activity 
ratio 
#17 0.138 ± 0.016 0.260 ± 0.035 1.884 0.785 ± 0.0509 0.860 ± 0.056 1.054 ± 0.206 0.427 ± 0.0837 1.343 0.497
#22 0.116 ± 0.021 0.472 ± 0.105 4.075 0.741 ± 0.039 0.813 ± 0.0430 1.899 ± 0.216 0.770 ± 0.0875 2.563 0.947
#29 0.0193 ± 0.0039 0.206 ± 0.0683 10.640 0.148 ± 0.0180 0.163 ± 0.0197 0.407 ± 0.0911 0.165 ± 0.0369 2.744 1.014
#44 0.216 ± 0.0024 0.296 ± 0.0606 13.690 0.127 ± 0.0095 0.139 ± 0.0104 0.717 ± 0.113 0.291 ± 0.0460 5.647 2.087
#50 0.0490 ± 0.0116 0.341 ± 0.0544 6.963 0.279 ± 0.0186 0.306 ± 0.0204 0.792 ± 0.154 0.321 ± 0.0625 2.838 1.049
#66 0.0283 ± 0.0051 0.144 ± 0.0438 5.100 0.419 ± 0.0719 0.460 ± 0.0789 0.700 ± 0.102 0.284 ± 0.0414 1.671 0.618
#42 0.0384 ± 0.0103 0.222 ± 0.0628 5.788 0.473 ± 0.0506 0.518 ± 0.0555 0.286 ± 0.053 0.116 ± 0.0216 0.605 0.223
#47 0.0141 ± 0.0033 0.337 ± 0.0299 23.860 0.121 ± 0.0090 0.133 ± 0.0099 0.424 ± 0.0791 0.172 ± 0.0321 3.501 1.294
#49 0.0295 ± 0.0018 0.194 ± 0.0332 6.591 0.360 ± 0.0375 0.395 ± 0.0411 0.877 ± 0.166 0.356 ± 0.0675 2.437 0.901
#62 0.0105 ± 0.0022 0.196 ± 0.0380 18.630 0.000 0.000 0.145 ± 0.048 0.0588 ± 0.0195 N/A N/A
TDP1 Activity level TDP1/TOP1 Activity Ratio
TOP1, TDP1, TOP1/TDP1 ratios of GBM tumors
Tumor ID
Protein level TOP1 Activity level
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Figure 3.4. Analysis of TOP1 protein expression and activity levels of GBM 
patient tumors 
(A) Coomassie blue staining of patient tumor WCEs (60 µg total proteins) following 
SDS PAGE. Tumor #17 was included in both gels. (B) TOP1 activity of GBM 
patient tumors was measured by relaxation assay. (C) TOP1 expression level in 
GBM patient tumors was measured by western blot. The signal intensity was first 
normalized to actin signal to correct for loading, then divided by the NHA signal 
intensity for comparison. (D) TOP1 activity is significantly correlated with TOP1 
protein level.  
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Figure 3.5. Analysis of TDP1 protein expression and activity levels of GBM 
patient tumors 
(A) TDP1 activity of GBM patient tumors was measured by gel-based assay. (B) 
TOP1 expression level in GBM patient tumors was measured by western blot. The 
signal intensity was first normalized to actin signal to correct for loading, then 
divided by the NHA signal intensity for comparison. (C) TDP1 activity is 
significantly correlated with TDP1 protein level.  
 
 
 
Figure 3.6. Analysis of TDP1/TOP1 ratios of GBM patient tumors 
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The bar graphs of the (A) TDP1/TOP1 protein ratio and (A) TDP1/TOP1 activity 
ratio of GBM patient tumor. (C) TDP1/TOP1 activity ratio is not significantly 
correlated with TDP1/TOP1 protein ratio.  
 
Figure 3.7. Correlations between patient age and survivals 
(A) Patient age correlates strongly with patient survivals in our GBM patient cohort. 
(B) Correlation between patient age and patient survivals from data in the TCGA 
database.  
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Table 3.4. Correlations of patient survival and diagnosis age among cancers 
from TCGA database 
 
 
Cancer name cancer Individuals R P
brain TCGA-GBM glioblastoma 451 -0.353 7.74E-16
brain TCGA-LGG brain lower grade glioma 125 -0.526 3E-10
skin TCGA-SKCM skin cutaneous melanoma 221 -0.301 5.09E-06
ovary TCGA-OV ovarian serous cystadenocarcinoma 341 -0.2 0.00019
kidney TCGA-KIRP kidney renal papillary cell carcinoma 44 0.316 0.03657
breast TCGA-BRCA breast invasive carcinoma 151 -0.166 0.0409
eyes TCGA-UVM uveal melanoma 23 -0.407 0.0539
kidney TARGET-WT wilms tumor 114 0.177 0.05956
liver TCGA-LIHC liver hepatocellular carcinoma 130 0.16 0.06828
pleura TCGA-MESO mesothelioma 75 -0.184 0.11407
colorectal TCGA-READ rectum adenocarcinoma 26 -0.289 0.1517
testic TCGA-TGCT testicular germ cell tumor 4 -0.854 0.16
bladder TCGA-BLCA bladder urothelial carcinoma 180 -0.103 0.17011
kidney TCGA-KIRC kidney renal clear cell carcinoma 176 0.09886 0.19177
soft tissue TCGA-SARC sarcoma 38 -0.214 0.19702
liver TCGA-CHOL cholangiocarcinoma 19 -0.299 0.21293
uterus TCGA-SARC sarcoma 14 -0.33 0.249
uterus TCGA-UCS uterine carcinosarcoma 35 -0.172 0.32275
thyroid TCGA-THCA thyroid carcinoma 16 0.177 0.51125
colorectal TCGA-COAD colon adenocarcinoma 101 0.0573 0.56917
blood TARGET-AML acute myloid leukemia 342 -0.0305 0.57441
lung TCGA-LUSC lung squamous cell carcinoma 215 -0.03 0.66319
pancreas TCGA-PAAD pancreatic adenocarcinoma 100 -0.044 0.66639
prostate TCGA-PRAD prostate adenocarcinoma 10 0.152 0.67546
esophagus TCGA-ESCA esophageal carcinoma 76 -0.048 0.68331
cervix TCGA-CESC cervical squamous cell carcinoma and endocervical 72 0.0454 0.70502
adrenal gland TCGA-ACC adrenocortical carcinoma 33 -0.066 0.71406
lung TCGA-LUAD lung adenocarcinoma 175 -0.027 0.71963
stomach TCGA-STAD stomach adenocarcinoma 171 -0.25 0.7501
lymph nodes TCGA-DLBC lymphoid neoplasm diffuse large B-cell lymphoma 8 0.123 0.77214
kidney TARGET-RT rhabdoid tumor 34 -0.049 0.78126
bone marrow TARGET-OS bone marrow 100 -0.025 0.80595
kidney TCGA-KICH kidney chromophobe 12 0.07017 0.82845
uterus TCGA-UCEC uterine corpus endometrial carcinoma 91 0.023 0.82865
head and TCGA-HNSC head and neck squamous cell carcinoma 223 0.008 0.90486
thymus TCGA-THYM thymoma 7 0.069 0.907
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Figure 3.8. Correlations between TOP1, TDP1, TDP1/TOP1 ratio in GBM 
patient tumors and patient ages  
Patient age at diagnosis does not correlate with (A1) TOP1 protein level, (B1) 
TDP1 protein, (B2) TDP1 activity, (C1) TDP1/TOP1 protein ratio, (D) TOP1 mRNA 
level, TDP1 mRNA level, nor TDP1/TOP1 mRNA ratio. Patient age at diagnosis is 
significantly correlated with (A2) TOP1 activity level and (C1) TDP1/TOP1 activity 
ratio.  
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Table 3.5. GBM tumor information from TCGA database 
 
  
GBM patients ID gender Age at diagnosis Days to death TOP1 mRNA TOP1 mRNA mRNA of TDP1/TOP1 ratio
4c42dc4e-66b7-40bf-9fbe-b92543248198 male 17 1537 31.900 2.145 0.0673
2188c194-dfe4-4471-9b8b-050db1a1062c male 24 632 34.153 2.441 0.0715
bde84ea9-55c9-4d6d-be86-58fd9222c1d6 male 24 1024 34.554 3.669 0.1062
054f472f-98cb-4559-b2e2-b5f800fc8eef male 24 603 34.271 3.933 0.1148
2f61ea6b-a3f2-477f-ab98-47ed07b3b2cd female 27 442 35.352 2.874 0.0813
4776b959-d5f5-41ad-ab39-dba6031f6884 male 27 510 25.441 4.121 0.1620
bc7a0c8f-c1c1-447c-8019-389e52525081 male 29 427 23.066 2.515 0.1090
edcfac32-adb4-4fe7-86a0-309d3c6430e5 female 29 448 23.997 1.961 0.0817
53abce1d-7e33-4ebd-832f-f3789f67377f male 31 2681 8.081 2.175 0.2692
5bbeb8a7-3ac2-4ef1-bd48-6f83bc994a75 male 32 362 15.272 2.220 0.1454
66bd4c9e-2ebd-4092-a2b0-69027e8af5b8 male 34 737 11.750 1.595 0.1358
0456a66b-c9b3-4eb1-9872-424a7ea712a2 male 34 28 15.753 1.363 0.0865
35a7e49e-747b-45ce-9a07-3a5faba0ca94 male 35 77 25.128 2.866 0.1140
eddbca7a-d668-4c5d-9843-340d7f18e30e male 37 405 21.413 2.436 0.1138
5ef9486a-aeff-421d-b620-03ef119d85a5 male 37 333 29.206 4.132 0.1415
5c984433-33cf-42fc-b3ba-511efcdcab19 male 38 360 35.332 3.161 0.0895
a589e2dc-7649-492c-9569-592698acaa6f female 38 666 22.079 2.414 0.1093
6ff96a7e-1b96-4530-b8a8-7f2e9e541955 male 38 550 31.292 1.840 0.0588
52408d9f-2637-4952-9b90-cb607a860f23 female 38 224 20.977 1.634 0.0779
43d98306-8b1f-4840-a1a0-146ba0c36400 male 38 360 20.004 2.872 0.1436
456bcab3-165d-456f-94e3-f34f81a61d2e male 38 385 21.042 2.776 0.1319
9b9654c9-5a64-4a8e-b1f0-987437e6012e male 39 29 20.328 1.796 0.0884
9ad6c241-ccc5-4532-a6ac-098271b13b5f male 39 771 15.321 1.563 0.1020
cd73f38a-f6ff-4e7b-bd43-ec7b82dbe7df female 39 883 30.408 1.562 0.0514
cdfcf14d-ed6c-419f-88f5-e7dee96fcaf6 male 39 460 9.536 1.702 0.1785
d6de8d1c-e5ff-45cd-b53e-f943d2578713 female 40 1458 29.639 3.011 0.1016
e921772f-f81a-49bc-b35e-3354c94447c0 male 40 82 11.761 2.194 0.1866
309005a2-93a8-4566-b8d3-6b9310144266 male 40 141 31.190 1.457 0.0467
3f960d3b-a58c-43d0-a8a4-f3555b399c9d male 40 254 15.046 2.734 0.1817
2f4a127f-101a-4192-b3e8-f9be2c8648bc male 41 5 26.085 3.625 0.1390
46bfebf4-0ef6-4348-81dc-d7d3cb52c08f male 41 544 37.923 3.849 0.1015
b1c4579c-72fa-4974-830c-b6a81ace45f4 female 41 532 24.388 2.715 0.1113
987cb702-057b-4198-8ef3-9cf6a9c51989 female 42 648 25.617 2.387 0.0932
d6a48eb1-7c20-4ae3-ae35-b6b641238ef1 female 42 537 29.487 1.461 0.0496
44ef426e-b67d-4b49-80a3-86681b9abf1a male 42 82 37.397 3.359 0.0898
7cada85b-00b1-41e5-9924-e09eb077ad56 male 43 394 29.963 2.860 0.0955
ee3fc631-1e88-4f70-ab31-335851b38640 male 43 98 28.374 3.825 0.1348
7cbabf1d-ec38-4048-ae1c-7d0f3001691b male 43 342 26.044 2.267 0.0870
af055b98-be6a-4012-ac64-f1b6539b23d0 female 43 357 43.525 3.813 0.0876
878584ad-e6b6-493a-9f7f-3e284f5d9f68 female 44 175 27.677 2.337 0.0844
5327e899-a20d-4571-8236-98454bad574e female 44 98 26.212 3.034 0.1157
a597bfa8-8c4d-4f8e-9d85-8a9fdc2c56ff male 44 231 19.172 3.468 0.1809
93ed7a2b-b0cb-4a84-871f-5c34a0b6a640 male 44 455 40.104 3.623 0.0903
15e058e8-2f33-4fb4-92af-3d9dea1fa906 male 45 178 18.679 2.880 0.1542
6e72d2e2-96fe-4fbb-9fe6-39ec28753eb6 male 45 154 26.335 2.546 0.0967
9d1d9ae5-4640-4060-a207-c9c5b0e905e1 male 46 535 23.610 3.199 0.1355
f4fe7c02-be19-4929-8638-960e5776494c male 46 114 31.792 2.940 0.0925
a515cf2d-e918-4958-9bf6-e611b425a97e female 46 543 17.586 2.035 0.1157
bf339349-062f-4ea9-a0b2-d87d3a21099e female 46 975 17.514 2.500 0.1428
c7b4fd72-b45d-4524-8424-983120abfec0 male 46 506 42.442 2.962 0.0698
6c5154d2-af36-492f-b520-d925528824e4 male 46 468 26.466 2.530 0.0956
dd76930a-1678-4b70-9864-730534174d41 female 47 300 23.716 2.301 0.0970
c184c3ca-7ad3-4202-b108-cb9fd5f5d947 female 47 460 46.993 5.343 0.1137
224235c1-5b6e-48d5-a5d1-777dfede0f1e female 47 598 17.665 3.124 0.1768
386b629e-fab1-4033-b088-45d6eeb4a13e male 47 239 16.842 2.594 0.1540
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159e0318-6173-440f-be07-8d956086e99d male 47 1062 24.125 1.201 0.0498
0389b35b-651b-4776-b12a-d315a100f47c male 47 1062 24.905 3.408 0.1369
0078b0c4-68a9-483b-9aab-61156d263213 female 47 485 34.656 6.190 0.1786
c970240f-03e2-4395-85be-5eb81a69b710 female 48 454 17.792 1.615 0.0908
e17a6048-7a72-42c0-ad3f-97cbff02bc9f male 48 737 31.303 2.129 0.0680
ea82c1da-eada-4108-80ec-77ce891d82a7 male 48 175 22.394 2.016 0.0900
c9e4f0bf-48fc-4600-9e03-314bc575273f female 49 335 31.834 2.219 0.0697
da5f6940-e8ee-4fd1-a8da-4cd68e02e59c female 49 76 33.123 2.977 0.0899
74139255-a635-4c87-814d-3dd04ed630a8 male 49 317 27.020 2.509 0.0929
2b82e941-1b16-444e-af41-24dbc0a7e8b5 female 49 675 24.694 3.139 0.1271
be3a7ef3-34ed-40e1-9d9c-187940596b26 male 49 480 39.127 2.705 0.0691
30011f30-2926-47f2-a8f3-4f1b58ffa227 male 49 485 17.701 1.864 0.1053
4b43da9d-60ee-4269-b44d-d92c034b844c male 49 313 17.235 1.731 0.1004
eae44c1c-1628-4b58-8b90-d3372e3577d5 male 49 323 31.890 2.242 0.0703
737b35e1-d668-4fce-9b6e-76946c7952b6 male 50 489 43.070 4.505 0.1046
5252c0b7-be05-4c0c-a8ac-afe9ad459489 female 50 772 27.948 2.694 0.0964
d558203d-3f70-42d4-accb-008ace280f48 male 50 157 35.324 2.649 0.0750
66afd908-0c76-469e-abc3-89563de338c6 female 50 6 22.215 1.542 0.0694
ea3b5da2-6a12-400c-bf0f-e442f5ec1132 female 50 97 27.143 3.502 0.1290
1f48f010-98fe-4b5a-b96a-14fb25eff23f male 50 2126 19.052 1.416 0.0743
8da3103e-3e6c-4176-a583-d5fe5e60601e female 50 1448 24.462 1.625 0.0664
79a68b32-29a3-47bf-9b2b-643ec7323d73 male 50 618 15.791 2.805 0.1776
7fe37feb-e205-4524-8c98-1f9ac5fe0700 female 51 419 28.882 2.594 0.0898
55a063b0-98ad-4700-b3ce-61bfe364fec8 male 51 133 20.809 3.045 0.1463
f19850cb-50c4-4f3a-ba80-b1464958ffa8 male 52 419 30.110 3.713 0.1233
01a92062-967a-4900-8dc7-a5ecd3b3f8e2 male 52 399 23.932 2.046 0.0855
e876dd29-68b0-4bf1-83d1-488c40068a35 male 52 585 31.055 3.453 0.1112
f45f4a30-6b4c-4f15-9140-959d6a25a45f male 53 505 16.488 2.149 0.1304
5613f5f6-086d-470b-8f77-6dcb7f8625b7 male 53 1426 17.188 2.639 0.1536
25f41de3-9d70-45df-913f-4fb3e5f0f7d6 male 53 22 8.419 1.844 0.2191
1e80ccf6-ef81-4662-bf5e-392f092c1e67 male 53 406 28.108 1.747 0.0622
8e6b9705-e9d2-4fbc-ac03-35c1a5115eef male 53 388 22.143 2.326 0.1051
1b25795e-69ad-47fd-bb2f-94ff0910fae1 male 53 766 29.979 2.758 0.0920
f5bc5d97-e054-4e53-992d-71b896bd97d5 male 53 375 36.813 3.217 0.0874
8df94420-c736-4a36-b001-5dbe3dff17f0 male 54 138 18.954 3.085 0.1627
149be735-d5db-43b6-80b7-d40e3a84500b male 54 828 23.600 2.226 0.0943
a2338b30-f511-4163-af3b-1e4a40ff00e1 male 54 68 27.196 3.962 0.1457
5a86d9f1-d38d-4b78-9a23-c7855a20ca2d female 55 164 13.604 2.800 0.2058
e2e83064-7d1c-4dd5-993f-cc7a5ee228ed male 55 803 18.690 2.182 0.1168
352768f9-3ce1-419c-beef-6515c78f5d7a male 55 148 15.385 1.899 0.1234
e0e1b5b3-6e3c-4b79-aa2a-32b320c3e45a male 55 232 25.652 3.174 0.1237
752a6e21-9a91-417f-beba-bfdf331d5cac female 56 279 27.794 3.508 0.1262
d9fcf27f-48e3-43fd-a8cf-3db246cf4221 male 56 343 28.702 2.302 0.0802
652a39f0-c539-4303-bedc-f0d7f4669d9f male 56 384 30.496 2.069 0.0678
884f867b-4a8b-4b67-8fe4-ab3f068be84e female 57 108 25.072 2.366 0.0944
d59ffef5-f39b-4627-a7c7-6920b99c2408 male 57 36 15.296 2.143 0.1401
69d56f2d-6924-409b-9d1e-c8d69b400270 female 57 270 20.519 2.227 0.1085
de7b7cac-f094-4d59-8651-e991e34ea093 female 57 225 22.209 2.598 0.1170
66f3c936-272e-4a1e-8567-f609af411329 female 58 64 18.000 1.614 0.0897
bc316a17-9d73-4ef3-97e9-c4ac5516b75a male 58 329 24.070 2.085 0.0866
314d9188-c8fd-43fc-905d-b6889de542c8 male 58 548 25.503 3.524 0.1382
72f88d18-03be-4b51-9f4a-1151521b7292 female 59 880 34.126 4.704 0.1378
cf286533-5c8a-40f3-9c69-f46264c7893b female 59 380 28.764 3.614 0.1256
51c3409d-5df7-4720-83db-0e6de065f82c female 59 83 19.547 3.039 0.1555
c34760a2-f70e-48c4-a7c2-eb359f8aeb71 female 60 142 16.686 1.922 0.1152
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c04657d2-b71b-4402-82fa-02747cce331d female 60 111 27.046 2.934 0.1085
f6b2f52b-284d-4bde-9a3d-a0f458d07f08 female 60 124 13.860 2.234 0.1612
6c28f086-6a25-40b6-93eb-bba0014acda6 male 60 33 34.970 2.794 0.0799
872abc8a-6c1f-4114-b993-7d0327fb38bd male 60 146 44.047 4.332 0.0984
34f216fb-09dc-48af-9e09-7d12cc07c1f7 female 61 577 28.215 3.159 0.1120
3caf009f-d9e0-4c57-b1d9-8eb59fc833bd male 62 448 22.704 2.031 0.0895
e6e2d4c3-d37c-4de3-ac68-b301800770f0 female 62 138 26.404 2.559 0.0969
69d0a566-5fbf-45f6-a240-649b06868e27 female 62 87 21.137 1.644 0.0778
e3251837-f6f3-4dad-856f-108e20d03dad male 64 382 28.725 3.565 0.1241
9348e446-0e43-4210-b07e-c534980cbf62 female 64 414 22.068 2.202 0.0998
ca893d12-3d6c-4e6f-b0e7-7f4eb8bb724b male 66 150 31.459 4.308 0.1369
543c0a7d-ccd7-4b8d-98fb-eabec806231d male 67 119 19.262 1.797 0.0933
dfa3ef71-7006-4c6d-81c4-e0c0c7b75c26 female 67 94 43.928 2.932 0.0668
d88bbd87-e876-4a44-96f5-c28ceac661b8 male 68 211 17.257 1.619 0.0938
722f462d-f939-4bc1-aae4-8f78b1335a87 male 70 26 14.316 3.110 0.2172
3a3fc890-1985-4353-861b-dc3abfb364b1 female 23 21.251 2.406 0.1132
620282f9-f932-4335-9c7d-ece53dcaf7a1 female 24 36.425 5.989 0.1644
a262928c-e20a-4c02-8114-1227e05c43e1 male 36 23.714 2.702 0.1139
c29d73c0-c885-4105-bf74-38e9178e71c9 male 44 21.983 1.685 0.0767
a2ac9937-f351-4d78-9261-264bf6c21e0c male 44 31.006 4.193 0.1352
74ce7e7f-e214-4b6e-8551-114a153ab7fb female 45 39.587 2.881 0.0728
d1547b99-3c96-4c62-8261-5111bcf860a9 female 46 29.720 3.213 0.1081
350232cb-b9ba-465b-be9a-81afbc6a92e9 male 46 30.292 2.484 0.0820
22e0c3ea-9f6d-4d73-9282-17ee4553f436 female 47 18.827 2.167 0.1151
8ff9f921-f9e9-41c1-a5d4-891fd4cfe979 male 51 30.612 2.786 0.0910
c2f7f72f-13ae-4efc-9cda-69ca037b4498 male 53 23.397 1.732 0.0740
b98184b9-6190-4e95-a1cf-8cffb44b9963 male 53 29.103 3.247 0.1116
521ea765-1bd1-423d-a75d-091243df37a9 male 53 32.048 4.436 0.1384
47a4161c-9c61-48f5-b9bc-a6d1acad4e5a male 57 10.318 1.965 0.1905
a28b256e-e085-467d-bdba-5c39718012d7 male 59 30.507 2.207 0.0724
7a650a2c-bc3f-4e0c-820e-4f492977107b male 62 34.485 2.505 0.0726
4644a15f-3115-4f27-86b2-b092419431e1 male 64 28.608 2.118 0.0741
d73ca945-b60b-4b5c-ac53-7ef2602a4951 female 65 30.005 2.764 0.0921
153c2442-ea61-4b5e-8c5c-c71d287c6055 female 67 36.851 3.954 0.1073
8d2e88d9-d8d0-4c42-8aa2-205a788dea58 male 67 30.594 4.738 0.1549
30256f61-7be9-4d47-8afd-afafa7a079c0 female 70 27.535 2.221 0.0806
7338e476-10ff-444a-a16f-429d28355f65 male 73 17.338 2.420 0.1396
ba383ea6-c885-49f0-bddc-e00be0230a6b female 73 35.299 4.273 0.1210
20bad0d5-3135-49a4-a119-fa7a1e56fd1b male 74 26.793 1.717 0.0641
2c5fa2d4-8e35-42e4-8bca-9fb3371a19c8 male 75 20.670 3.542 0.1713
98e2f2ec-bdcd-490a-bf45-600e3b6c7491 male 75 29.172 1.957 0.0671
aa7ad106-eadc-489e-83b2-5698652434ea female 77 30.517 3.112 0.1020
1030a6b9-0df8-4d60-b69f-2a36e630a6ad male 82 29.943 4.043 0.1350
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CONCLUSION 
        In this chapter, we observed a greater variation of TDP1/TOP1 activity ratio 
levels among the patient tumors than GBM cell lines, suggesting the variation of 
TDP1/TOP1 activity ratios has the potential to be utilized as a predictive biomarker 
in clinical trials. We also observed a positive correlation of GBM patient age with 
TOP1 activity level and a negative correlation of patient age with TDP1/TOP1 
activity ratio level, suggesting that elderly patients lacking TDP1 repair activity may 
benefit from chemotherapy treatment with TOP1 poisons. Combination treatment 
of TOP1 poisons and TDP1 inhibitors might be needed for the treatment of patients 
of younger age. In addition, we observed a negative correlation between patient 
age and survival time after diagnosis in both experimental results (n = 5) and TCGA 
database (n = 451), suggesting TOP1 activity and TDP1/TOP1 activity could be a 
potential prognosis biomarker in GBM. Patients with lower TOP1 activity and 
higher TDP1/TOP1 activity ratio might be more likely to have a longer survival time. 
As we concluded from the previous chapter, TDP1/TOP1 activity ratio might be a 
potential predictive biomarker of GBM response to IRT treatment, therefore 
TDP1/TOP1 activity ratio could also be explored as a prognosis biomarker for GBM 
cancers. Our hypothesis needs to be further confirmed in future studies.  
        GSC cell lines were also investigated in our study. However, neither TOP1, 
TDP1 alone, nor TDP1/TOP1 ratios are significantly correlated with IRT IC50s in 
GSC cell lines. The results are different from GBM cell lines as we concluded from 
the previous chapter that TDP1/TOP1 activity ratio is a predictive indicator for IRT 
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sensitivity for GBM cell lines. Further experiments with a higher number of GSC 
cell lines are needed to obtain a more rational conclusion.  
        According to Chapter II, there is no correlation between TOP1 and TDP1 at 
the protein or activity levels for the GBM cell lines results as well as the GBM cell 
lines data in the CellMinerCDB database. Results from this chapter, also indicated 
that there is no correlation between TOP1 and TDP1 in GSC cell lines. In contrast, 
we observed a significant correlation between TOP1 mRNA and TDP1 mRNA 
levels for GBM patient tumors in the TCGA database. There is also a significant 
correlation of TOP1 activity and TDP1 activity in the ten GBM patient tumors 
studied here (Table 3.6). Therefore, even though TOP1 and TDP1 might be 
independent of each other in cell line models, the relationship between these two 
activities in GBM patient tumors need to be further studied. 
        We observed that TOP1 and TDP1 protein levels do not correlate with their 
activity levels for GBM cell lines, suggesting that it might be due to the PTMs in 
cells. In this chapter, we observed a similar pattern in GSC cell lines. However, in 
GBM patient tumors, TOP1 and TDP1 protein levels have stronger correlations 
with their activity levels (Table 3.7). The results might suggest that in clinical GBM 
tumors, TDP1 and TOP1 activities are not as strongly modulated by PTMs as in 
GBM cell line models. The TDP1/TOP1 activity ratio is not consistently correlated 
with TDP1/TOP1 protein ratio, suggesting activity level measurements are 
necessary for biomarker screenings.  
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Table 3.6. Correlation between TOP1 and TDP1 levels in GBM cell lines, GSC 
cell lines, and GBM tumors 
 
 
Table 3.7. Correlation between protein level and activity level of TOP1, TDP1, 
as well as TDP1/TOP1 ratio in GBM cell lines, GSC cell lines, and GBM tumors 
 
  
 Database panel
TOP1 protein TOP1 mRNA
Gel-based assay FL-based assay
Set #1, GBM (n = 9) R=-0.114; P=0.771     
(ns)
R=0.141; P=0.717      
(ns)
R=0.072; P=0.854       
(ns)
N/A
Set #2, GBM (n = 9) R=0.475; P=0.198      
(ns)
R=0.266; P=0.490      
(ns)
R=0.085; P=0.829      
(ns)
N/A
Set #3, GBM (n = 9) R=-0.201; P=0.603     
(ns)
R=0.210; P=0.588      
(ns)
R=-0.059; P=0.881     
(ns)
N/A
Average of Set #1, 2, 
3 (n = 9)
R=0.091; P=0.836      
(ns)
R=0.016; P=0.967      
(ns)
R=-0.298; P=0.436     
(ns)
N/A
CCLE (n = 45) N/A N/A N/A R=0.065; P=0.673      
(ns)
GDSC (n = 41) N/A N/A N/A R=0.234; P=0.142      
(ns)
NCI-60 (n = 5) N/A N/A N/A R=0.142; P=0.819      
(ns)
GSC cell 
lines
GSC (n = 4) R=0.595; P=0.405      
(ns)
R=0.664; P=0.336      
(ns)
R=0.022; P=0.978      
(ns)
N/A
GBM Tumors (n = 10) R=0.490; P=0.150      
(ns)
R=0.606; P=0.084      
(ns)
R=0.729; P=0.03       
(*)
N/A
TCGA (n = 153) N/A N/A N/A R=0.539; P=6.3 × 10
-13 
(****)
vs TDP1 mRNA
GBM cell 
lines
GBM cell 
lines from 
database
Patients
Cell lines
Tumor
Cell type and Databases
Experimental results 
TOP1 activity 
vs TDP1 protein 
vs TDP1 activity
TOP1 protein 
vs TOP1 activity
Western blotting Gel-based assay FL-based assay Gel-based assay FL-based assay
Set #1, GBM (n = 9) R=0.629; P=0.069     
(ns)
R=0.708; P=0.033     
(*)
R=0.664; P=0.051     
(ns)
R=0.669; P=0.05     
(*)
R=0.829; P=0.0006     
(**)
Set #2, GBM (n = 9) R=0.182; P=0.639      
(ns)
R=0.495; P=0.176     
(ns)
R=0.427; P=0.251     
(ns)
R=0.745; P=0.021    
(*)
R=0.720; P=0.029     
(*)
Set #3, GBM (n = 9) R=0.338; P=0.374      
(ns)
R=0.512; P=0.158     
(ns)
R=0.774; P=0.014     
(*)
R=0.643; P=0.062     
(ns)
R=0.926; P=0.0004     
(***)
Average of Set #1, 
2, 3 (n = 9)
R=0.446; P=0.229      
(ns)
R=0.644; P=0.061     
(ns)
R=0.812; P=0.008     
(**)
R=0.799; P=0.01      
(*)
R=0.827; P=0.006     
(**)
GSC cell 
lines GSC (n = 4)
R=0.551; P=0.449      
(ns)
R=0.932; P=0.068      
(ns)
R=0.476; P=0.524      
(ns)
R=0.092; P=0.908      
(ns)
R=0.082; P=0.918      
(ns)
Tumor Patients GBM Patients (n = 10)
R=0.913; P=0.0002     
(***)
R=0.679; P=0.031     
(*)
R=0.798; P=0.006     
(**)
R=0.575; P=0.106     
(ns)
R=0.806; P=0.009     
(**)
GBM cell 
lines
Cell lines
Cell type
TDP1 protein TDP/TOP1 protein ratio 
vs TDP1 activity vs TDP1/TOP1 activity ratio
Experimental results
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CHAPTER IV: SUMMARY 
        The research of this dissertation aimed to identify potential predictive 
biomarkers for the response of devastating glioblastoma (GBM) cancer to 
topoisomerase I inhibitors treatment in order to improve the efficacy of 
chemotherapeutic treatment for individual patients. In our study, three different 
models, GBM cell line, GBM stem cell line (GSC), and GBM patient tumors were 
used for analyzing the protein expression level and activity level of the inhibitor-
targeted enzyme topoisomerase I (TOP1) and the essential repair enzyme tyrosyl-
DNA phosphodiesterase 1 (TDP1). Nine GBM cell lines (SNB75, U87, A172, U251, 
SF258, H4, SF295, SF539, SNB19), four GSC cell lines (GBM1A, GBM1B, GSC11, 
GSC23), and ten GBM patient tumors (#17, #22, #29, #42, #44, #47, #49, #50, 
#62, #66) were used for this study.  
        GBM cell lines and GSC cell lines were treated with increasing concentrations 
of Irinotecan (IRT) to obtain the IC50 values. Irinotecan sensitivities, Z-scores, of 
six different GBM cell lines (SF539, SF295, SF268, SNB18, U251, SNB75) were 
obtained from the CellMiner database. Irinotecan IC50 values of three different 
GBM cell lines (SF295, A172, U87) were obtained from the CancerDR database. 
The fold-increase in TOP1cc levels of two relatively resistant GBM cell lines (A172, 
SNB75) and three relatively sensitive GBM cell lines (SF295, H4, SNB19) with 15 
µM IRT treatment were determined by the RADAR assay. TOP1 and TDP1 protein 
levels from each cell type were determined by western blot analysis, while activity 
levels were ascertained by specific enzymatic assays. TOP1 activity levels were 
determined by the relaxation of the negatively supercoiled plasmid DNA. TDP1 
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activity levels were determined by the traditional gel-based assay and an 
alternative fluorescence-based assay. The two assays are strongly correlated 
(Table 4.1), indicating both assays could  be used for TDP1 activity measurement.   
 
Table 4.1 Correlations between gel-based assay and fluorescence-based 
assay for the measurement of TDP1 activity 
 
 
        By analyzing the correlations of TOP1, TDP1, and TDP1/TOP1 ratios with 
IRT sensitivities of GBM cell lines, we found that the experimental IC50s of IRT 
have the highest correlations with TDP1/TOP1 activity ratios (Table 4.2, first row). 
In addition, the IC50s of IRT from CancerDR database and the Z-scores of IRT from 
CellMiner database are also highly correlated with TDP1/TOP1 activity ratios 
(Table 4.2, third row and fourth row). Therefore, we suggest that TDP1/TOP1 
activity ratio might be a predictive indicator for the response of GBM cell lines to 
IRT treatment. Our hypothesis was further proven by analyzing the fold-increase 
in TOP1cc levels with 15 min, 15 µM IRT treatment. The lethal TOP1cc level is 
significantly correlated with TDP1/TOP1 activity ratios (Table 4.2, second row). 
This observation is consistent with a low TDP1/TOP1 activity ratio leading to 
Gel-based TDP1 
activity
Set #1, GBM (n = 9) R=0.968; P=4.7 × 10
-6 
(****)
Set #2, GBM (n = 9) R=0.914; P=0.0002  
(***)
Set #3, GBM (n = 9) R=0.897; P=0.0004   
(***)
Average of Set #1, 2, 
3 (n = 9)
R=0.943; P=4.4 × 10-5 
(****)
GSC cell 
lines
GSC (n = 4) R=0.988; P=0.001       
(**)
Tumor Patients GBM Tumors (n = 10) R=0.941; P=4.8 × 10
-5 
(****)
GBM cell 
lines
Cell type 
Cell lines
vs Fluorescence-
based TDP1 activity
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increased TOP1cc levels and greater Irinotecan sensitivity. Interestingly, 
TDP1/TOP1 activity ratios are also highly correlated with the sensitivities of GBM 
cell lines to TOP1 inhibitors, camptothecin and topotecan (Table 4.2, row five and 
row six). No correlations were observed between TDP1/TOP1 activity ratio and 
TOP2 inhibitors, etoposide and doxorubicin (Table 4.2, row seven and row eight). 
The evidence further confirmed that TDP1/TOP1 activity ratio might be a potential 
predictive biomarker of GBM cell lines to TOP1 inhibitors treatment. Additionally, 
increase in TDP1 catalytic activity in the WCE from WT-TDP1 but not H263A-TDP1 
was also observed along with no change in TOP1 catalytic activity, as expected. 
GBM cell line, H4, transfected with WT-TDP1 had significantly higher Irinotecan 
IC50 than H4 cells transfected with H236A-TDP1 clone (Figure 2.37), 
demonstrating the correlation between TDP1/TOP1 activity ratio and Irinotecan 
IC50 for GBM is significant. In addition, carboxylesterase isoform, CES2, which is 
able to convert IRT to the much more potent metabolite SN-38, has been found to 
be comparable among the nine GBM cell lines (Figure 2.36). The results further 
demonstrate that the relatively higher level of resistance of cell lines such as A172 
and SNB75 to Irinotecan was not due to lack of CES2 activity in these cells, and 
Irinotecan sensitivity of SNB19 was not due to the relatively high level of CES2 
being present in SNB19. The GBM cells with lower TDP1/TOP1 activity ratio would 
be more sensitive to TOP1 poison inhibitor is valid with the GBM CES2 activity 
data being taken into consideration. Therefore, we concluded that the TDP1/TOP1 
activity ratio might be a potential predictive indicator for the response of GBM cell 
lines to the treatment of TOP1 inhibitors.  
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        However, by analyzing the correlations of TOP1, TDP1, and TDP1/TOP1 
ratios with IRT sensitivities of the four GSC cell lines, we did not find any significant 
correlations between these factors and the experimental IC50s of IRT (Table 4.2, 
row nine). The TDP1/TOP1 activity ratio, which is not correlated with GSC 
sensitivities to IRT treatment, is acting differently from GBM cell lines, 
demonstrating that the differentiated progeny generated by GSC might behave 
differently from the established GBM cell lines (135). The results need to be further 
investigated in future study.  
Table 4.2. Correlations between TDP1/TOP1 activity ratio and GBM 
sensitivities to topoisomerase inhibitors treatment 
 
Gel-based assay FL-based assay
IC50 TOP1 inhibitor Irinotecan (n = 9) R=0.972; P=1.2 × 10
-5 
(****)
R=0.952; P=7.7 × 10-5 
(****)
TOP1cc 15 min, 15 µM Irinotecan (n = 6) R=-0.932; P=0.021     (*)
R=-0.885; P=0.046     
(*)
IC50 
(CancerDR 
Database)
TOP1 inhibitor Irinotecan (n = 3) R=0.991; P=0.0855     
(ns)
R=0.991; P=0.0851     
(ns)
Irinotecan (n = 6)
R=-0.871; P=0.024    
(*)
R=-0.862; P=0.027    
(*)
Camptothecin (n = 6)
R=-0.853; P=0.031    
(*)
R=-0.847; P=0.033    
(*)
Topotecan (n = 6)
R=-0.803; P=0.068    
(ns)
R=-0.804; P=0.054    
(ns)
Etoposide (n = 6)
R=-0.627; P=0.183    
(ns)
R=-0.699; P=0.122    
(ns)
Doxorubicin (n = 6)
R=-0.029; P=0.956    
(ns)
R=-0.097; P=0.856    
(ns)
GSC cell 
lines IC50 TOP1 inhibitor Irinotecan (n = 4)
R=0.469; P=0.531     
(ns)
R=0.247; P=0.753     
(ns)
Parameters
Average of TDP1/TOP1 activity 
ratio
Z-score 
(CellMiner 
Database)
TOP1 inhibitor
TOP2 inhibitor
GBM 
Cell linesCell 
lines
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        From this dissertation, we demonstrated that the TDP1/TOP1 ratio might be 
a predictive biomarker for GBM sensitivity to TOP1 inhibitors treatment. The GBM 
cell lines with relatively lower TDP1/TOP1 ratios are more sensitive to IRT or TOP1 
inhibitors treatment, such as SNB19, SF539, SF295, and H4 cell lines (Figure 4.1, 
panels A1, A2). On the other hand, GBM cell lines with relatively higher 
TDP1/TOP1 ratios are most likely to be resistant to IRT or TOP1 inhibitors 
treatment, such as SNB75, U87, and A172 (Figure 4.1, panels A1, A2). For making 
chemotherapeutic treatment more specific for individual patients, we analyzed ten 
different GBM patient tumors which were directly collected from surgery (Table 
3.1). By analyzing the TDP1/TOP1 activity ratio of the patient tumors, we found as 
high as ten-fold differences among these samples. The ratio might even be greater 
in #62, which has undetectable TOP1 activity. The patients with relatively lower 
level of TDP1/TOP1 activity ratio, such as #42, #17, #28, and #66 might be 
benefited from IRT or other TOP1 inhibitors treatment (Figure 4.1 panels B1, B2). 
While, patient with relatively higher level of TDP1/TOP1 activity ratio, such as #44, 
#47, #29, #59 and #62, might not respond from the treatment of TOP1 inhibitors 
(Figure 4.1 panels B1, B2). The patients with higher TDP1/TOP1 activity ratio 
probably should not be treated with TOP1 inhibitors to avoid side-effect from 
chemotherapy medicines that are not likely to be effective. Research on patient-
derived GBM xenografts in mice models is needed to confirm our hypothesis 
further.  
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Figure 4.1. TDP1/TOP1 activity ratios of GBM cell lines and patient tumors  
The box plots of (A1) gel-based TDP1/TOP1 activity ratio and (A2) fluorescence-
based TDP1/TOP1 activity ratio of three sets of GBM cell lines. The box plots of 
(B1) gel-based TDP1/TOP1 activity ratio and (B2) fluorescence-based 
TDP1/TOP1 activity ratio of GBM patient tumors. The box plots show the median 
of data from all three sets of experiments with minimum and maximum values at 
the bottom and top tail-ends. The relative levels were normalized to the levels 
present in NHA (red dotted line, relative ratio = 1) 
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APPENDIX 
Appendix I: Buffer Preparation 
Part 1: Reaction buffer 
10 x HTOP1 relaxation buffer (TopoGen) 
100 mM Tris-HCl (pH 7.9), 10 mM EDTA (pH 7.9), 1.5 M NaCl, 1 mM spermidine, 
1% (10 mg/ml BSA), 50% glycerol 
 
 
5 x HTDP1 gel-based assay buffer (TopoGen) 
100 mM Tris-HCl (pH 7.5) 500 mM KCl, 50 mM EDTA, 5 mM DTT 
 
 
 10 x HTDP1 FL-based assay partial buffer 
200 mM Tris-HCl (pH 8.0), 1 M KCl, 100 mM EDTA, 0.5% TritonX-100  
 
 
5 x HTDP1 FL-based assay buffer 
100 mM Tris-HCl (pH 8.0), 500 mM KCl, 50 mM EDTA, 50 mM DTT, 0.25% 
TritonX-10 
 
 
 
  
Reagent needed Volume
2 M Tris-HCl (pH 7.9) 0.5 mL
0.5 M EDTA (pH 7.9) 0.2 mL
5 M NaCl 3 mL
0.5 M, Spermidine 0.02 mL
100 mg/mL BSA 1 mL
100% Glycerol 5 mL
Water 0.28 mL
10 x HTOP1 
relaxation 
buffer
Reagent needed Volume
2 M Tris-HCl (pH 7.5) 0.5 mL
0.5 M EDTA (pH 7.5) 1 mL
2 M KCl 1.25 mL
1 M DTT 0.05 mL
Water 7.2 mL
5 x HTdp1 
reaction buffer 
(gel-based)
Reagent needed Volume
2 M Tris-HCl (pH 8.0) 20 mL
0.5 M EDTA (pH 7.5) 40 mL
2 M KCl 100 mL
100% TritonX-100 1 mL
Add water to 200 mL
10 x HTdp1 
partial reaction 
buffer (FL-
based)
Storage 10 x HTdp1 FL partial buffer at RT
Reagent needed Volume
10 x FL partial buffer 10 mL
1 M DTT 1 mL
Water 9 mL
5 x HTdp1 
reaction buffer 
(FL-based)
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Part 2: Dilution buffer 
1 x HTOP1 dilution buffer (TopoGen) 
20 mM KH2PO4 (pH 7.4), 1 mM EDTA (pH 7.4), 300 mM NaCl  
 
 
 
Part 3. Storage buffer 
 
1 x HTOP1 Storage buffer (TopoGen) 
20 mM NaH2PO4 (pH 7.4), 300 mM NaCl, 50 µg/mL BSA, 50% Glycerol, 50 mM 
Imidazole 
 
1 x HTDP1 storage buffer (Dr. Pommier) 
20 mM HEPES, pH 7.3, 50 mM KCl, 20 mM DTT, 1 mM EDTA, 50% glycerol  
 
 
 
Part 4. Stop solutions 
 
2 x gel-based assay stop solution (TopoGen):  
96% formamide, 20 mM EDTA, 0.03% xylene cyanol and 0.03% bromophenol 
blue 
  
6 x SDS stop solution:  
6% SDS, 0.6% bromophenol blue, 40% glycerol  
 
Reagent needed Volume
1 M KH2PO4 (pH 7.4) 0.2 mL
2 M NaCl 1.5 mL
0.5 M EDTA (pH 7.4) 0.02 mL
Water 8.28 mL
1 x HTOP1 
Dilution buffer
Reagent needed Volume
1 M NaH2PO4 (pH 7.4) 20 mL
5 M NaCl 60 mL
10% (100 mg/mL) BSA 0.5 mL
1 M Imidazole 50 mL
Water To 1 L
1 x HTOP1  
Storage buffer
Reagent needed Volume
1 M HEPES (pH 7.3) 0.2 mL
0.5 M EDTA (pH 7.3) 0.02 mL
2 M KCl 0.25 mL
1 M DTT 0.2 mL
100% Glycerol 5 mL
Water 4.33 mL
1 x HTdp1 
Storage buffer
Reagent needed Volume
100% formamide 9.6 mL
0.5 M EDTA (pH 8.0) 0.4 mL
Bromophenol blue 3 mg
Xylene cyanol 3 mg
2 x Stop Buffer
Reagent needed Volume
10% SDS 6 mL
Bromophenol blue 60 mg
100% Glycerol 4 mL
6 x SDS Stop 
Buffer
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4 x SDS protein loading buffer 
 
 
 
 
Part 5: Other assay buffers 
 
1 x Coomassie Brilliant Blue G-250 Staining 
35 mM (0.11%) HCl, 0.6%-0.8% CBB G-250  
 
1 x SDS running buffer 
25 mM Tris-HCl, 192 mM glycine, 0.1% SDS 
 
1 x Tank blotting buffer (Bjerrum Schafer-Nielsen buffer)  
48 mM Tris (pH 9.2), 39 mM glycine, 20% methanol, 0.1% - 0.4% SDS (alternative) 
 
50 x TAE (pH 8.5) 
2 M Tris, 50 mM EDTA, 1 M acetic acid 
 
  
Reagent needed Volume
0.5 M Tris-HCl (pH 6.8) 0.5 mL
SDS (solid/g) 0.8 g
100% glycerol 4 mL
Bromophenol blue 40 mg
Add water to 9.5 mL
Partial 4 x 
SDS protein 
loading buffer
Partial 4 x buffer above : Beta-Mercaptoethanol = 95 µL : 5 µL
Reagent needed Volume
G-250 6-8 g
12.1 M HCl (37.5%) 2.9 mL
Add water to 1 L
1 x Coomassie 
brilliant blue G-
250 Staining 
Stir 2-3 h, brown bottle, RT
Reagent needed Volume
Tris base (solid/g) 3.03 mL
Glycine (solid/g) 14.4 g
10% SDS 10 mL
Add water to 1 L
SDS running 
buffer
Reagent needed Volume
Tris base 5.82 g
Glycine 2.93 g
Methanol 200 mL
10% SDS(Alternative) 4 mL
Add water to 1 L
ICE Bag, stir bar, cold room, 100 V transfer 1 h
1 x Transfer 
buffer
Reagent needed Weight/Volum
Tris 242 g
0.5 M EDTA (pH 8.0) 100 mL
100% Acetic acid 57.1 mL
Water To 1 L
50 x TAE
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10 x TBE (~pH 8.3) 
0.89 M Trizma-Boric acid (pH 8.3), 0.02 M EDTA 
 
10 x TBS (Tris-Buffered Saline) 
200 mM Tris-HCl (pH 7.5), 1.5 M NaCl 
 
 
1 x TBST  
20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Tween 20 
 
1 × TE (pH 8.0) 
10 mM Tris-HC (pH 8.0), 1 mM EDTA (pH 8.0) 
 
1 × TE-NaCl (pH 8.0) 
10 mM Tris-HC (pH 8.0), 1 mM EDTA (pH 8.0), 200 mM NaCl 
 
 
  
Reagent needed Volume
Tris base 108 g
0.5 M EDTA (pH 8.0) 40 mL
Boric acid 55 g
Add water to 1 L
10 x TBE
Reagent needed Volume
Tris base-HCl (pH to 7.5) 12.114 g
NaCl 43.83 g
Add water to 500 mL
10 x TBS
Reagent needed Volume
10 x TBS 100 mL
Tween 20 1 mL
Add water to 1 L
1 x TBST
Reagent needed Weight/Volum
1 M Tris-HCl (pH 8.0) 20 mL
0.5 M EDTA (pH 8.0) 4 mL
Water To 2 L
1 × TE
Reagent needed Volume
1 M Tris-HCl (pH 8.0) 40 mL
0.5 M EDTA (pH 8.0) 8 mL
1 M NaCl 400 mL
Water To 4 L
1 × TE NaCl
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